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1 Introduction 
The goal of treatment of schizophrenic patients with antipsychotic drugs is to 
effectively control positive and negative symptoms at a lowest possible dosage. 
Therapeutic drug monitoring (TDM) is one of the applicable means to achieve this 
goal by measuring serum concentrations of the antipsychotic drugs. A pre-requisite 
for TDM is the availability of a laboratory method with sufficient sensitivity and 
specificity. 
1.1 General Description of Schizophrenia and Symptoms 
The German Society for Psychiatry, Psychotherapy and Neurology characterized 
schizophrenia as a disorder with a characteristic pattern of different psychological 
areas such as perception, ego functions, affective and psychomotor disturbance 
[DGPPN, 2006]. It is a disorder that must be present for at least six months, including 
at least one month of delusions (erroneous beliefs that usually involves a 
misinterpretation of perceptions or experiences), hallucinations (for example, visual 
and olfactory), disorganized speech, catatonic behavior or negative symptoms, which 
denote functional impairments [Benkert and Hippius, 2007]. The acute phase of 
schizophrenia may last several weeks before subsiding and the symptoms may recur 
after several years. During the chronic schizophrenic phase, the symptoms progress 
insidiously with persistent residual symptoms [Benkert and Hippius, 2007]. 
The two main types of schizophrenic symptoms are the positive symptoms and the 
negative symptoms. The positive symptoms are considered as an excess of normal 
functions of the brain. They are attributed to over-activity of dopamine neurons 
specifically in the mesolimbic pathway. Examples of positive symptoms are 
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delusions, hallucination and disorganized speech [Stahl, 1996]. The negative 
symptoms are diminutions or loss of normal functions of the brain. They involve other 
regions of the brain such as the dorsolateral prefrontal cortex and other 
neurotransmitter systems that might attribute to under-activity of distinct neuronal 
systems. Examples of negative symptoms are affective flattening (restriction in range 
and intensity of emotional expression), alogia (restrictions in the fluency of thoughts 
and speech), avolition (restrictions in the initiation of goal-directed behavior), 
anhedonia (lack of pleasure) and attention impairment. [Stahl, 1996]. 
One of the recognized diagnostic classification systems of schizophrenic diseases is 
the ICD system (see table 1) released by the World Health Organization (WHO). 
Table 1 shows the current version of ICD-10 with eight different codes (F20-F29), 
assigned to certain clinical categories. 
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Table 1. ICD-10 Classification of schizophrenia and schizophrenia-related sickness. 
ICD-10 Code ICD-10 Classification Clinical Categories 
F20 Schizophrenia Paranoid schizophrenia 
F21 Schizotypal disorder Schizophrenia simplex 
F22 Persistent delusional disorder Post-Schizophrenic depression 
F23 Acute and transient psychotic disorder Residual schizophrenia 
F24 Induced delusional disorder Catatonic schizophrenia 
F25 Schizoaffective disorder Hebephrenic schizophrenia 
F28 Other non-organic psychotic disorder Non-organic psychotic disorder 
F29 Unspecified non-organic psychosis Undifferentiated schizophrenia 
Note: The chapter five of the ICD-10 system describes the blocks F00-F99 mental and behavioral 
disorders, whereby F20-F29 belong to the group of schizophrenia, schizotypal and delusional 
disorders [World Health Organisation, 1993].  
 
1.2 Transmission of Neurotransmitters and Development of Schizophrenia 
The onset and the course of the schizophrenic sickness is regarded as a result of 
pathophysiological abnormalities during neurodevelopment [Liebermann, 1998]. 
Temporary changes in the neurochemical steady state due to environmental cues are 
suggested to trigger the symptoms. The onset of the schizophrenic sickness and the 
time for the manifestation of the symptoms can be both, in an early age as well as in 
adult age. If neurotransmission is interrupted early in the development, the brain may 
not reach its full potential, such as in the case of a mental retardation. If 
neurotransmission is interrupted later in life, the brain may regress from the potential 
it had earlier on, as in the case of various dementias [Stahl, 1996]. Hence, education 
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in the language and principles of chemical neurotransmission is crucial for a better 
understanding of the impact of neurological and neuropsychological diseases on the 
central nervous system and to interpret the behavioral consequences of 
antipsychotics [Stahl, 1996]. This can be achieved through knowledge of the 
mechanism of neurotransmission in pre- and postsynaptic neurons. 
Neurotransmission includes transmission of signals from the presynaptic neuron 
through the synaptic gap into the postsynaptic neuron (see figure 1). The synapses 
are dynamic and constantly changing in the brain. The signals from the presynaptic 
neuron cause a rush of calcium ions into the synaptic bouton which bind to receptors 
on the inside. The calcium binding to calcium-sensitive proteins in the presynaptic 
membrane stimulates the vesicles carrying the neurotransmitters in the presynaptic 
neuron, which thereupon merge with the presynaptic membrane to release their 
neurotransmitters into the synaptic cleft. Released neurotransmitters bind to 
receptors in the postsynaptic neuron and cause the activation of specific pathways. 
Connecting neurons can send and receive synaptic information from other neurons 
with the help of a neurotransmitter [Stärker, 2001]. Since the synapse is the site of 
chemical neurotransmission, information transfer in the brain is vitally dependent on 
these processes.  
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Figure 1. The synapses and the neuronal receptors of antipsychotic drugs [Stärker, 2001]. 
Note. D1-D5 represent different dopamine receptors where especially antipsychotic medications bind. 
After the release of dopamine (DA) from the vesicle, it can either bind on its receptor and/or be 
received back to the vesicle through the autorecetor (A). Dopamin D2 autoreceptors modulate DA 
neuron firing, DA release, and DA synthesis through a negative feedback mechanism [Calipari et al., 
2014]. 
Neurotransmitters are chemicals synthesized in the presynaptic cell and stored in the 
vesicles until latter are stimulated. Examples of neurotransmitters are dopamine, 
serotonin, GABA, adrenaline, noradrenaline, acetylcholine and histamine. They are 
biochemical substances that transmit, enhance, or modulate chemical impulses from 
one cell to another (see figure 1). Once the neurotransmitter has been released from 
the presynaptic neuron, it diffuses across the synapse where it hits target sites on 
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receptors with high affinity for that specific neurotransmitter. The vast majority of 
drugs such as antipsychotics known to work in the central nervous system (CNS), act 
upon the process of neurotransmission [Stahl, 1996] such as the mesolimbic, the 
nigrostriatal, mesocortical and the tuberoinfundibular dopamine pathways. 
1.3 Pathways of Dopaminergic Neurotransmission  
Dopamine and its activity in different neuronal pathways (see figure 2) play an 
important role in the genesis of schizophrenic illness. The neuroanatomy of 
dopamine neuronal pathways in the brain can explain both the therapeutic effects 
and the undesired effects of antipsychotic agents. Changes in the rate of receptor or 
enzyme synthesis can affect the amount of neurotransmitter available for 
neurotransmission, and can thereby alter the neurotransmission process [Stahl, 
1996]. 
The mesolimbic dopamine pathway is thought to control behavior and produce 
delusions and hallucinations when overactive. The nigrostriatal dopamine pathway 
controls movement. When dopamine receptors are blocked by more than 80% in the 
postsynaptic projections of this dopamine system, it produces disorders of movement 
that can appear very much like those in Parkinson’s disease. Since the nigrostriatal 
pathway extends to basal ganglia, a part of the extrapyramidal neuronal system of 
the central nervous system, undesired effects such as extra pyramidal motor 
symptoms (EPMS) can occur. The mesocortical dopamine pathway is related to the 
mesolimbic pathway and its role lies in mediating positive and negative psychotic 
symptoms. The blockade of this pathway will help to reduce negative symptoms. The 
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tuberoinfundibular dopamine pathway controls prolactin secretion. When the 
dopamine receptors in this pathway are blocked, prolactin levels rise [Stahl, 1996]. 
Knowing the molecular causes of what leads to abnormal neurotransmission can lead 
to a rationale for developing an antipsychotic therapy for the treatment of 
schizophrenia [Stärker, 2001]. All antipsychotic drugs capable of treating positive 
psychotic symptoms of schizophrenia are blockers of dopamine receptors, 
particularly D2 dopamine receptors. This is because scientific studies have proved 
that dysregulation of DA at D2 receptors are most intimately associated with the 
positive symptoms of schizophrenia [Ginovart and Kapur, 2012]. 
 
Figure 2. Neuronal pathways of dopamine neurotransmission in CNS [Haen, 2012]. 
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1.4 Phases of Schizophrenia and Therapeutic Goals  
The aim of modern pharmacotherapy is to attain the highest possible level of 
functioning of patients by using effective drugs with doses that are as low as possible 
and as high as necessary [Haen, 2002]. In order to achieve this, the Drug 
Commission of the German Medical Association (AKdÄ) and the German Society for 
Psychiatry, Psychotherapy and Neurology (DGPPN) have compiled guidelines for the 
treatment of schizophrenic disorders with therapeutic recommendations that reflect 
the current state of science. According to these guidelines, schizophrenia is indicated 
when there is evidence of the existence of acute psychotic states and when chronic 
disease progression is associated with cognitive and social impairment [DGPPN, 
2006]. To attain the therapeutic goal in the acute phase a therapeutic relationship 
between the therapist and the patient must be established. Clarification of the 
sickness and treatment concepts, taking measures to eliminate or reduce the 
symptoms and the disease-related impairments are all aimed to preventing harm to 
self and society.   
The long-term psychotic phase occurs mostly when there is a relapse in the sickness. 
Early detection of an impending relapse and relapse prevention are very important in 
order to implement a proper stabilization concept. For psychological symptoms that 
are in remission or have subsided, stabilization measures such as treatment of 
cognitive and social deficits and other negative symptoms are initiated. 
Harmonization and stabilization of environmental conflicts such as social contacts, as 
well as preparation and maintenance of rehabilitative measures are some other 
significant factors for successful therapy. These are aimed at the promotion of 
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compliance, preventing suicides and improving the patients’ quality of life [Stärker, 
2001]. 
Individual therapeutic responses and the occurrence of antipsychotic undesired 
effects require careful selection of substances, concomitant medications, dose, and 
application procedures. An optimal dose can be assumed if a good effect on the 
whole spectrum of psychotic symptoms with differential focus in each phase (see 
figure 3) of the sickness is achieved with minimal undesired effects. Antipsychotics 
should be preferred that show less dose-dependent extra pyramidal motor syndrome 
(EPMS) and at the same time do not exhibit effects on positive symptoms, but 
demonstrate better efficacy against the negative symptoms [Advokat et al., 2000].  
 
Figure 3. Stages of schizophrenic treatment [Falkai et al., 2007]. 
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A risk-benefit assessment of different antipsychotics as depicted in figure 3 is 
necessary and in case of serious undesired drug effects, a switch to a more tolerable 
antipsychotic (based on individual patients) is more advisable. After remission of 
symptom, the dose can gradually be reduced and adjusted to a lower maintenance 
dose in long-term treatment. 
The key criterion for a better integration of the patients is not necessarily complete 
symptom remission [Falkai et al., 2007], but how patients cope with demands made 
on them at work and in social life despite possibly still experiencing symptoms. The 
goal of the therapy should therefore go far beyond a response to treatment on the 
symptom level [Kasper, 1999; Gabel et al., 2002]. Objectives of psychological 
treatments in schizophrenia are the reduction of individual vulnerability, reduction of 
undesired effects of external stressors, promoting compliance, and increasing the 
quality life of the patients. Examples of psychological treatments are (1) psycho-
education for optimizing the process of preventing symptom-recurrence, and (2) 
cognitive behavioral therapy to reduce the intensity of positive psychotic symptoms 
and to encourage flexibility in the process of abstract thinking (alogia) [Stahl, 1996]. 
1.4.1 Therapy with Antipsychotics – Differentiation of schizophrenia from 
Psychosis 
Antipsychotics are a group of medication indicated for the treatment of psychosis in 
general and schizophrenia in particular. Though schizophrenia is one of the best 
known types of psychotic sickness and the most common psychotic disorder, it is not 
synonymous with psychosis, but is just one of the many causes of psychosis 
[Cannon et al., 1997; Howard et al., 2000]. The integration of genetic vulnerability in 
the expression of a disease, life event stressors (such as divorce and financial 
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problems), the individual’s personality, coping skills, and social support available from 
others and other environmental influences are important factors involved in the 
formation of psychiatric disorders including psychosis and schizophrenia [Stahl, 
2000]. 
Psychosis can be considered as a set of symptoms in which a person’s mental 
capacity, affective response, and capacity to recognize reality, communicate, and 
relate to others is impaired. Psychosis can be paranoid, disorganized and/or 
depressive. Paranoid psychosis is accompanied with preoccupations of delusional 
beliefs (paranoid projections), expression of feelings of hostility (hostile belligerence) 
and hearing voices that praise and extol (grandiose expansiveness). Disorganized 
psychosis consists of a conceptual disorganization (giving answers that are 
irrelevant, drifting off the subject), disorientation, and excitement. Depressive 
psychosis is characterized by retardation, apathy (for example, the manifestation of 
unusually slow speech and fixed facial expression) and anxious self-punishment and 
blame (for example, the tendency to blame or condemn oneself and preoccupation 
with suicidal thoughts) [Stahl, 1996]. 
1.4.2 The Use of Antipsychotics for the Treatment of Schizophrenia 
Basic treatments of schizophrenia are antipsychotic drugs, which block primarily 
dopamine receptors. Antipsychotic treatment can vary notably in terms of specific 
antipsychotic drug, dose, duration of treatment, and combinations with additional 
psychotropic drugs and drugs used in internal medicine. Some antipsychotic drugs 
such as melperone (MLP), benperidol (BPD), haloperidol (HLP), bromperidol (BRP), 
flupentixol (FLT), and zuclopenthixol (ZLT) act on different neurotransmitter receptors 
that mediate their undesired effects but not their therapeutic effects, namely the 
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antihistamine properties (weight gain), alpha-adrenergic-blocking properties 
(undesired cardiovascular effects), and muscarinic-cholinergic-blocking properties 
(dry mouth) [Stahl, 1996]. Antipsychotics differ in their undesired effect profiles, but 
not in their overall therapeutic profiles, because the various antipsychotic agents 
differ in terms of their ability to block the receptors. Some antipsychotics are for 
example more sedating than others and some are more prone to cause undesired 
cardiovascular effects than others. However, all antipsychotics reduce psychotic 
symptoms, especially positive psychotic symptoms in the group of schizophrenic 
patients [Voruganti et al., 2000].  
In contrast to oral antipsychotics, depot antipsychotics are poorly soluble in water and 
are released from the depot form into the blood stream very slowly (depot effect). 
They therefore have a longer onset and duration of action compared with oral 
administration. Examples of some depot antipsychotics are, among others, 
haloperidol decanoate, flupentixol decanoate, zuclopenthixol decanoate and 
risperidone decanoate. The choice of antipsychotic agent for the treatment of 
schizophrenia is mostly carried out under the consideration of present symptoms and 
the therapeutic goals set by the attending clinicians [Jauhar et al., 2012]. 
Long-term undesired effects have lead to the pursuit of antipsychotic treatments that 
would reduce or eliminate such problems yet still be powerful antipsychotic agents 
against positive symptoms. Troublesome undesired drug effects also lead to 
noncompliance, since patients frequently wish to discontinue their medications to rid 
themselves of the undesired effects despite a high risk of relapse of psychotic 
symptoms. Therefore, therapy success critically depends on stable medication, 
medication dose, and appropriately advicing the patients and attending clinicians, 
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which will allow for an adequate control of the serum concentrations to avoid 
undesired drug effects [Fleischhacker et al., 1994]. 
1.5 Indication for the Therapeutic Drug Monitoring of Antipsychotics  
Therapeutic Drug Monitoring (TDM) is a clinical laboratory determination of specific 
drugs in human serum or plasma at stipulated intervals that, with appropriate clinic-
pharmacological interpretations, aims to optimize individual therapies. TDM is 
generally used for drugs with narrow therapeutic ranges (such as anticonvulsants, 
antipsychotics, immunosuppressants, and other psychotropic medications), drugs 
with marked pharmacokinetic variability, drugs for which target concentrations are 
difficult to monitor, and drugs known to cause therapeutic and severe undesired drug 
effects despite the usual clinical dose. TDM can also be used for case-specific 
indications such as suspected drug interaction, suspected intoxication, no or 
insufficient therapeutic response, recurrence under maintenance dose, prevention of 
relapse in long-term therapy, suspected noncompliance and expensive 
pharmacovigilance, children and young people, patients aged over 65 years, 
comorbidity, and forensic indications [Greiner, 2008]. TDM of antipsychotic drugs in 
the blood of pregnant or breastfeeding women can, for example, help to limit drug 
exposure to the fetus or the newborn [American Academy of Pediatrics, 2000]. 
The practical indication for the correct TDM of antipsychotics in the treatment of 
schizophrenia can be derived from the guidelines of the association for neuro-
psychopharmacology and pharmacopsychiatry (AGNP). It is aimed at guiding 
clinicians in choosing correct therapeutic doses of different medications for individual 
patients. It is also a useful tool to optimize and illustrate the psycho-pharmacotherapy 
and the analytical principles of pharmacokinetic, pharmacogenetic and the present 
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scientific state of knowledge concerning the relationship between the plasma 
concentration and the clinical effect [Greiner, 2008].  
In practice however, the clinical use of TDM is rather limited. Moreover, clinical 
studies about the relationship between the given dose and drug concentration in 
blood and evaluation of therapeutically effective concentrations are rare.  
1.5.1 The AGNP Guidelines for the Application of TDM 
The TDM working group of the association for neuro-psychopharmacology and 
pharmacopsychiatry (AGNP) published guidelines on the best practical use of TDM in 
psychiatry. Reported therapeutic concentration values are obtained through the 
determination of serum antipsychotic concentrations of different patients. Reported 
recommendations were obtained after a detailed review of reliable scientific sources 
[Baumann et al, 2004]. Criteria for the evaluation of the sources were the presence of 
the established therapeutic reference ranges (TRR) and the presence of controlled 
clinical trials, which supports the usefulness of TDM and also gives hints of increased 
toxicity at higher therapeutic concentrations. The TDM Rating Levels according to the 
AGNP Guidelines for the use of antipsychotics are listed in table 2. 
Table 2. Application of TDM in antipsychotic therapy according to the guidelines of the AGNP 
[Baumann et al. 2004]. 
Level Characteristic Advantage Antipsychotics 
1. Highly 
recommended 
Established TRR, 
presence of controlled 
clinical trials 
Prevention of toxic 
concentrations and thereby 
an enhancement in 
patients’compliance, the 
Amisulpride 
Clozapine 
Fluphenazine 
Haloperidol 
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efficacy and safety of drug 
therapy 
Olanzapine 
Perazine 
Perphenazin 
Thioridazin 
2. 
Recommended 
Presence of 
therapeutic guidelines 
by at least one 
prospective study with 
defined improvement 
criteria 
Improvement of the 
therapeutic concept through 
the use of TDM 
Aripiprazole 
Bromperidol 
Chlorpromazine 
Flupentixol 
Fluspirilen 
Paliperidone 
Quetiapine 
Risperidon (plus 
9-OH-
Risperidon) 
Sertindole 
Sulpiride 
Ziprasidone 
3. Beneficial 
Presence of 
therapeutic guidelines 
derived from 
pharmacokinetic 
studies in 
pharmacokinetic 
steady states with 
retrospective analysis 
of TDM data. 
Testing the plausibility of the 
measured concentrations at a 
given dose and to check if 
clinical improvement can be 
achieved by non-responders 
with very low serum 
concentration through dose 
increase. 
Benperidol 
Chlorprothixene 
Iloperidole 
Levopromazine 
Melperone 
Pimozide 
Pipamperon 
Zotepine 
Zuclopenthixol 
4. Potentially Presence of TDM is not recommended for Asenapine 
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beneficial therapeutic values 
derived from 
pharmacokinetic 
studies in 
pharmacokinetic 
steady states in the 
absence of valid 
clinical data 
dose- finding but it can be 
potentially useful for specific 
indications or specific 
problems. It should therefore 
be limited for specific issues. 
Prothipendyl 
Note: The different TDM rating levels for the measurement of medications in human serum give 
general information on the recommended medications for the practice of TDM in order to achieve an 
expected therapeutic goal.  
The DRR data for study antipsychotic medications are derived from studies of drug 
concentrations of healthy individuals or patients treated with a constant dose (see 
table 3). The calculation of the dose-related reference range is the calculation of the 
dose of a medication, which will lead to a steady state concentration. D = D x F/τ = c 
x Clt (D = constant dose per day at steady state, c = blood concentration, Clt = total 
clearance of the drug. [Haen et al., 2008; Hiemke et. al., 2011]. 
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Table 3. Consensus data for DRR and TRR of the applied substances. 
Substances Consensus 
(C/D-low) 
Consensus 
(C/D-high) 
Consensus 
(TRR-low) 
Consensus 
(TRR-high) 
Melperone 0.14 0.28 30 100 
Benperidol 0.15 0.31 1 10 
Haloperidol 0.61 (oral) 0.99  1 10 
0.07 (decano-
ate) 
0.12 
(decanoate) 
Bromperidol 0.09 0.19 1 10 
Flupentixol* 0.78 0.87 1 10 
Zuclopenthixol 0.13 0.35 4 50 
Note: C/D-low and C/D-high are factors for calculating dose- related reference range, TRR = therapeu-
tic reference range. 
* The flupentixol-DRR factor applied in this work was derived from the pharmacokinetic data of 
flupentixol applicable at the TDM laboratory (C/D for flupentixol oral = 0.66 – 1.74 and C/D flupentixol 
decanoate = 1.65 – 4.35), which is difference from that of consensus.  
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1.5.2 Chemical Groups of Antipsychotic Drugs Analysed in this Thesis 
The chemical groups of antipsychotics studied here in this thesis are butyrophenones 
and thioxanthenes, subgroups of phenothiazines (see figure 4–figure 7) for the 
structures of these antipsychotics. The “R” in these figures denotes possible 
substituents. The chemical differences in the active groups of these substituents are 
one of the explanations for their different pharmacological effects, and at times 
demand different analytical methods for their therapeutic drug monitoring (TDM). The 
explanation of TDM to ward clinicians will help in clinical decisions and in the 
enhancement of individualized therapy.  
Phenothiazines and thioxanthenes have basic side chains of different derivates in 
position 10 of their ring system (see figures 4 and 5). The tertiary amino group of the 
side chain is separated from the tricyclic system by three carbon atoms. The 
antipsychotic effect of the derivates with aliphatic side chains is in relation to the dose 
of the given medication relatively small but slightly higher in piperidine-substituted 
and most pronounced in piperazine-substituted derivates [Gothert et al., 2009].  
Thioxanthenes are classified as a sub group of phenothiazines. The difference from 
phenothiazines is that the N-atom in position 10 of the ring system is replaced with a 
carbon atom (see figure 4). The side chain in Thioxanthenes is connected by a 
double bond to the ring system (see figure 5). An additional substitution in position 2 
leads to cis-isomers. The cis-isomers have higher antipsychotic potency than the 
trans-isomers. Flupentixol and zuclopenthixol belong to the thioxanthenes with a 
piperazine side chain. They are high-potency antipsychotics used in the treatment of 
different schizophrenic and psychotic symptoms. Their side effect profile and mode of 
action are similar to that of butyrophenones despite the differences in chemical 
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structure and dopamine receptor affinity. This is because they have a common site of 
drug action at the dopamine receptor subtype-D2 [Gothert et al., 2009].  
The potency of antipsychotic drugs is based on the ability of the drug to bind to the 
receptors. High-potency antipsychotics have for example a high affinity for the 
dopamine-2 (D2) family of dopamine receptors [Gothert et al., 2009].  
 
Figure 4. The substitution on the N-atom of the phenothiazine ring. 
 
 
Figure 5. The thioxanthene ring. 
Note: Substitution connected by a double bond to the ring system and the substitution of the H-atom at 
position 2. 
 
Butyrophenones and diphenylbutylpiperidenes have as a common structural feature 
a quadrinomial alkyl chain which closes with a piperidine ring and in some 
butyrophenones with a piperazine ring (see figure 6 and 7). The intensity of their 
antipsychotic effect can be compared to that of phenothiazines with piperazine side 
chain [Gothert et al., 2009]. Butyrophenones exhibit their pharmacological action on 
phenothiazine derivate 
thioxanthene derivate 
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the D2 receptors in the dopamine pathways, and thus allow the treatment of different 
psychotic disorders.  
 
Figure 6. Quadrinomial alkyl chain closes with a piperazine ring. 
 
Figure 7. The piperazine ring is substituted with a phenyl ring. 
Common undesired drug effects of butyrophenones and phenothiazines are EPMS, 
tremors and dry mouth. A discontinuation of antipsychotic drug treatment can be 
associated with patients’ vulnerability to relapse and the development of induced 
undesired drug effects which varies based on several factors such as gender, age, 
and pharmacokinetic interactions of the medication and/or co-medications taken by 
the patients [Kanner and Frey, 2000]. 
1.5.3 Determination of Serum Antipsychotic Concentrations 
The contribution of pharmacokinetic variability to differences in dose requirements of 
antipsychotics can be identified by measuring the serum concentration at a steady-
state (after at least 5 elimination half-lives by a constant dose) and modifying the 
butyrophenone derivate 
diphenylbutylpiperidene derivate 
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dose to attain a desired therapeutic concentration. Melperone has a mean elimination 
half-life of 6 ± 2 hours, benperidol 7.65 hours, haloperidol 22 ± 1 hours, bromperidol 
36 hours, flupentixol 29 ±1 hours [Jorgensen, 1980], and zuclopenthixol 20 hours. 
The information regarding the elimination half-life of the drugs mentioned was taken 
from their respective summary of product characteristics. 
An appropriate evaluation of the measured concentration requires the acquisition of 
correct timed blood samples. It is therefore recommended to draw blood samples at 
trough or just before the next dose, for example, in the morning before the first 
medication-intake, in the case of two or three daily administrations, and after the 
elapse of 24 hours since the last dose, in the case of once-a-day morning 
administration. In this way, the lowest concentration during the steady state, which is 
not strongly subjected to inter-individual variation, absorption and distribution 
problems, is less likely to be influenced. If the serum sample is drawn before 
distribution of antipsychotics into tissues is complete, the obtained concentration after 
measurement may be higher than the expected dose-related reference range and will 
lead to a false laboratory result and its clinical interpretation [Hiemke et al., 2011]. 
The dose-related reference range (DRR), the therapeutic reference range (TRR), the 
maintenance dose, co-medications and individual factors, like illness and age are 
some TDM tools for the control of serum antipsychotic concentrations. Significant 
numbers of patients who do not respond effectively to antipsychotic therapy, because 
of some pharmacokinetic and pharmacodynamics reasons [Hiemke et al., 2005] will 
thus be helped through TDM.  
A dose-related reference range (DRR) is a concentration range in which serum 
concentrations of a drug can be calculated with a given dose of the drug. It indicates 
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whether the measured concentration is within the expected range and if the 
administered dose is enough to yield the expected therapeutic concentration. There 
is a proportional relationship between the dose and drug concentration in 
pharmacokinetic balance (see table 3). The calculation is done based on the direct 
correlation between the drug dose D (maintenance dose in mg) to its concentration in 
serum c (ng/ml), and with the total clearance of the drug Clt (l/h) being the correlation 
coefficient D = D/ τ = c x Clt [Haen and Greiner, 2009]. The concentration of 
antipsychotics in human serum can however be influenced by the biological activities 
of some known metabolites [Calligaro et al., 1997; Sharma et al., 2005].  
The therapeutic reference range (TRR) is an optimum concentration of a particular 
drug in blood that gives the intended benefit, while minimizing or avoiding undesired 
effects. “It assumes that there is a plasma concentration range of the drug which is 
characterised by maximal effectiveness and maximal safety” [Hiemke et al., 2011]. 
The lower limit of the therapeutic reference range is the one derived from the mean 
plus one standard deviation (MW + 1SD) of the drug concentration evaluation of 
patients, who responded to the therapy after two weeks of drug administration. The 
therapeutic response is assessed according to the corresponding disease scale for 
schizophrenia when 84.14% of the measured value can be found on the scale [Sachs 
and Hedderich, 2006]. The upper limit of the therapeutic reference range indicates 
that at a particular concentration, 15.87% of the patients suffered from undesired 
drug effects. This upper limit should, however, be separately measured depending on 
the expected undesired effects such as EPMS und hypotension.  
The therapeutic reference range gives a population-based value that is applicable to 
all patients. Individual patients can show an optimal therapeutic response at a drug 
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concentration outside the given therapeutic reference range. Eventually, an 
“individual therapeutic concentration” of each patient in which an optimal response to 
the psycho-pharmacotherapy exists has to be identified [Hiemke et al., 2011]. The 
therapeutic reference ranges of antipsychotic drugs are supported by studies that 
have shown correlations between the serum concentrations and therapeutic effects 
[Hiemke et al., 2011]. 
In the TDM laboratory in Regensburg, the active metabolites of antipsychotics are 
measured and considered as well during the calculation of the measured 
concentrations. Drugs with inactive metabolites are calculated without the 
consideration of such metabolites. Examples of pharmacokinetic parameters for the 
calculation of an orally administered antipsychotic are listed in table 4. 
Table 4. Pharmacokinetic parameters of the orally administered study substances  
Substances 
 
 
 
 
Number 
of patient 
(n) 
 
                                                                    
Total 
clearance 
(Clt) 
 
ml/min 
Daily dose* 
 
 
 
mg 
Elimination 
half-life  
(t1/2) 
 
hour 
Bioavailability 
(F) 
 
 
% 
Excretion 
 
MLP 6 
1484-2898 25-400 mg /1-3 
times per day 
4-6 
60 Faeces* 
BPD 14 
1073-2240 1-40 mg 
/1-3 times per 
day 
Ca. 5 
50 Faeces* 
HLP 6 
420-680 3-15 mg/day 
12-36 
60 Faeces 
and urine* 
BRP 14 3570-7938 1-10 mg/ day 20-36 30* Faeces 
FLT 3 440-490 5-20 mg/ day 20-40 60 Faeces* 
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ZLT 8 
867-2300 2-50 mg  
distributed 1-3 
times/ day 
15-25 
40 Faeces* 
Note: According to TDM consensus, 2011, pharmacokinetic parameters of melperone [Borgstrom et 
al., 1982], pharmacokinetic parameters of benperidol [Seiler et al., 1994], pharmacokinetic parameters 
of haloperidol [Cheng et al., 1987], pharmacokinetic parameters of bromperidol [Lee et al., 2006], 
pharmacokinetic parameters of flupentixol [Jorgensen, 1980], and Pharmacokinetic parameters of 
zuclopenthixol [Jerling et al., 1996].  
* = information from the summary of product characteristics (SPC) for Melperon, Glianimon, Haldol, 
Impromen, Fluanxol, Ciatyl-Z. Substance excretion of MLP, BPD, BRP, FLT and ZLT through the urine 
is less than 10 %. 60% HLP is excreted through the faeces and 40 % through the urine. Individual 
dosing of all the study substances was recommended in their respective SPC. 
 
According to table 3, Jorgensen, 1980 expressed the value of the total clearance 
(0.44-0.49) in l/min which corresponds to 440-490 ml/min. Total clearance is the 
elimination of the drug from all the metabolizing/eliminating organs of the body, 
mainly liver and kidney, by scaling the drug elimination rate by the corresponding 
plasma concentration. Irrespective of the intra-individual variation observed during 
the estimation of the elimination half-life (t1/2), Jorgensen, (1980) gave 24 hours as a 
reasonable dose interval (τ ) for an oral flupentixol medication. The reason for the low 
bioavailability (F) was a result of the first part metabolism in the liver or an incomplete 
absorption of flupentixol [Jorgensen, 1980]. How long it will take to reach the steady-
state concentration was not mentioned in his work, but applying the given t1/2 , it could 
be assumed that the steady-state concentration of orally administered flupentixol will 
be reached between 4-8 days. Steady-state concentration (Css) is the serum 
concentration reached after five elimination half-life. That is when the rate of 
absorption of a medication is equal to the rate of elimination of the same medication. 
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Css is dependent on the dose, the dose interval, the bioavailability and the clearance 
{(C=D x F)/( τx Clt ±SD)}. 
The use of pharmacokinetic equations enables a mathematical calculation of the 
dose-related reference range of flupentixol. The proportionality factor (the reciprocal 
of the clearance and its variation) must be multiplied by the daily dose of the patient 
to obtain a defined range where 68.27% of the drug concentration is located. The 
upper value of the dose-related reference range is obtained by subtracting the 
standard deviation from the clearance, and the lower value of the dose-related 
reference range is obtained by adding the values of the standard deviation and the 
clearance (see table 5). The drug concentrations must correspond to the population 
in which the drug constant for the proportional relationship between dose and 
substance concentration was measured [Haen et al., 2008].  
Table 5. Example of calculating dose related reference range using available pharmacokinetic 
parameters for flupentixol. 
Parameter Equation 
Maintainance dose (D) 𝐷 =
𝐷
𝜏 
= 𝑐 𝑥 𝐶𝑙𝑡 
Concentration (c) C =
𝐷 𝑥 𝐹
τ x Clt
 
Concentration (css) Css = 𝐷 𝑥 
 𝐹
τ x Clt ± SD
 
Concentration (c) by F = 54%  C = 𝐷 𝑥 
 0.54
24h x (Clt ± SD)
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Concentration (c) by lower value of the dose-related 
reference range 
C = 𝐷 𝑥 
 0.54
τ x Clt +  SD
 
Concentration (c) by upper value of the dose-related 
reference range 
C = 𝐷 𝑥 
 0.54
τ x (Clt −  SD)
 
Note: D: dose, Clt: total clearance, t: time, F: bioavailability, τ: dose interval, SD: standard deviation.  
 
1.5.4 Description of the Nine-Fold Table for the Interpretation of Antipsychotic 
TDM 
A detailed overview of the relationship between the dose-related reference range and 
the therapeutic reference range is shown in the nine-fold table (see table 6). 
Drug substance can be defined by dose-related reference ranges and therapeutic 
reference range as “too low”, “expected” or “too high”, rated in relation to the 
administered dose and in relation to the therapeutic reference range. With the help of 
a nine-fold table, these 3 x 3 different ratings can be plotted against each other. The 
column shows the three possibilities for rating the therapeutic reference range 
(column A–C) and the horizontal line shows the three ratings of the dose-related 
reference range (lines 1–3). The nine-fold table enables a possible interpretation of 
the laboratory measurement under the consideration of both reference ranges. Nine 
interpretation constellations are possible for a single measurement. 
With the information shown on table 6, assuming that there are no concomitant 
medications and that the blood sample was taken before the next medication intake, 
the patient can be considered compliant, and the possibility of developing undesired 
effects is lower at this point, because the concentration is within the therapeutic 
reference range. Nevertheless, it cannot be considered a successfull therapy 
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because of high interindividuality of antipsychotic medications. The dosing of this 
group of medication strictly demands individual therapy for it to be as successful as 
expected.  
Table 6. An overview of the nine-fold table. 
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Concentration in Relation to Therapeutic Reference Range 
 
Too low expected Too high 
A B C 
Too low 1    
expected 2  X  
Too high 3    
Note: The letter "X" in B-2 of the nine-fold table shows that the measured concentration is within the 
DRR and also within the TRR.  
 
1.5.5 Serum Antipsychotic Concentration and Clinical Pharmacological Report 
To properly interpret a serum concentration, the TDM team must be informed about 
the maintenance dose, when the serum sample was taken in relation to the last 
administered dose, and when the therapy was initiated. To meet individual variations 
at the TDM laboratory, the response of the drug concentration is ideally 
supplemented by commentaries in the form of clinical pharmacological reports that 
provide clues to the cause of either “too high” or “too low” concentration in relation to 
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the dose administered to the patients. In this ways, the attending clinicians can 
therefore select suitable drugs for their patients at optimal applicable doses while 
taking into consideration the overall context of the pharmacotherapy [Greiner and 
Haen, 2007]. 
The existence of individual biological differences in the level of absorption such as 
food absorption, the differences in the metabolism due to polymorphisms of 
cytochrome P450 isoenzymes, xenobiotic transporters, drug interactions and the 
differences in the elimination activities of the body due to pathological changes of the 
excretory organs [Trenton et al., 2003] are always considered during the therapeutic 
drug monitoring. The above-mentioned difference makes it difficult to predict the 
exact concentration of the administered drugs in individual patients. Therefore the 
measurement of serum antipsychotic concentrations and its clinic-pharmacological 
interpretation for special groups of patients such as children and elderly patients is of 
particular importance.  
The metabolic systems of children are not fully developed, and may lead to higher 
concentrations when an adult dose is given. Older people are often affected by 
functional limitations of the excretory organs, such as the kidney and liver. Therefore 
a reduction of the clearance and an increase in the elimination half-life of the 
ingested drug are applied. The retention time of the drug in the body grows, and the 
concentrations of the active substance increase at a constant dose. A vast number of 
drug interactions caused by polymedications [Cozza et al., 2003] can lead to 
ineffectiveness of the drug in question as well as increase or decrease the serum 
drug concentrations through the inhibiting and inducing effects of the co-medications 
on the metabolizing enzymes.  
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Smoking is one of the factors that has been proven to affect the effectiveness of 
certain antipsychotic medications such as clozapine due to common metabolic 
pathways of nicotine and clozapine on CYP 1A of the cytochrome P450 system. The 
influence of narcotics [Haen and Wodarz, 1999], on the antipsychotic medications 
can be observed in the low serum concentrations often reached by smokers who are 
treated with clozapine. The explained relevant factors are summarized in the clinic-
pharmacological reports depending on individual case and measured drugs. 
1.6 Different Analytical Methods  
Medical professionals and researchers use different methods to predict patients’ 
responses to targeted therapies. Seiler et al. (1994) reported the pharmacokinetics 
and bioavailability of benperidol in schizophrenic patients. Their focus was on the 
pharmacokinetic and bioavailability differences of the various application forms (oral 
and intravenous) of benperidol [Seiler et al., 1994]. In their study, the plasma 
concentrations were determined by using high performance liquid chromatography 
and electrochemical detection (HPLC/EC). HPLC/EC is sensitive because it entails 
the use of high voltage that can be problematic in monitoring antipsychotics in 
plasma. Food and concomitant medications, however, can interfere with the target 
medication. Different plasma materials such as plasma proteins can influence the 
sensitivity and stability of the electrodes and cause false measurements of the 
targeted medication, and will thereby lead to false results.  
Furlant et al. (1987) also reported the determination of benperidol in human serum 
using an HPLC/ EC method. Although only a small volume of serum (1 ml) was 
required to obtain a desirable detection limit of 0.2 ng/ ml for benperdiol, the above-
mentioned disadvantages of HPLC/EC still remain a problem [Furlant et al., 1987]. 
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Furlant et al. (1987) and Seiler et al. (1994) applied similar analytical method 
(HPLC/EC) for their research, using the same substance (benperidol). Furlant et al. 
(1987) laid emphasis on the serum determination of benperidol, whereas Seiler et al. 
(1994) laid emphasis on the bioavailability of the different pahrmaceutical forms of 
benperidol in serum. 
Hiroshi et al. (2000), analyzed various butyrophenones and their analogues in whole 
blood by means of HPLC/MS. They succeeded to detect five butyrophenones and 
two analogues at a detection limit of 0.1 ng/ml [Hiroshi et al., 2000]. The use of 
HPLC/MS, however is complex. It is expensive and requires great expertise in order 
to operate. Many TDM laboratories cannot afford to operate under these conditions. 
They need simple analytical equipment which they can afford, for the measurment of 
drugs in human serum.   
The application of HPLC/MS for the simultaneous determination of clozapine, 
olanzapine, risperidone and quetiapine in plasma was also reported by Zhou et al. 
(2004). The samples were alkalinized and extracted twice before the HPLC 
preparation and measurement could take place [Zhou et al., 2004]. This is a delay in 
the analytical preparation, which will be avoided if the double extraction procedures 
are not applied.  
Zhu et al. (1998) reported the use of gas chromatography-mass spectrometry 
(GC/MS) with selected ion monitoring to determine clozapine (CLP) and its N-
demethylated metabolite in serum. The paper shows that the expected results were 
obtained and successfully used in clinical pharmacokinetic study of CLP [Zhu et al., 
1998]. The described GC/MS method in this paper requires an intensive preparation 
of the samples before measurement. GC is limited to volatile samples and it is not 
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suitable for temperature sensitive substances. The intensive preparation applied in 
this method is not time-saving and the limitation to volatile and temperature sensitive 
substances is a disadvantage to the robustness of the method, especially when other 
co-medications and unknown materials are present in the serum. MS as already 
explained above is expensive and operated by experts.  
The use of reversed-phase high performance liquid chromatography with ultra-violate 
detection (HPLC/UV) for determination of phenothiazines in human serum was 
described by Tanaka et al. (2007). He simultaneously separated twelve 
phenothiazines in human serum, with detection limits of 3.2 – 5.5 ng/ml. However, 
the authors needed a pre-step procedure before they could measure the substances 
[Tanaka et al., 2007]. Also, the high detection limits are not suitable for the serum 
determination of antipsychotics with low therapeutic refence range [Hiemke et al., 
2011] such as benperidol, haloperidol, and flupentixol (1– 10 ng/ml) substances.  
Other methods reported in the literature such as gas chromatography with nitrogen-
phosphorus [Bianchetti and Morselli, 1978] and the use of immunoassay for the 
determination of carbamazepine and phenytoin [Krasniqi et al., 2010] are time-
consuming and are not common methods for routine measurements in many 
therapeutic drug monitoring laboratories. 
There is a need for a new method to overcome the disadvantages of the currently 
available methods. 
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2 Aims and Objectives 
The objective of this thesis was the development of a method for the simultaneous, 
qualitative and quantitative measurement of melperone (MLP), benperidol (BPD), 
haloperidol (HLP), bromperidol (BRP), flupentixol (FLT) and zuclopenthixol (ZLT) in 
human serum. In order to meet the needs of clinicians and patients the method 
should be less expensive, more precise, faster, and also more reliable than existing 
methods. It should have the potential to be used in small-scale TDM laboratories. 
MLP, BPD, HLP, BRP,  FLT, and ZLT are frequently encountered in clinical 
toxicology, clinical pharmacology and forensic chemistry, generally for the treatment 
of schizophrenia and psychotic disorders. They have narrow therapeutic ranges and 
the quantity required to be effective is near the quantity that causes significant 
undesired effects such as EPMS. The low therapeutic reference ranges, including the 
inter-individuality in their metabolism, lead to the necessity of monitoring their 
therapeutic dosages and serum concentrations. Maintaining their steady state and 
determining an accurate individual therapeutic dose therefore requires an effective 
and practicable analytical method in measuring their concentrations in human serum. 
The application of TDM to antipsychotic drugs requires a valid analytical procedure 
for the measurement of drugs in human serum. This is also the condition for an 
effective TDM service [Hiemke et al., 2011].  
A method is necessary for the serum determination of these substances without 
interference to known and unknown impurities or other substances in human serum. 
The method should allow that many substances can be reliably measured at the 
same time. This will save time and also meet the needs of the clinicians and patients. 
TDM laboratories, especially the small-scale laboratories require a simple, precise 
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and less expensive method for the individual monitoring of antipsychotics in human 
serum. It should be a simple procedure without a pre-extraction phase, because this 
will enable a faster measurement and interpretation of the results for the benefits of 
the patients, waiting for the outcome of the measurement for continuation of their 
therapy.  
Summarizing the requirements, it was aimed to develop and validate a simple, rapid, 
inexpensive and robust method for determination of MLP, BPD, HLP, BRP, FLT, and 
ZLT in human serum. The method should also ensure measurements of low 
concentrations, especially for antipsychotics with narrow therapeutic ranges. 
MLP, BPD, HLP, BRP, FLT, and ZLT (with the exception of haloperidol) could not 
reliably and simultaneously be detected till date, with the already existing methods 
(see section 1.6) in small scale TDM laboratory such as the TDM laboratory in 
Regensburg. At the TDM laboratory in Regensburg, for example, haloperidol can be 
measured simultaneously with risperidone and paliperidone Therapeutic drug 
monitoring also includes clinical interpretation of the result. This requires expert 
knowledge to ensure that TDM promotes individualized therapy.  
This thesis presents an approach to solve these problems. The majority of 
established methods are either expensive, time-consuming, not sufficiently robust, 
limited to particular substance group (such as volatile substances by GC), very 
sensitive and /or they require special experts for the operation. This is a problem that 
should be resolved, so that especially small-scale TDM laboratories can operate with 
a simple, faster and precise method in measuring drug concentrations in human 
serum with the financial means available to them.  
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The research work for the development of a new analytical method, as well as 
relating the received laboratory results to daily clinical application of drugs, in order to 
help clinicians in promoting individualized antipsychotic therapy will be described. 
 
Questions Raised 
Based on the presented problems, the following questions were formulated: 
 Which HPLC method that uses isocratic or gradient elution is 
appropriate under the available laboratory condition for the separation 
of antipsychotics? 
 How can the given acceptance criteria for the validation of analytical 
methods be achieved? 
 How can these substances simultaneously be measured without 
interference? 
 How can this method provide reliable measurements for antipsychotics 
with low therapeutic concentrations and ranges expecially melperone, 
benperidol, haloperidol, bromperidol, flupentixol and zuclopenthixol? 
 How can users of this method in small-scale TDM laboratories be 
enabled to operate it without the involvement of specially trained 
experts? 
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3 Materials and Methods 
This secton is focused on the HPLC instrumentation applicable for the method 
development and the experimental works. At first, the applicable instruments and 
chemicals were introduced and subsequently the HPLC methods already in use and 
the different tests carried out for the method development are described. The last 
part of this section deals with the method for the analytical determination of the study 
substances in human serum through TDM and its clinical application. 
3.1 Materials 
The already existing materials at the TDM laboratory Regensburg and the materials 
to be tested for the new HPLC method development are described in the following 
sections. 
3.1.1 Laboratory Instrumentation 
A vortex device from Heidolph REAX TOP (Schwabach, Germany) and a Megafuge 
2.OR from Heraeus GmbH (Osterode, Germany) were applied for shaking and 
centrifugation. The HPLC system (Dionex GmbH, Idstein, Germany) consists of a 
P680LPG pump and a P680 series binary pump, an Ultimate 3000 auto sampler, a 
Rheodyne 6 port valve for automated column switching, a Lichrospher ADS-RP-4 
column for online sample preparation, a C18 reversed phase analytical column 
(Phenomenex Luna Phenyl-hexyl, 150 x 3.0 mm; 3 µm particle diameter) with a C18 
reversed phase guard column (Phenomenex Luna Phenyl-hexyl, 4 x 2.0 mm) from 
Phenomenex LTD (Aschaffenburg, Germany), a C18 reversed phase analytical 
column (Nucleodur 100-3 CN-RP, 150 x 4.6 mm; 3 µm particle diameter) with a C18 
reversed phase guard column (EC guard column 4 x 3 mm), a TCC 100 column 
 36 
 
oven, and a photodiode array detector (DAD-320S) for photometric detection at 
variable wavelengths. The list of the analytical columns applied during the method 
development can be found in table 7. The column properties are reported according 
to the manufacturers’ information. 
Table 7. Test analytical columns for the HPLC method development. 
Analytical Column 
Dimension 
(mm) 
Particle Size 
(µm) 
Column Manufacturer 
BetaBasic C4 150 x 4.6 mm 3 µm 
Thermo  
(Dreieich, Germany) 
BetaBasic C4 150 x 4.6 mm 5 µm 
Thermo  
(Dreieich, Germany) 
Betasil C8 250 x 4.6 mm 5 µm 
Thermo  
(Dreieich, Germany) 
Gemini C6  150 x 4.6 mm 5 µm 
Phenomenex  
(Aschaffenburg, Germany) 
Gemini-Nx C18 150 x 4.6 mm 5 µm 
Phenomenex  
(Aschaffenburg, Germany) 
Hypersil ODS 250 x 4.6 mm 5 µm 
Thermo  
(Dreieich, Germany) 
LiChrospher CN 250 x 4.6 mm 5 µm 
Mainz-AT  
(Mainz, Germany) 
Luna CN 250 x 4.6 mm 5 µm 
Phenomenex  
(Aschaffenburg, Germany) 
Luna Phenyl-Hexyl 150 x 3.00 mm 3 µm 
Phenomenex  
(Aschaffenburg, Germany) 
Luna Phenyl-Hexyl 150 x 3.00 mm 5 µm 
Phenomenex  
(Aschaffenburg, Germany) 
Nucleodur
 
100-3, CN-RP 150 x 4.6 mm 3 µm 
Macherey Nagel  
(Düren, Germany) 
Nucleosil C8 EC 150 x 4.6 mm 3 µm 
Macherey Nagel  
(Düren, Germany) 
PerfectSil 120 ODS-L 250 x 4.6 mm 5 µm 
Mainz-AT  
(Mainz, Germany) 
SphereClone ODS (2) 150 x 4.6 mm 5 µm 
Phenomenex  
(Aschaffenburg, Germany) 
Thermo Betasil C6  250 x 4.6 mm 5 µm 
Thermo  
(Dreieich, Germany) 
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Xterra Schild C18 100 x 4.6 mm 3. 5 µm 
Waters  
(Eschborn, Germany) 
Note: Though column materials from different manufacturer possess the same material, they do not 
exhibit the same characteristics during analytical procedures.   
3.1.2 Reagents and Chemicals 
Melperone hydrochloride (MLP) was obtained from Nordmark (Uetersen, Germany); 
desmethylcitalopram (DMC) from Lundbeck (Kopenhagen, Denmark), benperidol 
(free base-BPD) from Abbott Company (Wiesbaden, Germany); Haloperidol (HLP) 
and Doxepin (free base-DOX) were both obtained from Sigma-Aldrich (Steinheim, 
Germany), Bromperidol (BRP) from Janssen Cilag (Neuss, Germany), flupentixol-
dihydrochloride (FLT) and zuclopenthixol dihydrogenchloride (ZLT) from Bayer 
HealthCare AG (Leverkusen, Germany) respectively. Drug-free pool serum was 
obtained from healthy volunteers at the university hospital Regensburg, Germany. 
Oasis HLB cartridges was from Waters Corporation (Eschborn, Germany). Methanol, 
acetonitrile, TEMED (tetramethylethylendiamine), and phosphoric acid (all of HPLC 
grade) were purchased from Merck GmbH (Darmstadt, Germany). Demineralized 
water (Aqua dem.) used throughout the method development was produced by a 
Milli-Q Gradient A10 water purification system from Millipore (Bedford, MA, USA). 
The list of other chemicals already applicable in the TDM laboratory, which also 
served for experimental purposes during the method development, is shown in table 
8. 
Table 8. Active substances found in the antipsychotic co-medications. 
Substance 
Molecular Weight 
(g/mol) 
Manufacturer 
10-hydroxy-carbazepine 254.3 Novartis (Basel, CH) 
9-OH-Risperidone 420.5 Bio Trend (Köln) 
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Acetylsalicylic acid  180.2 Sigma-Aldrich (Steinheim) 
Alprazolam  308.8 Sigma-Aldrich (Steinheim) 
Amantadine (HCl) 187.8 Sigma-Aldrich (Steinheim) 
Amisulpride  369.5 Sanofi Aventis (Frankfurt a. M.) 
Amitriptyline (HCl) 313.9 Sigma-Aldrich (Steinheim) 
Amitriptylinoxide dihydrate  329.4 Sanofi Aventis (Frankfurt a. M.) 
Amlodipine besilate  567.1 Pfizer (Freiburg) 
Aripiprazole  448.4 
Bristol Meyers Squibb (Princeton, 
USA) 
Ascorbic acid  176.1 Sigma-Aldrich (Steinheim) 
Benperidol  381.4 Abbott (Wiesbaden) 
Biperiden (HCl)  347.9 Abbott (Wiesbaden) 
Bisoprolol hemifumarate 767.0 Merck KG (Darmstadt) 
Bromazepam  316.2 Sigma-Aldrich (Steinheim) 
Bromperidol  420.3 Janssen Cilag (Neuss) 
Bupropion (HCl)  276.2 Glaxo Smith Kline (Durheim, UK) 
Buspirone (HCl)  385.5 Sigma-Aldrich (Steinheim) 
Caffeine 194.2 Sigma-Aldrich (Steinheim) 
Carbamazepine  236.3 Sigma-Aldrich (Steinheim) 
Carbamazepine-10,11-epoxide  252.3 Sigma-Aldrich (Steinheim) 
Chlordiazepoxide (HCl) 336.2 Sigma-Aldrich (Steinheim) 
Chlorprothixene (HCl)  352.3 Sigma-Aldrich (Steinheim) 
Cisaprid 466.0 Sigma-Aldrich (Steinheim) 
Citalopram  324.4 Sigma-Aldrich (Steinheim) 
Citalopram (HBr)  405.3 Sigma-Aldrich (Steinheim) 
Clobazam  300.7 Sigma-Aldrich (Steinheim) 
Clomipramine (HCl) 351.3 Sigma-Aldrich (Steinheim) 
Clozapine  326.8 Sigma-Aldrich (Steinheim) 
Clozapine-N-oxide 342.8 Sigma-Aldrich (Steinheim) 
Dehydroaripiprazole  447.4 Labor Dr. Mark (Worms)  
Desipramine (HCl)  302.9 Sigma-Aldrich (Steinheim) 
Desmethylcitalopram (HCl) 347.0 Lundbeck (Kopenhagen, DK) 
Dextrane 162.1 Sigma-Aldrich (Steinheim) 
Diclofenac-Natrium  318.1 Sigma-Aldrich (Steinheim) 
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Dihydrocodeine hydrogentartra-
te  
451.5 Sigma-Aldrich (Steinheim) 
Dimethylbiguanide (HCl)  165.6 Sigma-Aldrich (Steinheim) 
Doxepin (HCl)  315.8 Sigma-Aldrich (Steinheim) 
Duloxetine (HCl)  333.9 Lilly (Indianapolis, USA) 
Enalapril maleate   492.5 LKT Laboratories (St. Paul, USA) 
Estradiol  272.4 Sigma-Aldrich (Steinheim) 
Fluoxetine (HCl) 345.8 Sigma-Aldrich (Steinheim) 
Flupentixol (x 2HCl)  503.1 Bayer HealthCare AG (Leverkusen) 
Fluperlapine 309.4 Biomol (Hamburg) 
Fluphenazine decanoate  591.8 FineChemicals (Eppindust, ZA) 
Fluvoxamine maleate  434.4 Solvay Pharma (Weesp, NL) 
Furosemide  330.7 Sigma-Aldrich (Steinheim) 
Gabapentin  171.2 Pfizer (Freiburg) 
Galantamine (HBr) 368.3 Alexis Biochem (Lausen, CH) 
Glimepiride  490.6 Sanofi Aventis (Frankfurt a. M.) 
Haloperidol  375.9 Sigma-Aldrich (Steinheim) 
Hydrochlorothiazide  297.7 Sigma-Aldrich (Steinheim) 
Imipramine (HCl)  316.9 Sigma-Aldrich (Steinheim) 
Lamotrigine  256.1 Glaxo Smith Kline (Durham, UK) 
Levodopa  197.2 LKT Laboratories (St. Paul, USA) 
Levomepromazine (HCl) 364.9 Tropon (Köln) 
Lorazepam  321.2 Sigma-Aldrich (Steinheim) 
Maprotillin (HCl)  313.9 Sigma-Aldrich (Steinheim) 
Melperone (HCl) 299.8 Nordmark(Uetersen) 
Memantine (HCl)  215.8 Enzo Life Science (Lausen, CH) 
Methylrisperidone  420.5 Sigma-Aldrich (Steinheim) 
Metoprolol tartrate  684.8 Sigma-Aldrich (Steinheim) 
Mianserin (HCl)  300.8 Sigma-Aldrich (Steinheim) 
Mirtazapine  265.4 Organon (Oberschleißheim) 
Monohydroxycarbamazepine 254.3 Novartis (Basel, CH) 
Nateglinide  317.4 Novartis (Basel, CH) 
N-Desmethylclozapine 312.8 Sigma-Aldrich (Steinheim) 
N-Desmethylolanzapine 298.4 Labor Dr. Mark (Worms) 
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Nitrazepam  281.3 Sigma-Aldrich (Steinheim) 
Norclomipramine (HCl)  337.3 Sigma-Aldrich (Steinheim) 
Nordiazepam 270.7 Sigma-Aldrich (Steinheim) 
Nordoxepine (HCl) 301.8 Sigma-Aldrich (Steinheim) 
Nortriptyline (HCl)  299.8 Sigma-Aldrich (Steinheim) 
O-Desmethylvenlafaxine 263.4 Wyeth (Münster) 
Olanzapine  312.4 Lilly (Indianapolis, USA) 
Omeprazole  345.4 LKT Laboratories (St. Paul, USA) 
Oxazepam  286.7 Sigma-Aldrich (Steinheim) 
Oxcarbazepine  252.3 Novartis (Basel, CH) 
Pantoprazole-Natriumsalt  406.4 Altana (Konstanz) 
Paroxetine(HCl)  365.8 Glaxo Smith Kline (Durheim, UK) 
Perazinbishydrogenmalonate  571.7 Altana (Konstanz) 
Phenytoin  252.3 Sigma-Aldrich (Steinheim) 
Pipamperone (x 2HCl) 448.4 Janssen Cilag (Neuss) 
Pirenzepin (HCl)  424.3 Sigma-Aldrich (Steinheim) 
Pregabalin  159.2 Pfizer (Freiburg) 
Primidone  218.3 Sigma-Aldrich (Steinheim) 
Promethazine (HCl)  320.9 Sigma-Aldrich (Steinheim) 
Propranolole (HCl)  295.8 Sigma-Aldrich (Steinheim) 
Quetiapine  383.5 Astra Zeneca (Wedel) 
Quetiapine fumarate  883.1 Astra Zeneca (Wedel) 
Ramipril  416.5 LKT Laboratories (St. Paul, USA) 
Reboxetine  313.4 Pfizer (Freiburg) 
Risperidone  426.5 Sigma-Aldrich (Steinheim) 
Rivastigmine hydrogentartrate 400.4 Novartis (Basel, CH) 
Sertraline  306.2 Pfizer (Freiburg) 
Sultiame 290.4 Desitin (Hamburg) 
Sumatriptan  295.4 Glaxo Smith Kline (Durham, UK) 
Testosterone  288.4 Sigma-Aldrich (Steinheim) 
Theobromine 180.2 Sigma-Aldrich (Steinheim) 
Theophylline 180.2 Sigma-Aldrich (Steinheim) 
Topiramate  339.4 Janssen Cilag (Schaffhausen, CH) 
Triamcinolone acetonide 434.5 Sigma-Aldrich (Steinheim) 
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Triamterene  253.3 Sigma-Aldrich (Steinheim) 
Triazolam 343.2 Sigma-Aldrich (Steinheim) 
Trimipramine maleate  410.5 Sigma-Aldrich (Steinheim) 
Valproic acid  144.2 Sigma-Aldrich (Steinheim) 
Venlafaxine (HCl)  313.9 Sigma-Aldrich (Steinheim) 
Ziprasidone  449.4 Pfizer (Freiburg) 
Zopiclone  388.8 Sanofi Aventis (Frankfurt a. M.) 
Zuclopenthixol (x 2HCl)  473.9 Bayer HealthCare AG (Leverkusen) 
Note: These active substances were evaluated from the AGATE pharmacovigilance program. 
3.1.3 Human Serum for HPLC Analysis 
Drug-free serum was pooled from the employees of the clinic and polyclinic for 
psychiatry and psychotherapy, university of Regensburg at the district hospital 
Regensburg. In the absence of suitable material, drug free serum was also obtained 
commercially from PAA Company (Colbe, Germany). The suitable serum material 
was sent to TDM laboratory for the method development and for daily routine 
applications. The patient drug serum was obtained from whole blood by using serum 
monovette supplied from Sarstedt Company (Nümbrecht, Germany). The serum 
monovette contains synthetic granulate for progranulation. 
3.1.4 Study Antipsychotics 
The study antipsychotics MLP, BPD, HLP, BRP, FLT, and ZLT exhibit different 
physicochemical properties (see table 9). These differences will be considered in the 
selection of column materials, the choice of the adequate mobile phase and the 
applicable HPLC method development. Their chemical structures are displayed in 
figure 8. 
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Table 9. Differences in the physicochemical properties of the applied antipsychotics for use in 
TDM. 
Properties Butyrophenones 
Phenothiazines 
(Thioxanthene class)  
Molar mass (g/mol) 263.35–420.3 473.89-507.44   
Appearance White powder  White powder 
PKa 5.4–9.1 6.18–7.6 
Soluble Water, methanol Water, methanol 
Melting point (
o
C) 151.5-211 194-216 
Protein binding (%) ≤ 50 > 90  95 ≥ 98 
Note: The values were derived from the summary of product characteristics of the drugs, the reports of 
Venkatesh et al. (2010), Bundesanzeiger Nr. 5 from 09.01.1992, Brittain (2007), Vincent et al. (1980), 
and Moffat et al. (2003).  
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Figure 8. Chemical structures of antipsychotic groups for the method development. 
Note: Target drug substances for TDM in human serum. 
 
3.1.5 The Hospital and the Clinic Ward 
The district hospital at the University of Regensburg is equipped with 611 beds. It 
consists of several neurologic and psychiatric clinics and polyclinics for children, 
adults and forensic. Attached to the clinic are nursing homes, nursing training school 
and an educational institute for human development. The clinic also operates 
outpatient clinics for children, youth and adult psychiatric patients. The clinic staff is 
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comprised of medical doctors with different specializations, psychologist, nurses, 
social workers and trainees in various departments [Zentrum für allgemeinpsychiatrie 
II der Klinik und Poliklinik für Psychiatrie und Psychotherapie der Universität 
Regensburg am Bezirksklinikum Regensburg, 2012.]. 
Station 1b belongs to the socio-therapeutic department of the hospital with 22 beds. 
It is specifically equipped to allow a certain connection between a stationary 
treatment and outpatient treatment. The working groups in this station are made up of 
medical doctors, nurses, psychologists, ergo-therapists, social workers, and intern 
students (medical students, and psychology students). Patients in ward 1b are 
patients with predominant schizophrenic and schizoaffective disorders. Outpatients 
visit the station for routine check-ups after an appointment with their attending 
clinicians and psychotherapist [Zentrum für allgemeinpsychiatrie II der Klinik und 
Poliklinik für Psychiatrie und Psychotherapie der Universität Regensburg am 
Bezirksklinikum Regensburg, 2012]. 
3.1.6 Materials for the Antipsychotics Data Analysis 
The TDM request form and the Konbest program will be applied to evaluate the TDM 
of antipsychotics and the influence of smoking on haloperidol and flupentixol serum 
concentration. The database of AGATE (Arbeitsgemeinschaft Arzneimitteltherapie 
bei psychiatrischen Erkrankungen), an independent and interdisciplinary quality 
assurance program for the pharmacotherapy will be applied for the evaluation of 
MLP-BPD data analysis on undesired drug effects [AGATE Pharmacovigilance 
Programm, 2012]. The frequency of haloperidol request and the impact on the 
medication cost was evaluated with ABDA data. The AGNP consensus C/D data will 
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be applied to monitor the comparison between the value of the measured 
concentration and the expected DRR. 
3.2 Method  
This section is divided into three sections. The frst section contains the description of 
the analytic method already applied in the TDM laboratory Regensburg and 
subsequently deals with the development and validation of a new chromatographic 
method suitable for analytical determination of melperone, benperidol, haloperidol, 
bromperidol, flupentixol and zuclopenthixol in human serum. The second section is 
focused on the routine measurements of patients’ samples with the validated 
analytical method and its application in TDM and at the clinic ward. The third section 
will deal with the method of data analysis. 
3.2.1 Current HPLC Method in TDM Laboratory Regensburg 
The TDM laboratory in Regensburg applies already some methods for the 
determination of varieties of drugs in human serum (see table 10). There is however, 
the need to support these methods with a new method in order to enable a 
measurement in cases where confirmations of the obtained results are requested and 
for the determination of antipsychotics that have not yet been tested in the TDM 
laboratory Regensburg.  
Table 10. The existing methods and parameters in the TDM laboratory Regensburg. 
Method Mobile phase (ml) pH 
Temp. 
(
o
C) 
Column 
TDM-1a 
ACN/KH2PO4-buffer  
(300 /700) 
3.0 25 
Thermo-Betasil C6, 5 µm 
250 x 4.6 mm 
TDM-1b 
ACN/KH2PO4-buffer  
(300 /700) 
3.0 25 
Thermo-Betasil C6, 5µm 
250 x 4.6 mm 
TDM-2 ACN/NH4-formiat-buffer 3.0 30 Thermo-Betasil C6, 5µm 
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(300/700) 250 x 4.6 mm 
TDM-3a 
ACN/MeoH/TEMED/H2O 
(660/200/8/1132) 
6.5 30 
PerfectSil 120 ODS-L 5 
µm 250 x4.6mm 
TDM-3b 
ACN/MeoH/TEMED/H2O 
(500/200/8/1229) 
7.0 30 
PerfectSil 120 ODS-L 5 
µm 250 x4.6 mm 
Note: Temp.: temperature, ACN: acetonitrile, NH4-formiat: ammonium formiate, MeOH: methanol, 
TEMED: tetramethylethylendiamine, KH2PO4: potassium dihydrogenphosphate.  
The routine measurements in the laboratory are carried out on different days of the 
week. If necessary, an exceptional measurement is always available. The 
measurement of serum concentration of some drugs can be carried out with different 
methods (see table 11), and can therefore be measured at different days within the 
week.  
 Table 11. Substances grouped according to their routine methods 1-3. 
Methods TDM-1a TDM-1b TDM-2 TDM-3a TDM-3b 
Substance 
Lamotrigine 
Aripiprazole 
Citalopram 
Escitalopram 
Venlafaxine 
Oxcarbazapine 
Citalopram 
Escitalopram 
Venlafaxine 
Amisulprid 
Mirtazapine 
Olanzapine 
Clozapine 
Quetiapin 
Duloxetine 
Ziprasidon 
Perazin 
Risperidon 
Paliperidon 
Haloperidol 
Note. Medications are grouped and measured at different days of the week. TDM 1a-3b represent dif-
ferent analytical methods.TDM: therapeutic drug monitoring.  
A separate method is applied in the TDM laboratory Regensburg for the 
determination of the serum concentration of tricyclic antidepressants (TCA) and 
benzodiazepines (BZD: see table 12). The test instructions for this method are 
supplied as a complete kit to the laboratory. 
Table 12. The TCA method and the substances applicable during the routine measurement. 
Parameter Method TCAs BZD 
Mobile phase NA Amitriptyline Alprazolam 
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PH value NA Amitriptylinoxid Bromazepam 
Temp. NA Clomipramine Chlordiazepoxide 
Column NA Desipramine Clobazepam 
  Doxepine Diazepam 
  Imipramine Flunitrazepam 
  Trimipramine Flurazepam 
  Maprotiline Nitrazepam 
  Nortriptyline Nordiazepam 
  Imipramine Oxazepam 
Note: NA: not available, Temp: temperature, TCA: Tricyclic antidepressants, BZD: Benzodiazepines. 
 
3.2.2 New Method Development by Automated Column Switching HPLC  
The target chromatographic method for the new development is the reversed phase 
chromatograpy (RPC). The following chapters describe the preparations’ steps to be 
taken before commencing with the separation of the substances. Then the 
measurements and the validation method are discussed. 
a) Treatment of Drug-Free Human Serum for HPLC Analysis 
The purification of drug free serum was carried out through a solid phase extraction 
(SPE) on Oasis HLB® cartridges 500 mg obtained from Waters GmbH (Eschborn, 
Germany). The Oasis HLB® cartridges 500 mg were washed with methanol and then 
with demineralised water (aqua dem.). After washing with aqua dem., the openings of 
the oasis were closed and then the drug free serum was applied to Oasis HLB® 
cartridges 500 mg for purification. After the solid phase extraction, the washed serum 
is collected in a test tube with the help of a vacuum pump. The serum is then 
transferred in a sterile 50 ml tube and stored at -20 oC to avoid degradation. When 
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needed, sterile tube containing 50 ml of the freshly treated drug free serum was used 
immediately. 
b) Preparation of Stock Solutions 
Two stock solutions were prepared for this work. The substances were first weighed 
accurately and transferred to a 25 ml round bottom flask, respectively. The stock 
solution A was obtained after completely dissolving 2.5 mg of each substance, 
respectively (melperone, benperidol, haloperidol, bromperidol, flupentixol, 
zuclopenthixol) in 25 ml methanol to give a concentration of 0.1 mg/ml. To prepare 
stock solution B, 5 µl was taken from stock solution A and diluted with 995 µl Aqua 
dem. The prepared solutions were filled in Eppendorf caps and stored frozen at -20 
oC for three months. 
c) Preparation of Calibrators 
Drug-free serum preserved at -20 oC was thawed prior to use and centrifuged. The 
stock solutions were allowed to adjust to room temperature before they were used. 
Three concentrations of the calibrators (L: low, M: middle, H: high) were prepared by 
spiking drug-free serum (final volume 2000 µl) with appropriate volumes of stock 
solution B of the six substances (see table 13). 
Table 13. The volume concentrations of butyrophenones and phenothiazines. 
Substances 
Low 
(volume in µl) 
conc. in ng/ml 
Middle 
(volume in µl) 
conc. in ng/ml 
High 
(volume in µl) 
conc. in ng/ml 
Butyrophenones 
Melperone (MLP) 
(100) 
25 
(228) 
57 
(460) 
115 
 49 
 
Benperidol (BPD) 
(8) 
2  
(40) 
10 
(120) 
30  
Haloperidol (HLP) 
(8) 
2 
(40) 
10 
(120) 
30 
Bromperidol (BRP) 
(12) 
3 
(60) 
15 
(120) 
30 
Phenothiazines 
Flupentixol (FLT) 
(24) 
6 
(70) 
17.5 
(140) 
35 
Zuclopenthixol (ZLT) 
(24) 
6 
(240) 
60 
(480) 
120 
Note: The calibrators were prepared of through reconstitution of the stock solutions. The values in 
brackets are the volume of stock solutions spiked in a drug-free serum. Conc: concentration. 
d) Preparation of Test Specimens  
Test specimens in drug-free serum were prepared by spiking different volumes of 
stock solution B of each substance to a drug-free serum to obtain the desired 
concentration for the measurement. The mixtures were vortexed and centrifuged for 
5 min. The prepared 20 ml drug solutions served for further separation processes. 
e) Preparation of the Mobile Phases  
An accurately weighed 5.44 g potassium dihydrogenphosphate was added to 2,000 
ml Erlenmeyer flask and dissolved first in 500 ml aqua dem. and stirred. While the 
solution was still stirring on a magnetic stirrer, the remaining 1,500 ml aqua dem. was 
added and the pH value was adjusted to pH 6 with orthophosphoric acid. The 
prepared buffer solution is the mobile phase A. 
Mobile phase B was prepared by adding an accurately weighed 300 ml acetonitrile 
(ACN) and 130 ml methanol (MeOH) in a 1,000 ml Erlenmeyer flask and stirred. After 
mixing the two organic phases, 570 ml aqua dem. was added to the mixture. The pH 
 50 
 
was set to 4.3 and later to 5.0 with orthophosphoric acid. The mobile phase B do not 
contain tetramethylethylenediamin (TEMED). 
Mobile phase C was prepared by adding an accurately weighed 300 ml acetonitrile 
(ACN) and 130 ml methanol (MeOH) in a 1.000 ml Erlenmeyer flask and stirred. After 
mixing the two organic phases, 100 ml Aqua dem. was added to the mixture and 
stirred for 2 min. after which 4 ml TEMED was added, and while still stirring, another 
450 ml Aqua dem. was added to the solution. After the adjustment of the pH to 5.0, 
the Erlenmeyer flask was filled up to the 1,000 ml mark with Aqua dem. 
f) Column Selection 
The selection of the suitable column for the determination of MLP, BPD, HLP, BRP, 
FLT and ZLT was carried out with 16 different columns of different physico-chemical 
properties. The mobile phases were each allowed to equilibrate for 60 min with 
different analytical columns. Thereafter, aliquots à 500 µl drug solutions were injected 
into the HPLC-System and analysed at temperatures between 20 oC to 40 oC. The 
flow rate was adjusted between 0.2 and 0.8 ml/min according to the particle size of 
the columns. Table 14 shows the application of different methods to examine the 
available columns in the laboratory, in order to choose the suitable columns for the 
method development. 
Table 14. Analytical columns and parameters for selection. 
Analytical Col-
umn 
Mobile Phase 
(ml) 
pH 
Value  
Inject. 
Vol  
(µl) 
Temp 
(
o
C) 
Conc. of Drug 
Solutions  
(ng/ml) 
ACN 
 
MeOH 
 
Buffer 
(B) 
H2O 
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TEMED 
(T) 
Thermo Betasil 
C6 
5 µm  
250 x 4.6 mm 
300 100 600 (B) - 4.3 100 25 100-1000 
Luna Phenyl-
hexyl  
3 µm 
150 x 3.00 mm 
300 100 600 (B) - 4.0 100-
750 
20-30 2-10 
300 130 4 (T) 566 5.0 
Hypersil ODS  
5 µm 
250 x 4.6 mm  
300 100 600 (B) - 4.3 100 30 100  
SphereClone  
ODS (2)  
5 µm 
150 x 4.6 mm  
300 100 600 (B) - 4.3 100 30 100-1000 
BetaBasic C4  
3 µm 
150 x 4.6 mm  
300 100 600 (B) - 4.3 100 25 100-1000 
Betasil C8  
5µm  
250 x 4.6 mm  
300 100 600 (B) - 4.3 100 25 100-1000 
Xterra Schild 
C18  
5 µm 
100 x 4.6 mm 
300 100 600 (B) - 4.0 100 30 1000 
PerfectSil 120 
ODS-L 
 5 µm 
250 x 4.6 mm 
330 100 4 (T) 566 6.5 100 30 100-200 
Gemini-Nx C18  
5 µm 
150 x 4.6 mm 
330 100 4 (T) 566 4.3 100 30-40 10-100 
Gemini C6  
5 µm  
150 x 4.6 mm 
330 100 4 (T) 566 4.3 100 30-40 10-500 
Luna Phenyl-
hexyl  
5 µm 
150 x 3.00 mm 
300 100 600 (B) - 4.3-5.0 100-
750 
20-30 2-10  
330 130 4 (T) 566 
Luna CN  330 130 4 (T) 566 4.3 750 30 100 
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5 µm 
250 x 4.6 mm  
LiChrospher CN 
5µm 
250 x 4.6 mm  
330 130 4 (T) 566 4.3 100 30 100 
BetaBasic C4  
5 µm 
150 x 4.6 mm  
330 130 4 (T) 566 4.3 100 30 10 
Nucleosil C8 EC 
3µm 
250 x 4.6 mm 
300 100 600 (B) - 4.0-5.0 100-
750 
20-30 2-100 
300 130 4 (T) 566 
Nucleodur CN-
RP 
100-3 
150 x 4.6 mm 
300 100 600 (B) - 4.0-5.0 100 30 10 
300 130 4 (T) 566 
Note: The measurement time was programmed to 120 min for each column, respectively. The buffer 
used was potassium dihydrogenphosphate. Inject. Vol: injection volume, Temp: temperature; Conc: 
concentration, TEMED: tetramethylethylendiamine, MeOH: methanol, ACN: acetonitrile. 
3.2.2.1 HPLC Separation Method for the Serum Determination of 
Antipsychotics 
The selected column was then applied for the separation of the study substances 
with HPLC. Two separation methods were tested, the isocratic and the gradient 
separation. An isocratic HPLC separation was carried out under a constant mobile 
phase composition. The gradient separation method was carried out with mobile 
phase C under a variable mobile phase composition. 
Isocratic HPLC Separation 
The frozen substance solutions were thawed prior to use and centrifuged. The 
reconstitution of the stock solutions was carried out with the drug-free serum. The 
mobile phase C (30% ACN, 13% MeOH, 0.4% TEMED and 56.6% aqua dem) was 
used for the analysis. The columns Luna phenyl-hexyl 150 x 3 mm, 3 µm for 
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butyrophenone and Nucleodur CN-RP 150 x 4.6 mm, 3 µm for phenothiazines were 
fixed into the HPLC equipment and equilibrate for 30 - 60 mins, respectively. 
Separate aliquots à 750 µl and 1250 µl of butyrophenone and phenothiazine 
specimens were injected into the HPLC-System, respectively. The flow rate for the 
HPLC analysis was set to 0.2 ml/min at the temperature of 20 oC for butyrophenones 
and 0.6 ml/min at the temperature of 30 oC for phenothiazines. The diod array 
detector set to record at WL 220, 230, 240, 245, and 248 nm was used to detect the 
substances. The correction factor of 0.88 by MLP, 0.86 by FLT and 0.85 by ZLT were 
considered in all the measurements. For the simultaneous determination of the 
substances, aliquot of each of the substances solution was added into the 1.5 ml 
HPLC glass tube and measured as already described. 
The acidity of the mobile phase for the simultaneous separation of butyrophenones 
was adjusted from pH 4.3 to pH 5 to obtain the expected resolution between 
melperone and benperidol. The chromatogram for all measurements was recorded 
and analysed by the software Chromeleon® Version 6.8 SP2 Build 2284 on the basis 
of peak height. The total chromatographic run time was 25 minutes and 30 minutes 
for butyrophenones and phenothiazines, respectively. 
Gradient HPLC Separation 
The gradient test was carried out by an intermixture of mobile phase C and a solution 
of hundred percent acetonitrile (100% ACN). The 100% ACN of HPLC purity grade 
was added in portions between 5-95% to the mobile phase C at different time 
intervals between 16 and 20 min. The percentage of the solvents and the time for the 
admixture are depicted in table 15. The mixing processes were carried out at different 
temperatures with the multiple step gradient method. The column applied for the 
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gradient measurement was Luna phenyl-hexyl 150 x 3 mm, 3 µm. The aliquots of the 
substance solutions, the injection volumn and the wave length were the same as 
described for iscocratic measurements. 
Table 15. The percentage volume of the solvents used during gradient measurements.  
Sample Number 
Mobile Phase A 
(Portion in %) 
Acetonitrile 
(Portion in %) 
Time for the Admixture  
(min.) 
A 85 15  20.0 
B 85 15 16.0 
C 80 20 16.0 
D 85 15 18.0 
E 90 10 16.0 
F 95 5 15.8 
G 90 10 16.2 
H 75 25 16.0 
Note: Each sample number has a different mixing process during the gradient HPLC measurement. 
3.2.2.2 Validation of the Newly Developed HPLC Method 
The validation steps and specifications applied were according to the guidelines of 
GTFCh (Society of Toxicology and Forensic Chemistry) [Paul and Musshof, 2009] in 
consideration of ISO 5725 (International Organization for Standardization), FDA (US 
Food and Drug Administration), guidance for industry on biomedical method 
validation (2001), set norms by the German institute of standardization [DIN 32645, 
1994], and the requirements of ICH (International Conference on Harmonization) 
[ICH-harmonised tripartite guideline-validation of analytical procedures, 1996]. The 
information received from the principles and practices of method validation [Fajgeli A, 
Ambrus A, 2000], and from the Kromidas’ book of analytical validation [Kromidas, 
1999] were equally considered during the validation process. 
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a) Calibration 
The calibration curve describes the linear relationship between measured values 
and/or measuring signal and the analyte concentration. The correlation coefficient 
provides information about the variation of the measured values to the calibration 
curve [Söfftge, 2000]. Calibration curves for the validation of this method were 
documented over a concentration range of 2, 4, 5, 6, 10, 25, 30, 50, 60, 90, 100, 120, 
150, and 200 ng/ml. The linear regression equations and the coefficient of certainty r2 
were obtained for all the substances by calculating a linear regression analysis. 
b) Limit of Quantification (LOQ) and the Limit of Detection (LOD) 
The limit of detection (LQD) is the lowest concentration in a sample that can be 
detected while the limit of quantification (LOQ) is the lowest concentration in a 
sample that be quantified. The lowest concentrations of analyte that can be detected 
in a sample can vary from the quantification limit of the samples depending on the 
applicable experimental conditions [Guidance for Industry on biomedical method 
validation, 2001]. The LOQ and the LOD of the measured antipsychotics were based 
on a signal-to-noise ratio of 10:1 and 3:1, respectively. Six different concentrations 
(5- 120 ng/ml for melperone, 1-10 ng/ml for benperidol, 1-10 ng/ml for haloperidol, 3-
20 ng/ml for bromperidol, 1-10 ng/ml for flupentixol and 2-16 ng/ml for zuclopenthixol) 
were analysed, starting with the lowest estimated concentration (n=4). The values 
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were verified by linear regression analysis over the data points. The calculation of 
LOD and LOQ was carried out according to DIN 32645 [DIN 32645, 1994] in 
consideration of p ≤ 0.01 (significance level) and k =3 (analytical uncertainty ≤ 33%). 
c) Recovery 
The recovery is a measure of the efficacy of the method in detecting all the analyte 
present in a sample [Braggio et al., 1990]. Through multiple measurements of 
different substance concentrations, the relationship between the mean value of the 
respective concentrations and the target value were analyzed [Söfftge, 2000]. The 
absolute recovery for the study substances in serum was determined at 
concentrations 22, 51, and 102 ng/ml for melperone; 2, 10, and 30 ng/ml for 
benperidol and haloperidol; 3, 15, and 30 ng/ml for bromperidol; 5, 15, and 30 ng/ml 
for flupentixol; 5.1, 51 and 102 ng/ml for zuclopenthixol. All the measured substances 
were compared to aqueous drug solutions, set to 100% (n=6) of the spiked drug 
serum samples. 
d) Precision  
Precision is the closeness of the measured data between series of measurements 
obtained from multiple sampling under the same analytical conditions [Shah et al., 
1992]. The coefficient of variation in percent was used to determine the variation limit 
of the analysis [Guidance for Industry on biomedical method validation, 2001]. The 
precision of serum samples containing 25, 57, 115 ng/ml of MLP; 2, 10 and 30 ng/ml 
of BPD; 2, 10 and 30 ng/ml of HLP; 3, 15 and 30 ng/ml of BRP; 6, 17.5, and 35 ng/ml 
of FLT; 5.1, 51, and 102 ng/ml of ZLT were assessed by repeated analyses on the 
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same day (intra-assay) and on six different days (inter-assay). The intra-assay 
variation was measured six consecutive times for each concentration, and the inter-
assay variation was measured twenty-four times for each concentration. The assays 
were expressed as the coefficient of variation (CV in %). 
e) Accuracy  
The accuracy describes the nearness of the experimental value to the expected 
value. The expected value was derived from the quality control of each 
chromatographic run. Deviations of the mean from the expected target value were 
expressed as % of the target value (bias). Accuracy was calculated as 100%-bias. 
The accuracy of the method was assessed by repeated analyses of self prepared 
quality control samples (concentration low: 25 ng/ml, middle: 57 ng/ml, high: 115 
ng/ml for MLP; low: 2 ng/ml, middle: 10 ng/ml, high: 30 ng/ml for BPD; low: 2 ng/ml, 
middle: 10 ng/ml, high: 30 ng/ml for HLP; low: 3 ng/ml, middle: 15 ng/ml, high: 30 
ng/ml for BRP; low: 6 ng/ml, middle: 17.5 ng/ml, high: 35 ng/ml for FLT; low: 5.1 
ng/ml, middle: 51 ng/ml, high: 102 ng/ml for ZLT). 
f) Stability 
The verification of the stability of the analytes in solvent and serum solution after a 
long storage period and after repeated freeze/thaw processes was carried out 
through the long-term stability and the freeze/thaw stability measurements. The 
solutions of MLP, BPD, HLP, BRP, FLT, and ZLT were determined by measuring the 
concentrations of 25 ng/ml and 115 ng/ml MLP, 2 ng/ml and 30 ng/ml BPD, 2 ng/ml 
and 30 ng/ml HLP, 3 ng/ml and 30 ng/ml BRP, 17.5 ng/ml and 35 ng/ml FLT, and 51 
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ng/ml and 102 ng/ml ZLT after 3 months, after 6 months and after 12 months [Shah 
et al.,1992]. Freshly self prepared standard solutions were measured alongside with 
the solutions for the stability test control. The freeze/thaw stability test was carried out 
with the same concentrations as in the long-term stability. The solutions were 
thawn/freezed and measured four times for each concentration (n = 12 for each 
substance). The mean stability data was calculated by setting the corresponding 
control value between 90 -100% according to DIN 32645. 
g) Robustness 
The reliability of the developed method when exposed to different parameters other 
than the ones used during the method development was analysed for 
butyrophenones and phenothiazines through the application of realistic changes. The 
test on robustness of the method was carried out through changes on the acidity of 
the mobile phase, composition of the mobile phase, temperature, chromatographic 
run time, as well as measurement with other available HPLC equipment. 
h) Selectivity 
The selectivity test is the measurement carried out to verify the interference of the 
test substances with other substances [Kromidas, 1999], such as substances that 
can be found in different co-medications or possible impurities in different solutions 
during the method development. The selectivity of this method was assessed with 
interference tests of 109 different substance solutions identified as the medications 
prescribed to schizophrenic patients. Then the retention time of the susbtances were 
compared with that of the study substances. 
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3.2.2.3 Patients’ Test Samples and Measurement 
The validated method was tested for the routine analysis of the patients’ samples. 
Test specimens from patients’ serum were received from clinic ward 1b and from the 
stored rest patients’ serum from the routine analysis in the TDM laboratory. Prior 
measurement, they were centrifuged for 3 min before analysis, transferred to HPLC 
vials. The standard solutions were thawed, centrifuged and filled in the HPLC vials. 
The same operational step was applied for the measurement of patients’ samples 
and the standard samples. The total chromatographic run was set at 30 minutes. 
Example chromatograms of all the study substances and the standard concentrations 
were collected. 
3.2.3 TDM Routine Analysis with the Validated Method 
The daily analysis of the patients’ samples containing the study medications were 
carried out with the validated method in the TDM laboratory. 
3.2.3.1 Type of Study Patients 
Patients were eligible for this retrospective study if they receive any of the study 
substances based on the diagnoses according to ICD-10 and/or suffering from 
psychological illness treated with any psychotropic medications. The attendance for 
the pharmacist discussion was directed to patients admitted in clinic ward 1B and 
out-patients of the same ward. Patients outside the clinic ward 1B were not forseen 
for the discussion. All the study patients were informed about the study and they 
voluntarily gave their consent. The patients’ name were not disclosed in this study.  
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3.2.3.2 TDM Request for the Study Substances 
The set criteria for the request of TDM in this study were suspect of undesired drug 
effect, drug interactions, lack of response to treatment, patients’ compliance, and 
change in dosage regime. The set time appropriate for the sample collection was the 
collection at steady-state concentration. The calculation of the dose required to reach 
a steady-state concentration (c) of a drug in serum is based on the direct correlation 
of the drug constant dose (D) per day, with the total clearance of the drug (Clt) being 
the correlation coefficient (c = D / Clt). With this information, the expected dose-
related serum concentration of a drug in a patients specimen can be calculated 
[Hiemke et al., 2011]. 
3.2.3.3 Laboratory Measurments and Data Analysis 
Patients’ serum samples were sent for qualification and quantification from various 
hospitals to the TDM laboratories. The samples were centrifuged at 20.000 rounds/ 
min for 10 min. 2 ml of each subordinate was transferred in sterile caps, stored at 5 
±3 °C for a maximum of two days. Prior measurement, they were centrifuged for 3 
min before analysis. 1.6 ml of each prepared patients’ sample and the standard 
samples were transferred to HPLC vials and analyzed.  
The graph of dose-concentration relationship of each substance was plotted using 
the values of measured serum concentration, the dose-related reference range DRR) 
and the therapeutic reference range (TRR). The DRR was calculated by multiplying 
the given C/D low and C/D high of the respective substances with the maintenance 
dose. The values of C/D low and C/D high and the TRR were obtained from the data 
 61 
 
of AGNP consensus guideline: update 2011. Boxplots were plotted as well to 
compare the relationship between the measured concentration and the DRR. 
Method of Data Collection 
The patients’ demographics and all the required information for the interpretation of 
the measured concentration such as patients age, gender, health status, diagnoses, 
treatment onset, co-medications, undesired drug effect and time of sample collection 
were recorded in the TDM request form. The records were transferred manually into 
Konbest. Konbest is a web-based laboratory information management system (LIMS) 
for TDM-laboratories [Koestlbacher and Haen, 2008]. The konbest data of the study 
substances were grouped in dose, measured concentration, dose-related reference 
range, undesired drug effects, co-medications, and frequency of request. The review 
of the administered co-medications was carried out by a sequential listing of all noted 
co-medications. The listed medications were alphabetically arranged according to 
their product names.  The evaluation was carried out with only the active substances 
contained in the co-medications. The number of co-medications administered per 
patients, the rate of drug administration and the co-medication with common 
metabolic pathways with HLP and FLT were evaluated.  
The ABDA (ABDA = The Federal Union of German Association of Pharmacists ) data 
analysis for HLP administration and Cost was analysed in two steps. First, the data 
for the frequency of administration in konbest was arranged. They were then sorted 
according to year. The number and frequency of administration each year were 
grouped in a table. Secondly, the medication costs documented in the database of 
the Federal Union of German Association of Pharmacists (ABDA) were assessed. 
The frequency of the dose administration for HLP was multiplied with the 
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documented HLP price in ABDA database to estimate the treatment cost for HLP. A 
graph was plotted for the illustrated cost-administration of HLP. 
AGATE Data Collection for Melperone and Benperidol Polymedication were derived 
from the pharmacovigilance data of the AGNP-group for the documentation of 
psychiatric medications and co-medications. Since 1995, the following five items 
have been recorded for each patient hospitalized in the AGATE hospitals at two 
particular days per year called index days (one in April, the other one in October): 
age, gender, diagnoses, medication, and dosage. The diagnoses for which 
melperone and benperidol were administered and the data documentation were 
classified according to the International Statistical Classification of Disease and 
Related Health Problems-9 and 10 (ICD-9 and ICD-10) [International Statistical 
Classification of Disease and Related Health Problems-9, 1975; International 
Statistical Classification of Disease and Related Health Problems-10, 2010]. The 
number of drug and the rate of drug administration per patients and the rate of TDM 
request were evaluated. 
Smoking and the Serum Concentration of HLP and FLT 
The patients’ data were arranged according to smokers and non-smokers. The data 
for smokers were further grouped into those that received co-medication and those 
who underwent monotherapy. The serum concentration reached by smokers and 
nonsmokers were compared for haloperidol and flupentixol, respectively.  
Furthermore, the serum concentrations reached by only patients who smoked during 
haloperidol and flupentixol therapy were compared. For the comparison, graphs of 
dose-concentration relationships and boxplots were plotted. C/D low x D and C/D 
high x D were used to calculate the dose-related reference range of each sample. 
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3.2.4 Clinical Application of Laboratory Values through TDM 
The measured drug concentrations in patients serum were analyzed, and with an 
accompanied clinical reports the values were sent to the respective clinics and 
attending clinicians. 
Five factors were applied for the interpretation of the laboratory values in the TDM 
laboratory: the dose-related reference range, the therapeutic reference range, the 
nine-fold table, the co-medications, and the CYP-Enzyme table [Haen et al., 2008], 
under consideration of the given patients’ and therapy information in the TDM request 
form. The drug-drug interaction from the CYP-Enzyme table, as authomatically 
selected by konbest for a particular sample was reviewed in connection with the 
measured concentration if applicable, and interpreted in terms of enzyme substract, 
enzyme induction or enzyme inbition and the possible impact in the serum 
concentrations. The contact channels to the attending clinicians were fax, telephone 
or email. Telephone contact was used in cases of a suspect intoxication. 
3.2.4.1 Therapeutic Drug Monitorin at the Clinic Ward 
At the clinic, the patients’ samples from ward 1B at the clinic and polyclinic for 
psychiatry and psychotherapy at the University of Regensburg were further 
discussed by the pharmacist during the clinic ward visitation and different cases were 
treated. Serum samples of the ward patients and the newly admitted inmates were 
accepted in TDM laboratory for the purpose of therapeutic drug monitoring using the 
developed method. The determined drug concentrations were returned together with 
a written clinical pharmacological report [Haen and Laux, 2011; Haen, 2011]. The test 
results were discussed under the consideration of two reference ranges: the 
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therapeutic reference range (TRR) and the dose-related reference range (DRR). The 
reason for either undesired drug effect, lack of effect, too high drug or too low drug 
concentration was discussed. These discussions also took place outside the ward 
visitations whenever the need arose. 
3.2.4.2 Routine Clinic Ward Visitation 
The participation at the daily ward meetings and the pharmaceutical advices to ward 
clinicians were carried out at several days in the week. The team discussion with all 
the team members of the station took place once a week. The documentation of the 
reported undesired drug effects and drug abuse took place two times in a week. The 
Triple-Team discussion between a Patient, a psychiatrist and the pharmacist took 
place once a week. The activities of the pharmacist at the station were 
pharmaceutical advises before and during the drug therapy, the documentation of the 
reported adverse drug reactions and the presentation of TDM results accompanied 
with advices on further drug therapy after literature researches. The methods of 
communication applied were written communication (emails) before and/or after the 
team discussion and oral communication, mostly during the team discussion. 
Request and questions regarding problematic therapies were forwarded to the 
pharmacist by the attending clinicians. Existing scientific studies regarding the 
possible intervention of a pharmacist at the clinic and its outcome were reviewed 
during the visitation period. 
Triple- Team Discussion (Patient-Clinician-Pharmacist) 
The discussion of the triple team was carried out in the office of the attending 
clinicians. Present during the discussion were the concerned patient, the psychiatrist 
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(attending clinicians) and the pharmacist. The concerned patients were always 
informed before each visit of the pharmacist and their consent were seeked. During 
this meeting, the present state of patients’ health conditions, the experienced 
undesired drug effects, compliance problem and possible drug abuse and/or over-
dose, especially when their expectations on the efficacy of the drugs were not 
reached, were discussed.  
The role of the pharmacist during the discussion consisted of giving pharmaceutical 
advices to the clinicians and the patients on the reported cases, documenting the 
reported undesired drug effects from the patient, remedying possible compliance 
problems due to the reported undesired drug effects, suggesting a better drug 
administration with the help of the clinician to reduce possible drug-drug interactions, 
and applying the therapeutic drug monitoring to optimize the patients’ individual 
therapy.  
3.2.4.3 Preparation of Clinic Ward Questionnaires 
Two questionnaires were developed: a questionnaire for the patients and a 
questionnaire for the attending clinicians. The questionnaire for the patients 
contained 13 questions with annonymised information about the patients, patients’ 
understanding about the therapeutic measures, and their knowledge about the 
administered drugs and possible undesired drug effects.  
The questionnaire for the attending clinicians contained 15 questions about the group 
of patients (based on diagnosis) treated during this research work, the improvement 
of the clinicians’ therapeutic decisions through the pharmacist advice and 
contribution, and the evaluation of the pharmacist’s activities in the clinic ward.  
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4 Results  
The results section describes the outcome of the different laboratory preparations 
and measurements including validation of the newly developed HPLC method. The 
method was applied in clinical practice. Moreover, an intervention of the pharmacist 
at the clinic ward was designed to guide antipsychotic therapy by TDM. The merge of 
the laboratory results with daily clinical practices and therapeutic decisions was 
considered as well. This section ends with data findings from Konbest, ABDA, and 
AGATE to support the goal of this research project. 
4.1 Method Development 
Several analytical columns, mobile phases and separation methods such as isocratic 
and gradient method were tested for suitability. At the end, the result of the validated 
applicable separation method will be demonstrated. 
4.1.1 Choice of Mobile Phase and Analytical Column 
Three mobile phases were prepared. Mobile phase A contains a 
dihydrogenphosphate buffer solution. Mobile phase B contains neither buffer nor 
TEMED, but only acetonitrile and methanol, while mobile phase C contains a TEMED 
solution. Nine columns were tested along with the prepared mobile phase at different 
analytical conditions. The peaks observed after the measurement with the solution of 
dihydrogenphosphate buffer (mobile phase A) were irregular. Double peaks were 
observed after the first measurement. Further measurements showed one peak and 
eventually no peak. (see figure 9 A). Though the measurements carried out with the 
pure drug solutions under the application of mobile phase B (mobile phase without 
TEMED and without buffer) yielded a good result, they, nevertheless did not show 
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any absorption in human serum even at a concentration of 100 ng/ml (see figure 9 
B). This corresponds with the expectation of irregular peaks by measurements of pH-
stable solutions without buffer. The measurement carried out in TEMED mobile 
phase (mobile phase C) showed reliable results at wavelengths of 245 nm and 230 
nm, respectively. Significant and reliable peaks were observed both in serum 
solutions as well as in pure drug solutions.  
 
Figure 9. Determination of antipsychotics in buffer solution and solution without TEMED. 
Note: First measurement and repeated measurement in human serum with dihydrogenphosphate 
buffer at concentration 100 ng/ml (A); measurement in human serum at 100 ng/ ml with neither 
TEMED nor buffer in the mobile phase (B). mAU = peak height. 
 
4.1.2 Comparison of TEMED and Dihydrogenphosphate Buffer Solutions 
The measurements carried out with the solution of dihydrogenphosphate buffer were 
not reliable. Inconsistent retention times and peak forms were observed. No 
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qualitative and quantitative analysis of the measured substances could therefore be 
conducted. 
The results obtained from the measurements carried out with different mobile phases 
showed the TEMED mobile phase (mobile phase C) to be more reliable. Good elution 
of the substances with baseline separation were observed at 20oC and 30oC. The 
qualification and quantification of all the applied antipsychotics were reliably analyzed 
at low concentrations between 2-10 ng/ml. The reliable peak height was observed at 
a molecular absorption unit of 245 nm for butyrophenones and 230 nm for 
phenothiazines (see figure 10). 
 
Figure 10. Comparing the measurement with dihydrogenphosphate buffer and TEMED mobile 
phase. 
Note: Measurement of flupentixol with dihydrogenphosphate buffer at conc. 100 ng/ml, WL 230 nm 
(upper chromatogramm); Measurement with TEMED in the mobile phase at conc. 100 ng/ml, WL 230 
nm (lower chromatogram). mAU = peak height. 
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4.1.3 Column Selection and Measurements with Buffer Mobile Phase  
Nucleodur CN-RP 150 x 4.6 100-3  
The measurements with the analytical Nucleodur column (Nucleodur CN-RP 150 x 
4.6, 100-3) in buffer showed chromatographic irregularities. Therefore, this method 
must be considered unreliable. In the first measurement, two peaks were observed. 
After the repetition of this measurement, one of the peaks was observed to have 
significantly reduced and no peak was seen in further measurements (see figure 9A). 
The parameters applied during the measurement are listed in appendix 1a 
Thermo Betasil C6 250 x 4.6 mm 5 µm  
The measurement at a concentration of 2000 ng/ml gave a molecular absorption unit 
of 14.8 mAU (see table 16). The reduction of the concentration to 400 ng/ml gave a 
molecular absorption unit of 2.7 mAU and the reduction to 200 ng/ml gave 1.2 mAU. 
The irregular chromatographic base lines observed at concentrations of 400 ng/ml 
and 200 ng/ml mean that the measurement is qualitatively and quantitatively 
unreliable (see figure 11A to 11C). The obtained results did not give any indication of 
the possibility for further reduction of the concentration to 2 ng/ml while applying the 
parameters listed in appendix 1b. 
Luna Phenyl-hexyl 150 x 3.0 mm 3 µm (and 5 µm) 
Sharp peaks were observed with Luna Phenyl-hexyl analytical column 3 µm. The 
obtained peak heights (see figure 11D) at the concentration of 10 ng/ml for each of 
the substances were qualitatively and quantitatively reliable and showed the 
possibility of measurements in lower concentrations. However, the columns were 
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easily blocked during the measurement with buffer mobile phase. The washing of the 
column for 5 minutes after each run did not prevent the blockage of the column. The 
column regeneration carried out with different isopropanole concentrations showed 
no better result either. The application of 5 µm particle size of Luna Phenyl-hexyl 
column with the chosen parameters (see appendix 1c) to prevent column blockage 
did not yield the expected results.  
Hypersil ODS 5 µm 250 x 4.6 mm  
The result received after the measurement at a concentration of 100 ng/ml was less 
than 1.0 mAU (see figure 11E). A reliable peak at 5 ng/ml was not obtained using this 
column and the applied parameters (see appendix 1d). 
SphereClone ODS (2) 150 x 4.6 mm 5 µm  
Different drug concentrations were tested with this column. None of them produced a 
reliable result. The peak height obtained after measuring the concentration of 1,000 
ng/ml was 20.2 mAU (see figure 11F). The reduction of the concentration by factor 10 
to100 ng/ml gave the peak height of 3.5 mAU (see figure 11G). Further reduction of 
the concentration to arrive at the lowest expected therapeutic concentration of the 
substance did not yield reliable results within the given parameters (see appendix 
1e). The obtained results were measured at a very low wavelength (WL) of 205 nm. 
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Table 16. Sample Chromatograms measured with buffer in mobile phase. 
Chromatogram Substance concen-
tration (ng/ml) 
pH value – 
mobile phase 
Wave 
length 
(WL) 
Column 
A 2000 4.3 230 Thermo Betasil C6, 5 
µm, 250 x 4.6 mm 
B 400 4.3 230 Thermo Betasil C6, 5 
µm, 250 x 4.6 mm 
C 200 4.3 230 Thermo Betasil C6, 5 
µm, 250 x 4.6 mm 
D 10 4.0 230 Luna Phenyl hexyl, 3 
µm, 150 x 3.0 mm 
E 100 4.3 230 Hypersil ODS, 5 µm, 
250 x 4.6 mm 
F 1000 4.3 205 Sphere Clone 
ODS(2), 5 µm, 150 x 
4.6 mm 
G 100 4.3 205 Sphere Clone 
ODS(2), 5 µm, 150 x 
4.6 mm 
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Figure 11. The application of buffer solution in mobile phase.  
Note: Buffer solution = (ACN 300 ml, MeoH 100 ml, buffer 600 ml); mAU = peak height.The column 
separation of antipsychotics at different concentrations (D = 10 ng/ml, E = 100 ng/ml) with different 
columns, sample substance is bromperidol (see table 16). 
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4.1.4 Column Selection with TEMED Mobile Phase 
PerfectSil 120 ODS-L 250 x 4.6 mm 5 µm  
The measurements in low concentrations were unreliable due to the observed 
irregular baseline. The base line was observed to be so irregular that the peaks of the 
concentration at 100 ng/ml could not be identified (see figure 12A, appendix 2a). The 
concentration of 200 ng/ml gave a peak height of 4.3 mAU (see figure 12B and table 
17). The reduction of the noise and the peak resolution were observed by an 
increase of the concentration to 1000 ng/ml. 
Gemini-Nx C18 5 µm 150 x 4.6 mm and 250 x 4.6 mm 
Gemini-Nx 5 µm, 150 x 4.6 mm and Gemini-Nx 5µm, 250 x 4.6 mm are the same 
column of different length. At the detection wavelength of 230 nm, a retention time of 
10.7 min (see figure 12C) was observed for the shorter column Gemini-Nx 5 µm 150 
x 4.6 mm, while 17. 8 min were observed for the longer column Gemini-Nx 5 µm, 250 
x 4.6 mm. The total chromatographic run for Gemini-Nx 5 µm 150 x 4.6 mm was 15.0 
min and 30 min for Gemini-Nx 5 µm 250 x 4.6 mm. The peak height obtained at the 
concentration of 200 ng/ml was 4.7 mAU. Concentrations of 2 and 5 ng/ml could not 
be identified with the applied parameters (see appendix 2b). 
Gemini C6 5 µm 150 x 4.6 mm  
The peak height reached at 2000 ng/ml was 14.7 mAU (see figure 12D). The 
detection wavelength was 230 nm and the retention time was 11.3 min. There was no 
peak observed at 10 ng/ml. The applied parameters for the measurement are listed in 
appendix 2c. 
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Nucleodur CN-RP 150 x 4.6 mm 100-3  
The measurement with TEMED mobile phase and the Nucleodur column showed a 
reliable result at a detection wavelength of 230 nm with a diode array detector, the 
retention time being 15.6 min for FLT and 14.4 min for ZLT (see figure 12E). These 
results were obtained after a 3% increase of the methanol portion of the mobile 
phase from 100 ml to 130 ml, 3% reduction of the acetonitrile portion from 330 ml to 
300 ml and an increase in the injection volume from 100 ml to 1250 ml (see appendix 
2d). The measurements at lower serum concentrations of phenothiazines were 
precise, reliable and satisfactory. Nucleodur column CN-RP with 3 µm particle size 
and column size of 150 x 4.6 mm was chosen for the serum determination of 
phenothiazines under the application of TEMED mobile phase. 
Luna Phenyl-hexyl 3 µm 150 x 3.0 mm 
The simultaneous determination of serum concentrations of BPD, HLP and BRP at 
2.0 ng/ml was carried out successfully (see figure12F), after a change in the mobile 
phase constituents and an increase of the injection volume to 750 µl (see appendix 
2e). The optimal wavelength obtained with a diode array detector was 245 nm. A pH 
value of 4.3 was observed to be optimal for the respective detection of MLP, BPD, 
HLP and BRP, but not for a simultaneous measurement of MLP and BPD. With a 
change of the pH value to 5.0, optimal and reliable simultaneous separations of all 
the applied butyrophenones were possible. 
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Luna Phenyl-hexyl 5 µm 150 x 3.0 mm 
The Luna phenyl-hexyl analytical column with 5 µm particle size was applied to 
resolve the column blockage. The result was poorer than expected. There was no 
chromatogram observed when the Luna Phenyl-hexyl column was applied in order to 
determine phenothiazines in human serum. The measurements carried out for 
butyrophenones could not be applied for lower concentrations.  
Table 17. Sample Chromatograms measured with TEMED in mobile phase. 
Chromatogram Substance con-
centration 
(ng/ml) 
pH val-
ue- Mo-
bile 
phase 
Analyte Wave 
length 
(WL) 
Column 
A 100 6.5 bromperidol 254 PerfectSil 120 
ODS -L, 5 µm, 
250 x 4.6 mm 
B 200 6.5 bromperidol 254 PerfectSil 120 
ODS -L, 5 µm, 
250 x 4.6 mm 
C 200 4.3 bromperidol 230 Gemini-NX, 5 
µm, 150 x 4.6 
mm 
D 2000 4.3 bromperidol 230 Gemini C6, 5 
µm, 150 x 4.6 
mm 
E 100 5.0 zuclopenthixol 210 Nucleodur CN-
RP, 150 x 4.6 
mm, 3 µm 
F 100 5.0 Benperidol, 
haloperidol, 
bromperidol,  
245 Luna Phenyl 
hexyl, 3 µm, 
150 x 3.0 mm 
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Figure 12. The selection of analytical column using TEMED solution.  
Note: TEMED solution = (ACN 330 ml, MeOH 100 ml, TEMED 4 ml, H2O 566 ml).The column separa-
tion of antipsychotics at different concentrations with different columns and substances (see table 17). 
Substance A – D = bromperidol, substance E = zuclopenthixol, substance F = benperidol, haloperidol 
and bromperidol. The concentration of Chromatogram A is 100 ng/ml, Chromatogram B = 100 ng/ml, 
Chromatogram C = 200 ng/ml, Chromatogram D = 2000 ng/ml, Chromatogram E = 100 ng/ml, Chro-
matogram F = 100 ng/ml. mAU = peak height. 
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4.1.5 Influence of Column Particle Sizes on the Measurement  
It was observed that the two different particle sizes (3 µm and 5 µm) of the Luna 
Phenyl-hexyl analytical column affect the obtained results in different ways. The 
highest flow rate was 0.2 ml/min. At a flow rate of 0.3 ml/min, the pressure reached 
290 bars and led to the shutdown of the HPLC equipment.  
The results obtained with the column particle size of 3 µm were more precise and 
reliable (see table 18). A flow rate of 0.2 ml/min and a temperature of 20 oC gave an 
optimal result at a wavelength (WL) of 245 nm (see figure 13). The result of the peak 
area (see table 19) showed higher values for the 5 µm particle size (see figure 14). 
The peaks were so wide that the results of the lower concentrations from 2 to 5 ng/ml 
could not be interpreted (see figure 15). 
Table 18. Differences in peak height of Luna Phenyl-hexyl particle sizes at 100 ng/ml.  
Substance 
5 µm 
(mAU ± SD) 
3 µm  
(mAU ± SD) 
Melperone 14.9 ± 0.03 18.7 ± 0.01 
Benperidol 11.5 ± 0.01 13.5 ± 0.02 
Haloperidol 6.6 ± 0.03 9.6 ± 0.05 
Bromperidol 3.5 ± 0.02 6.1 ± 0.01 
Note. SD:standard deviation, mAU: peak height. 
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Figure 13. Differences between the peak height of Luna Phenyl-hexyl columns. 
Note: 3 µm and 5 µm are the tested particle sizes, conc.: 100 ng/ml. The columns are the peak heights 
obtained at wave length 245 nm. 
Table 19. Differences in peak area of Luna Phenyl-hexyl particle sizes measured at 100 ng/ml. 
Substance 
5 µm 
(mAU x min ± SD) 
3 µm 
(mAU x min ± SD) 
Melperone 7.7 ± 0.01 5.4 ± 0.03 
Benperidol 8.6 ± 0.04 4.3 ± 0.02 
Haloperidol 6.7 ± 0.02 4.6 ± 0.02 
Bromperidol 3.7 ± 0.01 3.1 ± 0.03 
Note: SD: standard deviation, mAU x min: peak area. 
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Figure 14. Differences between the peak area of Luna Phenyl-hexyl columns. 
Note: 3 µm and 5 µm are the tested particle sizes, conc.: 100 ng/ml. The columns are the peak areas 
obtained at wave length 245 nm. 
 
Figure 15. Example of chromatogram with Luna Phenyl-hexyl 5 µm 150 x 3.0 mm. 
Measurement at conc.: 5 ng/ ml, WL 245 nm with TEMED in mobile phase; mAU = peak height. The 
tested substances are melperone, benperidol, haloperidol and bromperidol, measured with TEMED 
mobile phase. The observed wider peaks proved problematic for the measurements in lower concen-
trations. 
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4.1.6 Summary of Results of the Column Selection 
The tested columns were made of different materials and they gave different results 
during the test (see table 20). For the selected columns, pressure and column-
clogging problems were handled by cleaning intervals after each run of 2 to 5 min 
and washing the column (including the inverted position) once a week for at least 30 
minutes.   
Table 20. Characteristics of the applied analytical columns. 
Analytical Column Properties of the Package Material 
Thermo-Betasil C6 5 µm 
250 x 4.6 mm 
Hexylsilane chemically bonded to totally porous silica particles 
[HPLC column selection, 2010]. It is designed for small mole-
cules, and gives good results with acids, bases and neutral 
bonding. 
Luna Phenyl-hexyl  
3 µm 150 x 3.00 mm 
The phenyl bonded phase uses a phenyl ring with a hexyl link-
er and is densely bonded to Luna silica surface. Dense bond-
ing and the hexyl linker reduce bonded hydrolysis and increase 
chemical stability, which can lead to an optimal retention of ar-
omatic and polar, amine compounds [HPLC column guide-
Phenomenex, 2012] 
Hypersil ODS 5 µm  
250 x 4.6 mm  
Octadecyl silane (C18) ligand is chemically bounded to silica 
[HPLC column selection, 2010]. It is applied for the separation 
of wide range of compoubds including nonpolar, moderately 
polar, and lipophilic compounds such as triglycerides [HPLC 
column guide-Thermo, 2012]. 
SphereClone ODS (2)  
5 µm 150 x 4.6 mm  
Octadecyl silane (C18) ligand is chemically bounded to silica 
[HPLC column guide-Phenomenex, 2012]. It can be applied for 
the separation of diverse analytes. 
BetaBasic C4 3 µm  
150 x 4.6 mm  
Butyl silane is chemically bonded to porous silica particles 
[HPLC column guide-Phenomenex, 2012]. It is used for small 
molecules, peptides and protein digets. 
BetaBasic C4 5 µm  
150 x 4.6 mm 
Butyl silane is chemically bonded to porous silica particles 
[HPLC column selection, 2010]. The difference with number 5 
is based on the particle size. 
Betasil C8 5µm  
250 x 4.6 mm  
Octasilane is chemically bonded to porous silica particles 
[HPLC column guide-Phenomenex, 2012; HPLC column selec-
tion, 2012]. This type of column is designed for small mole-
cules, and gives good results with acids, bases and neutral 
bonding. 
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Xterra Schild C18 5 µm 
100 x 4.6 mm 
The function is based on the first generation of hybrid particle 
technology; they are mearnt to deliver sharp symmetrical peaks 
for basic compounds [HPLC column guide-Waters, 2012]. 
PerfectSil 120 ODS-L  
5 µm 250 x 4.6 mm 
Octasilane (C18) is chemically bonded to porous silica particles 
[HPLC Säulen-high lights, 2012; HPLC column guide-
Phenomenex, 2012; HPLC column selection, 2010]. It can be 
applied for the separation of diverse analytes. 
Gemini-Nx C18 5 µm 
 150 x 4.6 mm 
Rugged Gemini column that controls the selectivity of ionizable 
compounds for optimized methods. They are meant to have 
consistent performance in both volatile and non-volatile buffers 
[HPLC column guide-Phenomenex, 2012]. 
Gemini C6 5 µm  
150 x 4.6 mm 
Phenyl group is bonded to the organo-silica surface using a 6-
carbon chain for a low bleed aromatic selective phase [HPLC 
column guide-Phenomenex, 2012]. 
Luna phenyl-hexyl 5 µm 
150 x 3.00 mm 
Descriptions correspond to Luna Phenyl-hexyl  
3 µm 150 x 3.00 mm with the exception of the particle size of 5 
µm. 
Luna CN 5 µm  
250 x 4.6 mm 
Contains smooth silica, which allows for a more uniform bond-
ing with improved resistance to bonded phase hydrolysis to 
produce a stable CN phase, applicable for carboxyl, carbonyl 
and amine containing compounds [HPLC column guide-
Phenomenex, 2012]. 
LiChrospher CN 5 µm 
 250 x 4.6 mm  
Particles of silica with gamma-cyanopropyl function, LiChro-
sphere 
® 
100 CN has both weak polar properties and weak hy-
drophobic properties, which is expected to enable the separa-
tion of complex samples. It is applicable both for normal phase 
chromatography and reverse phase chromatography [LiChro-
spher® HPLC columns, 2012]. 
Nucleosil CN-RP 3 µm 150 
x 3.0 mm 
Polar to mid-polar cyano-(nitrile)-modified silica for reversed 
phase, normal phase and molecules containing pi electron sys-
tems (e.g. analytes with double bonds) chromatography. Nu-
cleosil ® CN-RP columns are based on robust silica [MN appli-
cation database, 2012]. 
Nucleodur 100-3 CN-RP 
150 x 4.6 mm 
Cyano nitrile modification is for reverse phase separations. It 
possesses a high retention capacity especially for very polar 
and unsaturated compounds and its retention characteristic is 
different compared with C8 and C18 types. This is because the 
materials are based on high purity and very pressure stable sil-
ica.  [Instruction leaflet Nucleodur® CN / CN-RP]. 
Note: The descriptions of the applied columns were according to the manufacturers. 
The selected columns for the determination of antipsychotic serum concentrations 
were Luna Phenyl-hexyl 3 µm 150 x 3.0 mm and Nucleodur CN-RP 3 µm 150 x 4.6 
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mm under the application of TEMED mobile phase (mobile phase C). The difference 
in the silica bonding of Luna Phenyl-Hexyl column and Nucleodur  CN-RP column is 
represented in figure 16. The Luna Phenyl-hexyl 3 µm 150 x 3.0 mm was applied for 
the determination of butyphenones (MLP, BPD, HLP, BRP) in serum. The Nucleodur 
CN-RP 3 µm 150 x 4.6 mm was used for the determination of phenothiazines (FLT, 
ZLT) in serum.  
 
Figure 16. The difference in the silica bonding of Luna Phenyl-Hexyl column and Nucleodur  
CN-RP column. 
 
Illustrations on the practical criteria for the selection of the appropriate columns are 
depicted in table 21 and 22. The columns were tested in mobile phase with buffer 
soluion and mobile phase containing TEMED. The mobile phase with buffer consists 
of 30 vol% ACN, 10 vol% MeOH, and 60 vol% buffer. The TEMED mobile phase 
consists of 30 vol% ACN, 13 vol% MeOH, 0.4 vol% TEMED, and 56.6 vol% 
demineralized water.  
 Phenyl-hexyl phase of Luna phenyl-hexyl column Cyanonitril phase of Nucleodur CN-RP column 
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Table 21. Practical selection of analytical columns through the test with buffer solution. 
Column 
Result 
Advantage Disadvantage 
Nucleodur CN-
RP 150 x 4.6 
100-3 
- 
The measurements showed chromato-
graphic irregularities and therefore an unre-
liable column.  
Thermo Betasil 
C6 250 x 4.6 
mm 5 µm 
- 
The measurement at a concentration of 
2000 ng/ml gave a molecular absorption 
unit of 14.8 mAU. The reduction of the con-
centration to 400 ng/ml gave a molecular 
absorption unit of 2.7 mAU and the reduc-
tion to 200 ng/ml gave 1.2 mAU. The irregu-
lar chromatographic base lines observed at 
concentrations of 400 ng/ml and 200 ng/ml 
made the measurement qualitatively and 
quantitatively unreliable 
Luna Phenyl-
hexyl 150 x 3.0 
mm 3 µm  
Sharp peaks were observed 
with Luna Phenyl-hexyl ana-
lytical column 3 µm at 10 
ng/ml. The qualitative and 
quantitative measurement in 
lower concentrations can be 
obtained with this column. 
A slight blockage of the column during the 
measurement with buffer mobile phase was 
observed. The washing of the column for 5 
minutes and more after each run did not 
prevent blockage of the column. The col-
umn regeneration carried out with different 
isopropanole concentrations showed no 
better result.  
Luna Phenyl-
hexyl 150 x 3.0 
mm 5 µm 
Lower back pressure 
The application of 5 µm particle size of a 
Luna Phenyl-hexyl column within the cho-
sen parameters to prevent column blockage 
was not successful, and quantitative meas-
urements of lower serum concentrations 
were however not realized. 
Hypersil ODS 
5 µm 250 x 4.6 
mm 
- 
The result received after the measurement 
in serum at a concentration of 100 ng/ml 
gave a molecular absorption unit of less 
than 1.0 mAU. It showed that a reliable 
peak by 5 ng/ml cannot be obtained with 
this column. 
SphereClone 
ODS(2) 150 x 
4.6 mm 5 µm 
- 
Different concentrations tested with this col-
umn did not give a reliable result. The peak 
height obtained after measuring the concen-
tration of 1000 ng/ml was 20.2 mAU. Re-
duction of the concentration by factor 10 to 
100 ng/ml gave the peak height at 3.5 mAU. 
Further reduction of the concentration to ar-
rive at the lowest expected therapeutic con-
centration of the substance did not yield re-
liable results.  
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PerfectSil 120 
ODS-L 5 µm 
250 x 4.6 mm 
- No detection 
Gemini-Nx 5 
µm 150 x 4.6 
mm, 
- No detection 
Gemini-Nx 5 
µm 250 x 4.6 
mm, 
- No detection 
Gemini C6, 5 
µm 150 x 4.6 
mm. 
- No detection 
BetaBasic C4 
150 x 4.6 mm 
3 µm 
 
Good for measuring sub-
stances in clear solutions 
without particles. 
Production of high back pressure, which 
lead to an inefficient measurement in hu-
man serum. 
BetaBasic C4 
150 x 4.6 mm 
5 µm 
 
Large particle size, good for 
measuring substances in se-
rum. 
Measurement of the applied antipsychotics 
in low concentrations (2-10 ng/ml) was not 
possible. 
Betasil C8 250 
x 4.6 mm 5 µm 
 
Longer column length and 
large particle size enables 
the measurement 
A longer retention time, longer measure-
ment period and no detection at low con-
centrations (2-10 ng/ml) 
Note: Column selection using buffer mobile phase (Mobile Phase A). The advantage and disad-
vantage refer to the results obtained after measurement with HPLC device. 
Table 22. The use of TEMED mobile phase for the selection of column. 
Column  
Result 
Advantage Disadvantage 
PerfectSil 120 
ODS-L 250 x 
4.6 mm 5 µm 
The improvement of the noise 
and the peak resolution were ob-
served at an increase of the con-
centration to 1000 ng/ml. This 
showed that this column is better 
used for measurements at high 
substance concentrations. 
 
The measurements in low concentra-
tions were very unreliable because of 
the observed noise. The base line 
was observed to be so irregular that 
the peaks of the concentration at 100 
ng/ml could not be identified. The 
concentration of 200 ng/ml gave a 
peak height of 4.3 mAU. 
Gemini-Nx C18 
5 µm 150 x 4.6 
mm and 250 x 
4.6 mm 
The total chromatographic run 
was 15.0 min. 
The peak height obtained at the con-
centration of 200 ng/ml was 4.7 mAU. 
The concentrations at 2 and 5 ng/ml 
could not be identified because of the 
low peak height and the noise ob-
served.  
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Gemini-Nx C18 
5 µm 250 x 4.6 
mm  
Low back pressure 
The total chromatographic run was 30 
min. Measurement in low concentra-
tions was not reliable. 
Gemini C6 5 µm 
150 x 4.6 mm 
- 
There was no peak observed at 10 
ng/ml. The peak height received at 
2000 ng/ml was 14.7 mAU. Detection 
wavelength was 230 nm and retention 
time was 11.3 min. 
Nucleodur CN-
RP 150 x 4.6 
mm 100-3 
The measurement showed a reli-
able and satisfactory result at a 
detection wavelength of 230 nm 
with diode array detector. 
5 min column wash after each run to 
avoid blockage 
Luna Phenyl-
hexyl 5 µm 150 
x 3.0 mm 
- 
There was no peak observed for 
measurements carried out in low con-
centrations 
Luna Phenyl-
hexyl 3 µm 150 
x 3.0 mm 
 
The determination of low serum 
concentrations at 2.0 ng/ml was 
carried out successfully. The op-
timal wavelength obtained with a 
diode array detector was 245 nm 
and pH at 5.0.  
5 min column wash after each run to 
avoid blockage 
Thermo Betasil 
C6 5 µm 250 x 
4.6 mm 
- No absorption 
Hypersil ODS 
250 x 4.6 5 µm 
- No absorption 
SphereClone 5 
µm ODS(2) 150 
x 4.6 mm. 
- No absorption 
Xterra Schild 
C18 100 x 4.6 
mm 3. 5 µm 
 
A very short column, possibility of 
measuremnt in a very short time. 
No detection observed, built up a very 
high back pressure during the meas-
urement. 
LiChrospher CN 
250 x 4.6 mm 5 
µm 
 
- 
Detection was only observed at higher 
concentrations from 100 ng/ml up-
wards, longer measurement period. 
Luna CN 250 x 
4.6 mm 5 µm 
- No detection observed 
Note: Column Selection using TEMED Mobile Phase (Mobile Phase C). The advantage and 
disadvantage refer to the results obtained after measurement with HPLC device. 
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4.1.7 Isocratic Separation of Butyrophenones 
The simultaneous separation of melperone and benperidol at pH 4.3 was not reliable. 
During column selection, it was observed that both substances have a tendency to 
overlap. Haloperidol and bromperidol gave good results for this pH value. The 
chosen mobile phase for this initial separation was the mobile phase C containing 
TEMED, and the chosen column was the Luna Phenyl-hexyl 150 x 3.0 mm 3 µm. 
Wavelength, temperature, flow rate, and the acidity of the mobile phase were the 
factors considered for the analytic separation. 
4.1.7.1 Wavelengths and Retention Times 
The measurements were successfully carried out at wavelengths of 230 nm and 245 
nm. The measurement at 230 nm gave smaller molecular absorption units compared 
with the measurement at 245 nm. The result obtained at a wavelength of 245 nm 
(see table 23) was maintained because of its reliability and precision for the 
qualitative and quantitative evaluation of MLP and BPD in human serum. 
Table 23. The simultaneous measurement of MLP and BPD. 
Substances 
Concentration  
(ng/ml) 
Retention Time 
(min) 
Standard Deviation 
(SD) 
melperone (MLP) 
25 15.84 0.02 
57 15.74 0.02 
115 15.69 0.14 
benperidol (BPD) 
2 17.3 0.09 
10 17.16 0.03 
30 17.06 0.03 
Note: The retention times of melperone and benperidol were measured four times (n=4) at 
the wavelength of 245 nm, n: number of measurements for each concentration. 
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4.1.7.2 Influence of the Temperature  
The observation was made that the lower the temperature, the better the separation 
of the peaks. The result of a measurement carried out at a temperature of 30 oC 
showed a poor resolution of melperone and benperidol peaks (see figure 17). Well-
distinguished melperone and benperidol peaks were observed after a reduction of 
the temperature to 20 oC. 
 
Figure 17. Effect of different temperatures during the HPLC separation of MLP (a) and BPD (b). 
Note: Tested temperatures were 20 
o
C, 25 
o
C, and 30 
o
C, at conc. 100 ng/ml.Measurement with 
TEMED mobile phase (30 vol% ACN, 13 vol% MeoH, 0.4 vol% TEMED, and 56.6 vol% demineralized 
water). mAU = peak height. 
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4.1.7.3 Influence of the Flow Rate 
Best separation of MLP and BPD was achieved after a reduction of the flow rate to 
0.2 ml/min. Measurements carried out with lower flow rates of 0.15 ml/min and 0.1 
ml/min showed prolonged retention times and poor resolution of both substances 
(see figure 18). The flow rate of 0.2 ml/min was therefore set for further 
measurements. 
 
Figure 18. The variation of the flow rate at 0.1 ml/min and 0.15 ml/ min. 
Note: Tested during the separation of melperone and benperidol. at conc. 100 ng/ml. Mobile phase 
(30 vol% ACN, 13 vol% MeoH, 0.4 vol% TEMED, and 56.6 vol% demineralized water). mAU = peak 
height. 
 
4.1.7.4 Influence of pH 
The TEMED gave the mobile phase the expected stability at an optimal pH value of 
5.0. The pH value of the TEMED mobile phase prepared between pH 4.0 and pH 4.3 
did not show any improvement on the separation of melperone and benperidol. An 
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increase in the acidity to pH 5.0 showed a reliable and precise separation (see figure 
19). 
 
Figure 19. A reliable separation of MLP (a) and BPD (b) at an increase of the pH value of the 
mobile phase to pH 5.0. 
Note: Conc. 100 ng/ml. Mobile phase (30 vol% ACN, 13 vol% MeoH, 0.4 vol% TEMED, and 56.6 vol% 
demineralized water). mAU = peak height. 
 
Summary of Results of the Qualitative Separation of MLP and BPD 
An observation was made during the measurement that the wavelength necessary 
for the reliable identification and separation of melperone and benperidol was 245 
nm. A temperature above 20 oC showed an irregular base line and a flow rate above 
0.2 ml/min caused a high back pressure. The set parameters for further qualification 
and quantification of both substances are listed in table 24. In general, baseline 
separation of melperone and benperidol was successfully achieved at pH 5.0, a 
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constant temperature at 20 oC, and a flow rate of 0.2 ml/min. These parameters were 
used for the simultaneous separation of all the butyrophenones for this study.  
Table 24. Parameters for the separation of melperone and benperidol. 
Parameters Set Values 
Wavelength 245 nm 
Temperature 20 
o
C 
Flow rate 0.2 ml/min 
Mobile phase acidity pH 5.0 
Column Luna Phenyl-hexyl 150 x 3.0 mm, 3 µm 
Mobile phase  
(30 vol% ACN, 13 vol% MeOH, 0.4 vol% 
TEMED, and 56.6 vol% demineralized water). 
Note: These are fixed parameters for further measurements of melperone and benperdiol. 
4.1.8 Application of the Gradient HPLC Separation Method 
The result of the simultaneous test carried out for the determination of antipsychotics 
in human serum showed a gap on the chromatographic scale during the evaluation. 
The multistep gradient applied to close the gap (see figure 20) and reduce the total 
chromatographic run did not yield the expected result. 
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Figure 20. An acceptable chromatographic separation with isocratic HPLC analysis before the 
application of gradient method. 
Note: a: MLP, b: BPD, c: HLP, and d: BRP, at conc. 100 ng/ml. Mobile phase solvent consists of ACN, 
MeoH, TEMED, and demineralized water. mAU = peak height. 
The separation of antipsychotics through the addition of 15% acetonitrile (ACN) to 
85% mobile phase C gave a poor result after 20 min chromatographic run. It was 
observed that the change in the time of admixture (admixture: mixing procedures) 
partially showed a better resolution of the peaks. The detection of the substances by 
an addition of 25% ACN to mobile phase C (see figure 21-25 and figure 27-28) was 
not reliable. An acceptable result was achieved by adding 5% acetonitrile to 95% of 
mobile phase C at 15.8 min (see figure 26). The table illustrating the gradient 
mixtures can be found in appendix 3. 
 
Figure 21. 85% mobile phase C + 15% ACN admixed from 20 min., conc.: 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
The separation between melperone and benperidol worsened, but the total run time 
decreased slightly. 
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Figure 22. 85% mobile phase C + 15% ACN admixed at 16 min, at conc. 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
The separation between melperone and benperidol became better, but the separa-
tion between haloperidol and bromperidol worsened. The retention time of benperidol 
was observed to have shortened. 
 
Figure 23. 80% mobile phase C + 20% ACN admixed from 16 min, at conc. 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
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The separation between melperone and benperidol was optimal. The 5% variations 
between mobile phase C and ACN did not improve the separation of haloperidol and 
bromperidol. 
 
Figure 24. 85% mobile phase C + 15% ACN admixed from 18 min, at conc. 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
The issue of the haloperidol-bromperidol separation remained.  
 
Figure 25. 90% mobile phase C + 10% ACN admixed at 16 min, at conc. 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
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The resolution of the bromperidol peak was not reliable. 
 
Figure 26. 95% mobile phase C + 5% ACN admixed from 15.8 min, at conc. 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
An optimal separation of the four substances (MLP, BPD, HLP, BRP) was achieved.  
 
Figure 27. 90% mobile phase C + 10% ACN admixed from 16.2 min at conc. 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
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An irregular base was observed during the measurement. 
 
Figure 28. 75% mobile phase C + 25% ACN admixed from 16.2 min, at conc. 100 ng/ml. 
Note: Mobile phase solvent consists of ACN, MeoH, TEMED, and demineralized water. mAU = peak 
height. 
No reliable UV-absorption was obtained. UV-absorption: ultra violett absorption. 
Comparison of Isocratic and Gradient Separation 
The best results from the two developed methods were compared in order to choose 
the preferred analysis for the method validation. The same analytical column (Luna 
Phenyl-hexyl 150 x 3.0 mm 3 µm), run time (25 min) and wavelength (245 nm) were 
used for both the gradient and for the isocratic analysis. The mobile phase for the 
isocratic separation was constant, while that of gradient speraration was varied. 
Though the consumption of the analytical solutions was slightly higher by the 
gradient method (see table 25), the two methods did not show any significant 
difference in their results. 
Table 25. Differences of the isocratic and gradient measurement. 
Parameters Isocratic Gradient 
Column 
Luna Phenyl-hexyl 150 x 3.0 
mm 3 µm 
Luna Phenyl-hexyl 150 x 3.0 
mm 3 µm 
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Run time (min) 25 min 30 min 
Separation Insignificant Insignificant 
Peak height difference Insignificant Insignificant 
Mobile phase con-
sumption  
Less consumption Higher consumption 
Cost Less expensive Comparably more expensive 
Note: The separation of the substances was carried out with the same parameters for both separation 
methods as mentioned in the table, in order to enable a valid comparison. 
4.1.9 Validation of the Newly Developed Isocratic HPLC-Method 
Table 26 shows the parameters for the validation of butyrophenones and 
phenothiazines. The correction factor of 0.88 for MLP, 0.86 for FLT and 0.85 for ZLT 
were considered in all the measurements, because the raw substances available 
were in the form of salt with a molecular weight of 299.8 g/mol for MLP, 503.1 for FLT 
and 473.9 for ZLT.   
Table 26. Parameters for the validation of MLP, BPD, HLP, BRP, FLT and ZLT. 
Parameters Butyrophenones Phenothiazines 
Mobile phase 
30 vol% ACN, 13 vol% MeOH, 0.4 
vol% TEMED, and 56.6 vol% demin-
eralized water 
30 vol% ACN, 13 vol% MeOH, 0.4 
vol% TEMED, and 56.6 vol% de-
mineralized water 
Mobile phase 
acidity 
pH 5.0 pH 5.0 
Extraction col-
umn 
LiChrosphare ADS-RP-4, 25 µm x 2 
mm, 20 µm 
LiChrosphare ADS-RP-4, 25 µm x 2 
mm, 20 µm 
Analytical col-
umn 
Luna Phenyl-hexyl  150 x 3.0 mm, 3 
µm 
Nucleodur CN-RP 150 x 4.6 mm, 3 
µm 
Injection vol-
ume 
750 µl 1250 µl 
Temperature 20 
o
C 30 
o
C 
Flow rate 0.2 ml/min 0.6 ml/min 
Wavelength  245 nm 230 nm 
Detector UV/VIS UV/VIS 
Note: ACN: acetonitrile, MeOH: methanol, TEMED: tetramethylethylendiamin, Vol: volume. 
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4.1.9.1 Calibration and the Calibration Curve 
The respective concentrations of the applied antipsychotics were measured seven 
times successively (see table 27). The result of the mean correlation coefficients 
which is the measure of linearity was satisfactorily obtained.  An example of the 
calibration curve of zuclopenthixol is shown in appendix 4. 
Table 27. Calibration results of the applied antipsychotics.  
Substances Concentration Range (ng/ml) Correlation Coefficient (r
2
) Linear Equation 
Butyrophenones 
Melperone 2-200 0.9958 Y= 0.1729x - 0.3425 
Benperidol 2-200 0.9878 Y= 0.1285x + 0.3048 
Haloperidol 2-200 0.9856 Y= 0.1045x + 0.1126 
Bromperidol 2-200 0.9910 Y= 0.0775x – 0.0651 
Phenothiazines 
Flupentixol 5-100 0.9990  Y= 0.0615x – 0.0655  
Zuclopenthixol 4-150 0.9958  Y= 0.0591x – 0.0897  
Note: The linear equations and correlation coefficients (r
2
) of the linearity test were obtained after sev-
en times (n= 7) measurements of each concentration. Y: dependent variable 
4.1.9.2 Substance Recovery  
The amount of substance lost during the sample preparation and possible 
interference of serum materials during the measurements were both successfully 
controlled. A proportional reduction of the amount of substance was observed both in 
using the peak height as well as the peak area. The evaluated substance recoveries 
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(see table 28) ranged between 88.8 % and 109.5 %. This result corresponds with the 
acceptable bias of ± 20% specification of DIN 32645. 
Table 28. Mean substance recovery in % ± standard deviation. 
Substances Concentration (ng/ml) Recovery ± SD (%) 
Butyrophenones 
Melperone 
(factor = 0.88) 
22 107.9 ± 2.0 
50.2 104.2 ± 1.0 
101.2 92.4 ± 2.7 
Benperidol 
2 95.5 ± 1.6 
10 91.3 ± 4.0 
30 95.9 ± 1.1 
Haloperidol 
2 105.6 ± 2.0 
10 92.1 ± 0.6 
30 88.8± 4.2 
Bromperidol 
3 103.9 ± 2.6 
15 107.5 ± 1.0 
30 109.5 ± 0.9 
Phenothiazines 
Flupentixol  
(factor = 0.86) 
5.2 93.9 ± 3.0 
15.1 108.1 ± 4.0 
30.1 91.2 ± 1.7 
Zuclopenthixol 
(factor = 0.85) 
5.1 90 ± 2.6 
51 102.4 ± 1.0 
102 93.3 ± 0.05 
Note: The yield of antipsychotics during the test on recovery was carried out six times (n = 6) with 
three different concentrations for each substance. The factors of melperone, flupentixol, and zuclopen-
thixol were considered in relation to their different salts. SD: standard deviation. 
4.1.9.3 Intraday Precision 
Six different chromatographic runs were performed under identical conditions within a 
day. The measurements evaluated are the substance peak height (mAU). The 
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variation coefficients obtained were between 0.39% and 13.52%. The required limit 
for the coefficient of variation (CV) according to DIN 32645 is ± 15%. The obtained 
results correspond with the given specification (see table 29). 
Table 29. The evaluation of intraday measurement. 
Substance 
Concentration 
 (ng/ml) 
Mean 
(mAU) 
SD CV (%) 
Butyrophenones 
Melperone 
(factor = 0.88) 
 
22  
 
4.7935 0.0742 1.55 
50.2 10.5272 0.0924 0.88 
101.2 20.7535 0.2091 1.01 
Benperidol 
2 
 
0.2730 0.0110 4.03 
10 1.2612 0.0733 5.81 
30 3.5778 0.0356 0.99 
Haloperidol 
2 0.1330 0.0072 5.41 
10 0.6407 0.0289 4.51 
30 2.0377 0.0214 1.05 
Bromperidol 
3 0.1250 0.0169 13.52 
15 0.6158 0.0551 8.95 
30 1.2508 0.0101 0.81 
Phenothiazines 
Flupentixol 
(factor = 0.86) 
5.2 0.5133 0.0280 5.45 
15.1 1.4630 0.0080 0.55 
30.1 2.9024 0.0700 2.41 
Zuclopenthixol 
(factor = 0.85) 
5.1 0.7590 0.0400 5.27 
51 8.4468 0.0900 1.07 
102.1 18.263 0.0710 0.39 
Note: The precision of measurements within a particular day was carried out six times (n=6) for each 
concentration. SD: standard deviation, CV: coefficient of variation, mAU: peak height. 
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4.1.9.4 Interday Precision 
The measurement was carried out uniformly for six consecutive days. The obtained 
variation coefficients (CV) were between 0.74 % and 13.12% (see table 30). The 
values of the coefficient of variation obtained met with the ±15% requirement of DIN 
32645. 
Table 30. The result of interday measurements.  
Substance Concentration (ng/ml) 
Mean 
(mAU) 
SD CV (%) 
Butyrophenones 
Melperone 
(factor = 0.88) 
22 3.2968 0.1074 3.25 
50.2 6.78037 0.2696 3.98 
101.2 13.9556 0.2744 1.97 
Benperidol 
2 0.1998 0.0129 6.46 
10 0.7727  0.0768 9.94 
30 2.6310 0.0967 4.47 
Haloperidol 
2 0.1053 0.0080 7.69 
10 0.4438 0.0420 9.42 
30 1.2624 0.0820 6.50 
Bromperidol 
3 0.1268 0.0108 8.52 
15 0.5331 0.0340 6.38 
30 1.0704 0. 0460 4.30 
Phenothiazines 
Flupentixol 
(factor = 0.86) 
5.2 0.1376 0.0012 0.87 
15.1 0.3643 0.0058 1.59 
30.1 0.7470 0.0055 0.74 
Zuclopenthixol 
(factor = 0.85) 
5.1 0.3580 0.0300 8.38 
51 5.1011 0.6501 12.74 
102.1 10.1374 1.3302 13.12 
Note: The precision of measurements for six days was carried out 4 times (n=4) for each 
concentra-tion. SD: standard deviation, CV: coefficient of variation, mAU: peak height. 
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4.1.9.5 The Accuracy of the Method 
The evaluation (in bias %) of the deviation of the obtained values proved the 
accuracy of the method. The values obtained for all the analytes were within the 
acceptable range of bias at ±15% (see table 31), notwithstanding the possible 
systematic error. 
Table 31. The accuracy of the method for the determination of antipsychotics in human serum. 
Substance 
Concentration 
(ng/ml) 
Target Value 
(mAU ± SD) 
Measured Value 
 (mAU ± SD) 
Bias 
 (%) 
Butyrophenones 
Melperone 
(factor = 0.88) 
22 3.4470 ± 0.11 3.7043 ± 0.12 7.46 
50.2 7.1135 ± 0.58 7.4103 ± 0.47 4.17 
101.2 15.8533 ± 0.20 14.6528 ± 0.61 -7.57 
Benperidol 
2 0.1713 ± 0.02 0.1635 ± 0.03 - 4.55 
10 0.8923 ± 0.16 0.8145 ± 0.01 -8.71 
30 2.6933 ± 0.18 2.5840 ± 0.06 - 4.06 
Haloperidol 
2 0.1338 ± 0.01 0.1413 ± 0.16 5.61 
10 0.6388 ± 0.03 0.5880 ± 0.05 - 7.95 
30 2.0290 ± 0.02 1.8023 ± 0.05 - 11.17 
Bromperidol 
3 0.1308 ± 0.01 0.1360 ± 0.00 3.98 
15 0.6340 ± 0.02 0.6818 ± 0.02 7.54 
30 1.2525 ± 0.01 1.3715 ± 0.07 9.50 
Phenothiazines 
Flupentixol 
(factor = 0.86) 
5.2 0.1600 ± 0.01 0.1680 ± 0.00 4.87 
15.1 0.4300 ± 0.02 0.4200 ± 0.01 -2.58 
30.1 0.8600 ± 0.02 0.8300 ± 0.03  -3.31 
Zuclopenthixol 
(factor = 0.85) 
5.1 0.5641± 0.03 0.6310 ± 0.06 11.88 
51 8.4470 ± 0.09 8.6050 ± 0.01 1.87 
102 18.2630 ± 0.07 17.0810 ± 0.01 - 6.47 
Note: The accuracy of the method was carried out 12 times (n=12) for each concentration. 
SD: stand-ard deviation, mAU: peak height. 
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4.1.9.6 Lower Detection (LOD) and Quantification Limit (LOQ)  
The obtained limit of detection gave the lowest concentration of analytes in the 
sample material, in which the signal-to-noise ratio is at least 3:1 (S/N=3). The 
obtained limit of quantification gave the minimum concentration of analyte in the 
sample that was quantitatively determined with accepted precision and accuracy. 
The concentrations were detected with a probability of 50% as specified by DIN 
32645 and the results obtained correspond to the requirements (see table 32). 
Table 32. The result analysis of LOD and LQD. 
Substance 
Concentration  
(ng/ml) 
Limit of Detec-
tion 
(ng/ml) 
Limit of Quantification 
(ng/ml) 
Butyrophenones 
Melperone 
(factor = 0.88) 
5-120 
(measured in 13 steps) 
7.3 22 
Benperidol 
1–10  
(measured in 6 steps) 
0.7 2.0 
Haloperidol 
1–10  
(measured in 6 steps) 
0.7 2.0 
Bromperidol 
3–20  
(measured in 6 steps) 
1.5 4.5 
Phenothiazines 
Flupentixol 
(factor = 0.86) 
1-10  
( measured in 6 steps) 
1.72 5.2 
Zuclopenthixol 
(factor = 0.85) 
2–16  
( measured in 8 steps) 
1.67 5.01 
Note: The limit of detection and limit of quantification were obtained by measuring each con-
centration four times (n=4). LOD: limit of detection, LQD: limit of quantification. 
 
4.1.9.7 Long-term Stability  
The stability of the substances in the sample solution during long-term storage at -20 
oC for 12 months was analyzed with serum and with drug solution . According to DIN 
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32645, the mean stability of the substances should lie between 90-110% of the mean 
of the corresponding control samples.  
The amount of the freshly prepared test samples served as the 100% yield. The 
antipsychotic substances in solution were observed to decrease below the given 
specification after 3 months (see table 33). The stability of the substances in sample 
solution is therefore proven for 3 months when stored at -20 oC. 
Table 33. Long-term stability of the substances in sample solution. 
Substance 
Conc. 
(ng/ml) 
Current Test 
(mAU ± SD) 
3 Months  
Mean % ±SD 
6 months 
Mean % ±SD 
12 months  
Mean % ±SD 
Butyrophenones 
Melperone 
(factor = 0.88) 
22 3.60 ± 0.12 93.92 ± 4.4 47.20 ± 0.2  37.00 ± 0.8 
50.2 6.21 ± 0.03 89.62 ± 0.4 51.00 ± 0.6 38.00 ± 1.0 
102.1 12.65± 0.6 90.60 ± 2.8 68.50 ± 1.2 48.00 ± 2.6 
Benperidol 
2 0.24 ± 0.0 90.00 ± 4.2 60.40 ± 2.1 42.30 ± 3.3 
10 0.65 ± 0.0  92.30 ± 2.5 60.70 ± 3.3 41.90 ± 1.8 
30 1.94 ± 0.2 89.50 ± 1.3 52.10 ± 2.6 36.40 ± 4.2 
Haloperidol 
2 0.13 ± 0.0 99.00 ± 2.2 45.00 ± 4.0 46.00 ± 3.2 
10 0.69 ± 0.0 91.27 ± 0.8 58.40 ± 2.1 44.80 ± 3.4 
30 2.06 ± 0.0 89.96 ± 5.4 37.00 ± 3.1 56.00 ± 4.2 
Bromperidol 
3 0.13 ± 0.0 109.90 ± 1.6 66.00 ± 3.3 47.00 ± 2.1 
15 0.63 ± 0.0 91.46 ± 2.2  72.83 ± 2.2 54.50 ± 3.5 
30 1.25 ± 0.0 90.38 ± 1.2 54.00 ± 1.8 65.00 ± 2.7 
Phenothiazines 
Flupentixol 
(factor = 0.86) 
5.2 0.52 ± 0.0 91.69 ±3.8 39.00 ± 1.9 32.00 ± 7.6 
15.1 1.52 ± 0.0 90.36 ± 1.9 38.19 ± 3.3 30.79 ± 2.6 
30.1 3.00 ± 0.1 89.89 ± 1.3 37.97 ± 2.7 31.94 ±1.0 
Zuclopenthixol 
(factor = 0.85) 
5.1 0.76 ± 0.1 90.78 ± 3.9 66.93 ± 2.1 41.90 ± 3.1 
51 8.60 ± 0.1 90.05 ± 0.2 72.23 ± 1.4 34.93 ± 4.3 
102.1 17.85 ± 0.1 89.74 ± 0.7 72.66 ± 0.8 41.34 ± 0.3 
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Note: The long-term stability measurements of substance solutions stored at -20 
o
C for 12 months 
were carried out by measuring each concentration four times (n= 4). SD: standard deviation, mAU: 
peak height. 
4.1.9.8 Freeze/ Thaw Stability  
The stability of the substances in the sample solution was analyzed under the TDM 
routine conditions for a given time interval. The solutions were stored in eppendorf 
caps for 30 minutes at -20oC until frozen. They frozen solutions were thawed within 
15 minutes at room temperature under centrifugation, respectively. This process was 
carried out repeatedly for the sample solutions and four times for each concentration. 
The results (see table 34) obtained correspond to the specification according to DIN 
32645, which is between 90–110% of the mean of the corresponding control value. 
Table 34. Freeze/thaw stability test result for antipsychotics. 
Substance 
Conc. 
(ng/ml) 
Mean Measure-
ment 
(mAU ± SD) 
Mean Control 
Measurement 
(mAU ± SD) 
Mean (%) ± SD 
Butyrophenones 
Melperone 
(factor = 0.88) 
22 3.40 ± 0.1 2.28 ± 0.0 149.12 ± 4.4 
50.2 6.72 ± 0.4 5.84 ± 0.1 115.07 ± 6.8 
101.2 13.96 ± 0.4 13.85 ± 0.4 100.79 ± 2.9 
Benperidol 
2 0.20 ± 0.0 0.14 ± 0.0 142.86 ± 7.1 
10 0.61 ± 0.0 0.62 ± 0.2 98.39 ± 4.8 
30 1.60 ± 0.0 1.89 ± 0.2 84.66 ± 2.1 
Haloperidol 
2 0.12 ± 0.0 0.13 ± 0.0 92.30 ± 0.0 
10 0.48 ± 0.0 0.64 ± 0.0 75.00 ± 0.0 
30 1.31 ± 0.1 2.03 ± 0.0 64.53 ± 4.9  
Bromperiol 
3 0.14 ± 0.0 0.13 ± 0.0 107.69 ± 0.0 
15 0.56 ± 0.1 0.63 ± 0.0 88.89 ± 15.9 
30 1.13 ± 0.1 1.25 ± 0.0 90.4 ± 8.0 
Phenothiazines 
Flupentixol 5.2 0.54 ± 0.0 0.51 ± 0.0 105.88 ± 0.0 
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(factor = 0.86) 15.1 1.57 ± 0.0 1.46 ± 0.0 107.53± 0.0 
30.1 3.1 ± 0.0 2.90 ± 0.1 106.90 ± 0.0 
Zuclopenthixol 
(factor = 0.85) 
5.1 0.56 ± 0.0 0.62 ± 0.0 90.32 ± 0.0 
51 6.48 ± 0.0 6.56 ± 0.1 98.78 ± 0.0 
102.1 13.94 ± 0.0 13.47 ± 0.0 103.49 ± 0.0 
Note: The freeze/thaw stability measurements of substance solutions were carried out by 
measuring each concentration four times (n=12 for each substance). SD: standard deviation, 
mAU: peak height. 
 
4.1.9.9 Test of Robustness 
The observation made was that the developed method remained unaffected by small 
and deliberate changes carried out during the measurements. This is proof of the 
reliability of the method. The pH value of the mobile phase was observed to have an 
impact on the measurement. There was no substance absorption observed at pH 6.0 
(see table 35). 
Table 35. Parameters applied to prove the robustness of the developed method. 
Parameter 
Standard 
condition 
Modifi-
cation 
Impact on 
the Method 
Standard 
condition 
Modifi-
cation 
Impact on 
the Method 
Butyrophenones Phenothiazines 
Temperature 
(
o 
C) 
30 40 Noise 30 40 Noise 
Total run time 
(min) 
35 25 
Wider peak, 
but still relia-
ble 
35 25 
Wider peak, 
but still reli-
able 
pH value 5  
4.3 
Interference 
between 
MLP & BPD 
5 
5.2 None 
5.2 None 
6 
No absorpti-
on 6 
No absorpti-
on 
ACN/ MeOH 
portion (ml) 
130/ 300 
100 
/330 
None 130/ 300 
100 
/330 
None 
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Acetonitrile 
(ml) 
300 
350 
(+5%) 
Slight peak 
deformation 
300 
350 
(+5%) 
Slight peak 
deformation 
Methanol (ml) 130 80 (-5%) 
Slight peak 
deformation  
130 80 (-5%) 
Slight peak 
deformation  
Note: The robustness of the method was measured four times (n=4) at a concentration of 100 
ng/ml for each substance. 
 
4.1.9.10 Selectivity 
The test substances were detected and quantified without the interference of other 
substances. The examined substances were the substances administered in 
combination with antipsychotic medications. These substances were developed from 
the pharmacovigilance data of the AGATE group in the psychiatry. The 
butyrophenone and the phenothiazine substances were examined at the optimal 
wavelength of 245 nm and 230 nm, respectively (see appendix 5 and appendix 6).  
The results of the validation were successful; the substances meet all the required 
criteria for the determination of drugs in human serum for the purpose of therapeutic 
drug monitoring 
4.1.9.11 Routine Application of the Validated Method 
The validated method was applied for routine measurement of each substance. The 
blank serum do not contain any substance, the standard sample contains drug 
substances at known concentrations. The patients’ samples were measured in a 
single procedure together with the blank, and the standard sample (see table 36 and 
figure 29 - 34). 
Table 36. Routine measurement of the substances. 
Substance Conc. 
(ng/ml) 
Peak height 
(mAU ± SD) 
Retention time 
(min ± SD) 
Amount (ng/ml) Therapeutic 
reference range 
(ng/ml) 
Melperone 22 4.98 ± 0.19 14.77 ± 0.02 22.09 ± 0.85 30 - 100 
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 50.2 11.075 ± 0.08 14.65 ± 0.005 49.12 ± 1.1 
102.1 22.909 ± 0.12 14.64 ± 0.015 102.22 ± 0.54 
Pat. serum   4.187 14.586 18.58 
      
Benperidol  2 0.156 ± 0.003 16.32 ± 0.03 2.03 ± 0.003 1 - 10 
10 0.741 ± 0.001 16.39 ± 0.005 9.64 ± 0.005 
30 2.315 ± 0.008 16.33 ± 0.015 30.12 ± 0.011 
Pat. serum  0.171 16.40 2.2 
      
Haloperidol  2 0.089 ± 0.001 24.13 ± 0.002 2.18 ± 0.01 1 - 10 
10 0.444 ± 0.003 24.22 ± 0.003 10.88 ± 0.6 
30 1.24 ± 0.002 24.17 ± 0.005 29.79 ± 1.1 
Pat. Serum  0.20 23.90 4.95  
      
Bromperidol 
 
3 0.1285 ± 0.007 27.25 ± 0.06 3.07 ± 0.16 1 - 10 
15 0.637 ± 0.01 26.75 ± 0.08 15.27 ± 0.19 
30 1.261 ± 0.012 26.76 ± 0.065  30.64 ± 0.22 
Pat. Serum   0.502 27.05 12.02 
      
Flupentixol 
 
5.2 0.115 ± 0.02 14.89 ± 0.003 5.24 ± 0.06 1 - 10 
15.1 0.332 ± 0.04 14.94 ± 0.05 15.18 ± 0.04 
30.1 0.657 ± 0.02 14.96 ± 0.01 30.02 ± 0.02 
Pat. Serum   0.182 14.85 8.28 
      
Zuclopenthixol  
 
5.1 1.489 ± 0.005 20.75 ± 0.002 5.4 ± 0.005 4 - 50 
51 11.937 ± 0.006 20.70 ± 0.001 51.84 ± 0.003 
102.1 23.34 ± 0.013 20.69 ± 0.005 102. 09 ± 0.002 
Pat. Serum  8.961  20.65  38.93 
Note.: SD = standard deviation; Amount = concentration obtained after measurement. 
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Sample Chromatograms of the Substances Measured with the Validated Method  
 
Figure 29. The standard MLP sample used during the measurements. 
Note: measured concentration of 22 ng/ml, the blank serum sample (0 ng/ml) and the patient’s sam-
ple. mAU = peak height. 
The blank serum, top left, does not contain MLP. The smallest standard 
concentration applied is 22 ng/ml, see chromatogram, top right. The chromatogram 
of the patient’s serum with the dose of 25 mg is underneath. The concentration 
obtained (18.58 ng/ml) is within the therapeutic reference range for MLP (30 - 100 
ng/ml). Mobile phase solvent consists of 30 % ACN, 13 % MeOH,  0.4 % TEMED, 
and 56.6 % demineralized water. 
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Figure 30. The standard BPD sample used during the measurements. 
Note: measured concentration of 2 ng/ml, the blank serum sample (0 ng/ml), and the patient’s sample. 
mAU = peak height. 
The blank serum, top left, does not contain BPD. The smallest standard 
concentration applied is 2 ng/ml, see chromatogram top right. The chromatogram of 
the patient’s serum with the dose of 26 mg is underneath. The concentration 
obtained (2.20 ng/ml) is within the therapeutic reference range for BPD (1- 10 ng/ml). 
Mobile phase solvent consists of 30 % ACN, 13 % MeoH, 0.4 % TEMED, and 56.6 % 
demineralized water. 
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Figure 31. The standard HLP sample used during the measurements. 
Note: measured concentration of 2 ng/ml, the blank serum sample (0 ng/ml), and the patient’s sample. 
mAU = peak height. 
The blank serum, top left, does not contain HLP. The smallest standard 
concentration applied is 2 ng/ml, see chromatogram top right. The chromatogram of 
the patient’s serum underneath has no dose information. The concentration (4.95 
ng/ml) obtained is within the therapeutic reference range for HLP (1- 10 ng/ml). 
Mobile phase solvent consists of 30 % ACN, 13 % MeOH, 0.4 % TEMED, and 56.6 
% demineralized water. 
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Figure 32. The standard BRP sample used during the measurements. 
Note: measured concentration of 3 ng/ml, the blank serum (0 ng/ml) and the patient’s sample. mAU = 
peak height. 
The blank serum, top left, does not contain BRP. The smallest standard 
concentration applied is 3 ng/ml, see chromatogram top right. The chromatogram of 
the patient’s serum has no dose information. The concentration (12.02 ng/ml) 
obtained is slightly above the therapeutic reference range for BRP (1- 10 ng/ml). 
Mobile phase solvent consists of 30 % ACN, 13 % MeOH, 0.4 % TEMED, and 56.6 
% demineralized water. 
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Figure 33. The standard FLT sample used during the measurements. 
Note: concentration of 5.2 ng/ml, the blank serum sample (0 ng/ml), and the patient’s smaple.  mAU = 
peak height. 
The blank serum, top left, does not contain FLT. The smallest standard concentration 
applied is 5.1 ng/ml, see chromatogram top right. The chromatogram of the patient’s 
serum with the dose of 15 mg is underneath in the diagram. The concentration 
obtained (8.28 ng/ml) is within the therapeutic reference range for FLT (1- 10 ng/ml). 
Mobile phase solvent consists of 30 % ACN, 13 % MeOH, 0.4 % TEMED, and 56.6 
% demineralized water. 
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Figure 34. The standard ZLT sample used during the measurements. 
Note: concentration of 5.1 ng/ml, the blank serum sample, and the patient’s sample.  mAU = peak 
height. 
The blank serum, top left, does not contain ZLT. The smallest standard concentration 
applied is 5.1 ng/ml, see chromatogram top right. The chromatogram of the patient’s 
serum with the dose of 200 mg /14 days (14.29 mg/day) is underneath in the 
diagram. The concentration obtained (38.93 ng/ml) is within the therapeutic reference 
range for ZLT (4- 50 ng/ml). Mobile phase solvent consists of 30 % ACN, 13 % 
MeOH, 0.4 % TEMED, and 56.6 % demineralized water. 
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4.2 Application of the Developed Method for TDM 
The developed method was applied for the therapeutic drug monitoring of the 
substances administered to patients at different doses. The results of the measured 
serum samples were either within the expected reference ranges, below or above it. 
The interpretation of the result depends on individual patients’ factors that have 
impact on the serum concentration such as gender, age, co-medications, clinical 
status and the history of their sicknesses. 
4.2.1 Demographic Data of Study Patients 
Some patients’ data-information were not given, so that in some cases, the numbers 
used for the evaluation were less compared to the total number of patients (see table 
37). The main diagnoses were determined especially, according to chapter five, 
mental and behavioural diaorders of the International Statistical Classfication of 
Diseases and Related Health Problems revison 10, Version for 2010.  
Table 37. Summary Data of Study Patients. 
Substances Number of 
patients 
(n) 
Age 
(year) 
 
(Mean ± 
SD) 
Hight 
(cm) 
(Mean ± 
SD) 
Weight 
(kg)  
(X ± SD) 
BMI (cm 
/m
2
) 
 
(X ± SD) 
Gender 
(M, 
male;  
F, fe-
male) 
Main 
Diagnoses 
MLP 7 52.86 ± 
11.7 
n = 4 
168.43 
70.57 ± 
11.06 
26 ± 5.9 M = 5 
F = 2 
n = 6 
F20.0 = 4 
F25.1 = 1 
F20.5 = 1 
BPD 5 48.8 ± 
14.1 
170.8 ± 
7.2 
79 ± 18.8 27.2 ± 
6.5 
M = 1 
F = 4 
F20.0 = 4 
F25.1 = 1 
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HLP 566 49.75 ±  n = 318 
168.6 ± 
4.2 
n = 461 
77.4 ± 
12.1 
n = 436 
22.62 ± 
10.3 
M = 229 
F = 337 
n = 467 
F20 = 76 
F20.0 = 
179 
F* = 210 
G40 = 1 
G81.1 = 1 
 
BRP 2 58.6 ± 
13.4 
NN n = 1 
60.9 
26 ± 3.5 F = 2 F20 
FLT 41 46.0 ± 
10.8 
n = 32 
171.66 ± 
10.8 
83.80 ± 
19.9 
n = 34 
29.9 ± 
7.9 
M = 22 
F = 19 
n = 32 
 
F20.0 = 27 
F25 = 1 
F25.2 = 3 
F33.2 = 1 
ZLT 3 56.7 ± 
8.7 
n = 2 
172.5 ± 
0.5 
n = 2 
85.5 ± 
11.5 
n = 2 
29.0  ± 
4.0 
M = 2 
F = 1 
n = 2 
F20 = 1 
F20.5 =1 
Note: F*: These are subdivisions of other main diagnoses stated for HLP. F32=5, F40.2=1, F60.3=1, 
F03=4, F05.0=1, F06.2=1, F06.8=2, F07.1=1, F10.0=1, F10.1=12, F10.2=2, F10.7=3, F13.2=1, 
F19.2=7, F20=76, F20.0=179, 20.1=9, F20.2=13, F20.3=2, F20.5=30, F21=2, F22.0=3, F25=3, 
F25.0=11, F25.1=3, F25.2=16, F25.9=6, F29=16, F31=2, F31.0=1, F31.1=1, F32.2=2, F32.3=1, 
F33.1=1, F33.2=1, F33.3=5, F41.1=1, F43.1=1, F60=1, F60.2=12, F60.3=3, F60.7=1, F61=1, F70=5, 
F70.0=2, F71=6, F71.1=4, F72.1=2, F84.1=1, G40=1, G81.1=1. NN = not known. 
 
4.2.2 Doses and Drug Concentrations 
The relationship between the administered dose and the serum concentrations 
obtained, were calculated. Some request forms did not indicate any dose, so that the 
dose-related concentration could not be calculated. The bioavailability and 
elimination half-life of the substances were taken from the summary of their product 
characteristics. 
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4.2.2.1 Dose- concentration relationship of measured MLP sample and the 
DRR 
The explanation for the calculation of the dose-related reference range with the 
fraction of concentration and dose is derived from the AGNP Consensus Guidelines 
for Therapeutic Drug Monitoring in Psychiatry: Update 2011 [Hiemke et al., 2011], 
which according to the consensus is based on the study of Borgstrom et al. (1982). 
The multiplication of the factor 0.14 with the maintenance dose ( C/D low x dose) 
gives the low value of the dose-related reference range (DRR-low) for melperone and 
the multiplication of the factor 0.28 with the maintenance dose (C/D high) gives the 
high value of the dose-related reference range (DRR-high) for melperone. One 
measured serum sample of melperone was within the expected DRR at concentra-
tion of 3.5 ng/ml with the administered dose of 25 mg. Three samples were below the 
DRR and three samples were not calculated, because of the missing dose infor-
mation (see table 38 and figure 35). The measurements of the samples with missing 
dose information were requested in other to verify if the patient take the medication. 
The value of the measured concentration ranges from 4 – 19 ng/ml and the DRR 
ranges from 0 – 21 ng/ml. All the measured patients' samples contain co-
medications.   
Table 38 TDM information of MLP in measured patients’ serum. 
Dose  
(mg/d) 
Conc.  
(ng/ml) 
DRR  
(ng/ml) 
TRR  
(ng/ml) 
30 13 4-8 30-100 
25 4 4–7 30-100  
NN 13 NN 30-100 
NN 4 NN 30-100 
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25 19 4–7 30-100 
75 6 11–21 30-100 
NN 15 NN 30-100 
Note: NN: not known, DRR: dose-related reference range, Conc: concentration. TRR: therapeutic ref-
erence range, Conc: concentration.  
 
 
Figure 35. Dose-concentration relationship of seven MLP patients' specimens. 
The horizontal area indicates the therapeutic reference range (TRR) and the 
triangular area the dose-related reference range (DRR).  
 
4.2.2.2 Dose- Concentration Relationship of Measured BPD Sample and the 
DRR 
The explanation for the calculation of the dose-related reference range with the 
fraction of concentration and dose is derived from the AGNP Consensus Guidelines 
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for Therapeutic Drug Monitoring in Psychiatry: Update 2011 [Hiemke et al., 2011], 
which according to the consensus is based on the study of Seiler et al. (1994). 
From the given maintenance dose of 40, 26, 32, and 12 mg BPD, a concentration of 
7.0, 2.2, 13, and 12 ng/ml were measured, respectively. Two measurements were 
above the expected therapeutic reference range (see table 39 and figure 36). The 
value of the measured concentration is higher when compared with that of the 
corresponding values of DRR. The measured concentration ranges from 2.2 ng/ml to 
13 ng/ml and the expected DRR ranges from 1.8 ng/ml to 12.4 ng/ml. All the meas-
ured patients' samples contain co-medications. 
Table 39 TDM information of BPD in measured patients’ serum. 
Dose 
(mg) 
Conc.  
(ng/ml) 
DRR  
(ng/ml) 
TRR 
 (ng/ml) 
40 7.0 6.0 – 12.4 1-10 
26 2.2 3.9 – 8.06 1-10 
32 13.0 4.8 – 9.92 1-10 
12 12.0 1.8 – 3.72 1-10 
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Note: DRR: dose-related reference range, TRR: therapeutic reference range, Conc: concentration.  
 
Figure 36. Dose-concentration relationship of four BPD patients' specimens. 
The horizontal area indicates the therapeutic reference range (TRR) and the triangu-
lar area the DRR.  
 
4.2.2.3 Dose- Concentration Relationship for HLP 
The explanation for the calculation (see table 40) of the dose-related reference range 
with the fraction of concentration and dose is derived from the AGNP Consensus 
Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 [Hiemke et 
al., 2011], which according to the consensus is based on the study of Cheng et al. 
(1987). 
Table 40 Calculation of dose-related reference range for haloperidol. 
Factor Multiplication Result Value 
C/D low x Dose   DRR-low  0.6 
C/D high x Dose DRR-high  1.0 
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Note. C/ D low and C/ D high are factors obtained from the study of Cheng et al. (1987) for calculat-
ing dose-related reference range. DRR = Dose-related reference range. 
Thirty-five samples with the maintenance dose of oral haloperidol (see table 41) were 
measured, respectively. There was no dose information for two samples. Sixteen 
samples were within the TRR and fourteen samples were above the TRR. No 
concentration was obtained in three samples (see figure 37). The maximum 
measured concentration is higher than that of DRR (see figure 38). Six of the meas-
ured patients' samples do not contain co-medications (see table 42). The mean 
measured concentration was 5.67 ng/ml and the median is 6.95 ng/ml. The values 
are low compared to the data of patients’ samples that contain co-medication. Their 
mean measured concentration was 12.53 ng/ml and the median was 10.00 ng/ml. 
Table 41 TDM information of HLP in patients’ serum. 
Dose 
(mg) 
Conc.  
(ng/ml) 
DRR  
(ng/ml) 
TRR 
 (ng/ml) 
NN 0.0 0.0 1 - 10 
NN 1.6 0.0 1 - 10 
0,5 1.0 0.3 – 0.5 1 - 10 
1 1.4 0.6 – 1.0 1 - 10 
3 1.4 0.8 - 3.0 1 - 10 
5 0.0 3.0 - 5.0 1 - 10 
5 3.4 3.0 - 5.0 1 - 10 
5 20 3.0 - 5.0 1 - 10 
6 1,7 3.6 - 6.0 1 - 10 
7,5 8,2 4.5 - 7.5 1 - 10 
8 2,9 4.8 - 8.0 1 - 10 
8 7 4.8 - 8.0 1 - 10 
10 7,3 6.0 - 10.0 1 - 10 
10 11 6.0 - 10.0 1 - 10 
10 35 6.0 - 10.0 1 - 10 
10 5 6.0 - 10.0 1 - 10 
10 6,9 6.0 - 10.0 1 - 10 
10 49 6.0 - 10.0 1 - 10 
10 7,3 6.0 - 10.0 1 - 10 
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15 12 9.0 - 15.0 1 - 10 
15 21 9.0 - 15.0 1 - 10 
20 8,8 12.0 - 20.0 1 - 10 
20 25 12.0 - 20.0 1 - 10 
20 22 12.0 - 20.0 1 - 10 
20 18 12.0 - 20.0 1 - 10 
20 20,3 12.0 - 20 1 - 10 
20 2,9 12.0 - 20.0 1 - 10 
20 7,59 12.0 - 20.0 1 - 10 
25 13 15.0 - 25.0 1 - 10 
30 18 18.0 - 30.0 1 - 10 
30 0 18.0 - 30.0 1 - 10 
30 21 18.0 – 30.0 1 - 10 
30 10 18.0 – 30.0 1 - 10 
40 26 24.0 - 40.0 1 - 10 
50 1,7 30.0 - 50.0 1 - 10 
Note: DRR: dose-related reference range, TRR: therapeutic reference range, Conc: concentration.  
NN = not known. 
Table 42 Data of patients’ HLP samples without co-medication. 
Dose (mg) Conc. (ng/ml) DRR TRR 
7.5 8.2 4.5 – 7.5 1 - 10 
8.0 7.0 4.8 -8.0 
1 - 10 
10.0 6.9 6.0 – 10.0 
1 - 10 
10.0 7.3 6.0 – 10.0 
1 - 10 
20.0 2.9 12.0 – 20.0 1 - 10 
50.0 1.7 30.0 – 50.0 1 - 10 
Note: Six patients’s samples were without co-medication. Three concentrations of the measured se-
rum samples were within the dose-related reference range and therapeutic reference range at the 
maintenance dose of 8.0 mg and 10.0 mg. 
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Figure 37. Dose-concentration relationship of thirty-five HLP patients' specimens. 
The horizontal area indicates the therapeutic reference range (TRR).The triangular 
area the dose-related reference range (DRR). 
 
Figure 38. Comparison between the measured concentration and the dose-related reference 
range (DRR) of haloperidol. 
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The comparison between the measured concentration and the dose-related refer-
ence range (DRR) was evaluated. Q = quartile. For measured concentration, Q1 = 
1.7 ng/ml, minimum = 0 ng/ml, median = 7.59 ng/ml, mean = 11.35 ng/ml, maximum 
= 49 ng/ml, Q3 = 20. For DRR, Q1 = 4.0 ng/ml, minimum = 0ng/ml, median =8.0 
ng/ml, mean = 11.6 ng/ml, maximum = 40.0 ng/ml, Q3 = 16 ng/ml. The values of the 
measured concentrations and the DRR are at close intervals to the mean and the 
median.  
 
4.2.2.4 Dose- Concentration Relationship of Measured BRP Samples and the 
DRR 
The explanation for the calculation of the dose-related reference range with the frac-
tion of concentration and dose (C/D) is derived from the AGNP Consensus Guide-
lines for Therapeutic Drug Monitoring in Psychiatry: Update 2011 [Hiemke et al., 
2011], which according to the consensus is based on the study of Lee et al. (2006). 
Three patients’ serum samples containing bromperidol were measured. One of the 
samples has no dose information (see table 43). The concentrations of 8 ng/ml and 2 
ng/ml obtained for two serum samples with doses of 6 mg and 3 mg, respectively, 
were within the TRR (see figure 39). The DRR was obtained by multiplying each 
dose with factor 0.09 (C/D low) and 0.19 (C/D high). The measured three samples 
contain co-medications. The mean measured concentration was 7ng/ml and the me-
dian was 8 ng/ml.  
Table 43 TDM information of BRP in patients’ serum. 
Dose Conc.  DRR  TRR 
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(mg) (ng/ml) (ng/ml)  (ng/ml) 
6 8 0.54 – 1.14 1-10 
NN 12 0.00 1-10 
3 2 0.27 – 0.57 1-10 
Note: DRR: dose-related reference range, TRR: therapeutic reference range, Conc: concentration. NN 
= not known" 
 
Figure 39. Dose-concentration relationship of three BRP patients' specimens. 
The horizontal area indicates the therapeutic reference range (TRR). The triangular 
area the dose-related reference range (DRR). All the corresponding DRR of the 
maintenance dose were outside the therapeutic reference range.  
 
4.2.2.5 Dose- concentration relationship of measured FLT samples and the 
DRR 
The explanation for the calculation of the dose-related reference range with the frac-
tion of concentration and dose (C/D) is based on the available pharmacokinetic data 
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for flupentixol. The values of (C/D low) and C/D high were multiplied with the mainte-
nance dose (see table 44) to obtain the DRR. 
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Table 44 Calculation of dose-related reference range of flupentixol. 
Factor Multiplication Result Value 
Applied Data 
C/D low x Dose   DRR-low  0.66 (oral); 1.65 (depot) 
C/D high x Dose DRR-high  1.74 (oral); 4.35 (depot) 
Consensus Data 
C/D low x Dose DRR-low 0.78 
C/D high x Dose DRR-high 0.87 
Note: C/ D low and C/ D high are factors obtained from the applicable data for calculating dose-related 
reference range for depot and oral flupentixol. DRR = Dose-related reference range. Applied data = 
data used in TDM laboratory Regensburg; Consensus data = data derived from AGNP-consensus 
guideline. 
Oral flupentixol dose was administered to 29 patients with schizophrenic and psy-
chotic disorders and 13 patients received depot-flupentixol (administered depot-
flupentixol dose were: 100 mg/14d, 60 mg/14d, 65 mg/14d, 50 mg/14d and 17.2 
mg/14d).  
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Forty measured patients’ samples contain co-medications. Two samples do not con-
tain co-medication (see table 45). The dose information of two patients out of these 
forty samples was not given (see table 46) and there was no measurement carried 
out with one of the patient’s FLT serum sample because the sample did not fulfill the 
laboratory requirements. The sample volume was 0.5 ml instead of recommended 2 
ml. The sample collection was carried out after the medication intake instead of the 
recommended trough concentration by sample collection before the next medication 
intake. The concentration of 19 samples was within the TRR and 15 samples were 
above it (see figure 40). The mean measured concentration for samples containing 
co-medication was 9 ng/ml and the median was 7 ng/ml (see figure 41). 
 
Table 45 Data of patients’ FLT samples without co-medication. 
Dose (mg) Conc. (ng/ml) DRR TRR 
6.0 23 4 – 10 1 - 10 
20.0 7 13-35 
1 - 10 
Note: Monotherapy with oral flupentixol, mean measured concentration was 15.10 ng/ml. 
Table 46 TDM information of all measured FLT in patients’ serum. 
 Dose  
(mg) 
Conc.  
(ng/ml) 
DRR  
(ng/ml) 
TRR 
(ng/ml) 
7.14 20 12 - 31 1 – 10 
7.14 21 12- 31 1 – 10 
10.00 4 7 - 17 1 – 10 
7.14 0 12 - 31 1 – 10 
20.00 17 13- 35 1 – 10 
10.00 24 7 - 17 1 – 10 
7.14 3 12 - 31 1 – 10 
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7.14 9 12- 31 1 – 10 
15.00 2 10 - 26 1 – 10 
7.14 13 12- 31 1 – 10 
5.00 25 3- 9 1 – 10 
10.00 5 7 - 17 1 – 10 
20.00 0 13- 35 1 – 10 
4.29 11 7- 19 1 – 10 
7.14 12 12 - 31 1 – 10 
NN 7 0 1 – 10 
30.00 2 20 - 52 1 – 10 
30.00 30 20 - 52 1 – 10 
1.00 7 1 - 2 1 – 10 
15.00 7 10 - 26 1 – 10 
3.57 3 6 - 16 1 – 10 
20.00 2 13- 35 1 – 10 
4.00 0 3 - 7 1 – 10 
10.00 0 7 - 17 1 – 10 
1.23 3 2- 5 1 – 10 
4.29 7 7- 19 1 – 10 
10.00 5 7 - 17 1 – 10 
5.00 0 3- 9 1 – 10 
6.00 23 4 - 10 1 – 10 
15.00 22 10 - 26 1 – 10 
20.00 20 13- 350 1 – 10 
15.00 0 10 - 26 1 – 10 
20.00 7 13- 35 1 – 10 
4.00 13 3 - 7 1 – 10 
15.00 8 10 - 26 1 – 10 
15.00 0 10 - 26 1 – 10 
10.00 0 7 - 17 1 – 10 
20.00 10 13- 35 1 – 10 
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NN 18 0 1 – 10 
4.64 9 8 - 20 1 – 10 
7.14 7 12 - 31 1 – 10 
10.00 18 7 - 17 1 – 10 
Note: DRR = dose-related reference range, TRR = therapeutic reference range, Conc: concentration. 
NN = not known. 
 
Figure 40. The dose-concentration relationship of fourty-two flupentixol patients' specimens. 
The horizontal area indicates  the therapeutic reference range (TRR) and the 
triangular area the dose related reference range (DRR).  
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Figure 41. Measured concentration of flupentixol in comparison with the expected DRR. 
The comparison between the measured concentration and the dose-related refer-
ence range (DRR). Q = quartile. For measured concentration Q1 = 2.2 ng/ml, mini-
mum = 0 ng/ml, mean = 9.35 ng/ml, maximum = 30 ng/ml, Q3 = 16.60 ng/ml, median 
= 6.95 ng/ml. For DRR Q1 = 12.0 ng/ml, minimum = 0 ng/ml, median = 18 ng/ml, 
mean = 15.89 ng/ml, maximum = 36.0 ng/ml, Q3 = 24 ng/ml.  
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Comparison of Consensus DRR-Data with the Applied DRR-Data for FLT 
The DRR of the measured concentrations were compared between the consensus 
data and the applied data. The Flt maintenance doses were multiplied with the con-
sensus data of 0.78 (C/D low) and 0.87 (C/D high), to obtain the corresponding DRR 
for FLT (see table 47). The calculation with the applied DRR data has been shown in 
table 46 above.  
Table 47 Result of the DRR calculated according to consensus. 
Dose (mg) Concentration (ng/ml) 
  Measured conc. (ng/ml) DRR low DRR high 
7.14 19.5 5.6 6.2 
7.14 21.0 5.6 6.2 
10.00 4.4 7.8 8.7 
7.14 0.0 5.6 6.2 
20.00 16.6 15.6 17.4 
10.00 24.0 7.8 8.7 
7.14 3.0 5.6 6.2 
7.14 9. 5 5.6 6.2 
15.00 1.7 11.7 13.1 
7.14 13.0 5.6 6.2 
5.00 25.0 3.9 4.4 
10.00 4.8 7.8 8.7 
20.00 0.0 15.6 17.4 
4.29 10.9 3.4 3.7 
7.14 12.3 5.6 6.2 
NN 7.0 0.0 0.0 
30.00 2.2 23.4 26.1 
30.00 30.0 19.8 52.2 
1.00 6.9 0.78 0.87 
15.00 6.7 1.7 13.1 
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3.57 2.9 2.8 3.1 
20.00 1.8 15.6 17.4 
4.00 0.0 3.1 3.5 
10.00 0.0 7.8 8.7 
1.23 2.8 1.0 1.1 
4.29 6.5 3.4 3.7 
10.00 4.5 7.8 8.7 
5.00 0.0 3.9 4.4 
6.00 23.4 4.7 5.2 
15.00 22.3 11.7 13.1 
20.00 20.0 15.6 17.4 
15.00 0.0 11.7 13.1 
20.00 6.8 15.6 17.4 
4.00 13.3 3.1 3.5 
15.00 8.3 11.7 13.1 
15.00 0.0 11.7 13.1 
10.00 0.0 7.8 8.7 
20.00 10.0 15.6 17.4 
NN 18.0 0.0 0.0 
4.64 8.6 3.6 4 
7.14 7.0 6.0 6.2 
10.00 18.0 7.8 8.7 
Note: The DRR was calculated according to values in the TDM consensus. DRR = dose-related ref-
erence range. NN = not known.  
 
The consensus DRR data is narrow and closer to the therapeutic reference range 
while the applied DRR data is wider and above the therapeutic reference range. The 
low DRR value of the consensus data is comparably higher than that of the applied 
data (see figure 42). More than half of the measured concentrations were above the 
consensus DRR range.  
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Figure 42. Consensus FLT DRR data in comparison with the applied FLT DRR data. 
 
4.2.2.6 Dose- concentration relationship of measured ZLT samples and the 
DRR 
The explanation for the calculation of the dose-related reference range with the frac-
tion of concentration and dose is derived from the AGNP consensus for therapeutic 
drug monitoring in the psychiatry: update 2011, which according to the consensus is 
based on the study of Jerling et al. (1996). The DRR was obtained by multiplying 
each dose with factor 0.13 (C/D low) and 0.35 (C/D high).   
Three ZLT serum samples comprised of 2 oral ZLT and 1 depot ZLT. Oral ZLT dose 
administered were 12 and 20 mg/day, depot ZLT administered was 200 mg/14 days 
(see table 48). Two out of the three measured samples contain co-medications. One 
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of the samples was administered as monotherapy with a depot application. All the 
measured concentrations are within the TRR but above the DRR (see figure 43).  
Table 48 TDM information of ZLT in measured patients’ serum. 
 Dose  
(mg) 
Conc.  
(ng/ml) 
DRR  
(ng/ml) 
TRR 
(ng/ml) 
200/14 day (14.29/day)  39 2 – 5 4 - 50 
20 27 3 – 7 4 - 50 
12 9 2 - 4 4 – 50 
Note: DRR = dose-related reference range, TRR = therapeutic reference range, Conc: concentration.  
 
Figure 43. The The Dose-Concentration-Relationship of three zuclopenthixol patients' 
specimens. 
The horizontal area indicates the therapeutic reference range (TRR) and the triangu-
lar area the dose related reference range (DRR).  
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4.2.3 Results of Antipsychotic TDM Data Evaluation 
The routine application of the developed and validated method was successful. The 
recorded data in konbest and other databases applicabale to this work were 
reveiwed and compared with the study substances under the application of different 
parameters. The results of the data evaluations were successfully applied in the clinic 
pharmacological interpretations of the laboratory values of individual patients and in 
the pharmacist advice to the attending clinicians at the clinic ward. For the study 
substances, the serum concentrations were measured with the validated method. A 
reliable interpretation of the values were satisfactorily carried out and then submitted 
to the attending clinicians. Possible drug interactions between the recorded co-
medications in konbest and the administered substances were also reviewed during 
the TDM clinic-pharmacological interpretation. The evaluation cost of haloperidol was 
carried out with the help of ABDA database. The recorded pharmacovigilance data of 
melperone and benperidol in the psychiatry was carried out with AGATE database. 
The comparison of C/D values of AGNP consensus data with the measured 
concentration of the study susbstances were satisfactorily carried out through the 
data extraction of the AGNP Consensus Guideline: update 2011. 
4.2.3.1 The Konbest Data of Melperone 
Seven patient’ specimens (= 100%) were measured. The maintenance dose of 
melperone was not given in 42.86% of the delivered patients’ sample. 57.86% of the 
samples indicated the maintenance dose, from which the dose-related reference 
range were analyzed and evaluated. The Konbest data showed a maintenance dose 
between 25 to 75 mg. The measured concentrations calculated from the 
maintenance dose were between 4 and 19 ng/ml; the recorded dose-related 
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reference ranges were between 4 and 21 ng/ml. Melperone was administered as 
reserve medication in all the study patients. The patients received other medications 
alongside with melperone. The co-medications in two of the measured samples lead 
to an increase of the concentration. The co-medications are; risperidon, clozapin, and 
propranolol.  
4.2.3.2 The Konbest Data of Benperidol 
Serum samples of different patients containing BPD and other co-medications from 
different hospitals were measured in the TDM laboratory using the described 
validated method. The samples were prepared in one single operation with three 
standard serum solutions (2, 10 and 30 ng/ml). The results of the measured patients’ 
samples are on table 39. According to the patients’ information recorded in the 
konbest, all the four patients were seriously sick before the administration of 
benperidol. Three patients got better, but one patient got worse at a serum 
concentration of 11.80 ng/ml, the maintenance dose of 12 mg and with the 
corresponding dose- related-reference range of 1.8– 3.72 ng/ml. Recorded co-
medications were biperidene, bisoprolol, clozapine lorazepam, pirenzepine, valproic 
acid and zuclopenthixol. 
4.2.3.3 The Konbest Data of Haloperidol 
The total of 566 (100%) patients’ haloperidol data was recorded in the Konbest 
program. 59.54% of the patients were male and 40.46% were female. The average 
age of the patients treated with haloperidol was 49.75 ± 5.6 years. 66 recorded 
undesired effects were observed, but could neither be traced to haloperidol serum 
concentration nor to the co-medications alone. 16 patients experienced undesired 
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effects though their serum concentrations were below the therapeutic reference 
range. Inter-individualities of the obtained patients’ serum concentrations were 
observed. 28 patients got better at haloperidol serum cencentration above the 
therapeutic reference range. At concentration below the therapeutic reference range, 
17 patients got better. 75 patients whose haloperidol serum concentrations were 
within the expected therapeutic reference range got better. Other patients health 
statues were not recorded.  
Frequency of TDM HLP Request 
The frequency of HLP-request has increased continuously since the development of 
konbest, and the tendency of further increase is accordingly anticipated from the data 
(see figure 44). The frequency of HLP request in 2008 slightly, but insignificantly de-
clined when compared with that of 2007. The lowest frequency was registered in 
2006 and the highest in 2011.  
 
Figure 44. The annual request of haloperidol. 
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Administration of Haloperidol in Combination with other Medications 
The number of co-medications evaluated as active substances which was 
administered to the patients during haloperidol therapy was 206 (see table 49). The 
total frequency of administration was 2077 (100%). The most frequently co-
administered medications to haloperidol were biperidene (7.17%), lorazepam 
(6.45%), olanzapine (6.07%), valproic acid (5.58%), pantoprazole (4.53%), clozapine 
(4.24%). Sixty-nine co-medications (active substances) have the same metabolic 
pathway with haloperidol (CYP 1A2, CYP 2D6, and CYP 3A4) as substrates. Fifty-
one are CYP enzyme inhibitors and fifteen CYP enzyme inducers. Some active 
substances act as inhibitors, inducers as well as substracts (see table 49). 
CYP –enzyme inhibitors cause an elevation of drug serum concentration in a toxic 
level which for example lead to undesired drug effect. CYP-enzyme inducers cause 
the reduction of drug serum level which among others lead to lack of or reduced 
effect. It was observed that co-medications were administered because of 
comorbidities and for the treatment of undesired effects. 
Table 49. The recorded HLP co-medications according to Konbest data. 
Co-medication (active 
substance) 
Frequency of 
administration 
Percentage  
frequency of 
administration 
CYP  
inhibitor 
CYP in-
ducer 
Substrates 
Acarbose 3 0.14 - - - 
Acetylcystein 4 0.19 - - - 
Acetylsalicylsäure 34 1.64 - - - 
Agomelatin 2 0.10 - - 1A2 
Algeldrat 1 0.05 - - - 
Allopurinol 20 0.96 - - - 
Alprazolam 1 0.05 - - 3A4 
Ambroxol 1 0.05 - - - 
Amisulprid 17 0.82 - - - 
Amitriptylin 23 1.11 1A2, 2D6 - 3A4 
Amlodipin 9 0.43 2D6, 3A4 - - 
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Aripiprazol 27 1.37 - - 2D6, 3A4 
Ascorbinsäure 1 0.05 - - - 
Atenolol 1 0.05 - - - 
Atorvastatin 2 0.10 3A4 - - 
Atropa belladona 2 0.10 - - - 
B-acetyldigoxin 3 0.14 - - - 
Baclofen 1 0.05 - - - 
Beclometason 2 0.10 - 3A4 - 
Benperidol 4 0.19 - - 1A2, 2D6, 
3A4 
Bezafibrat 3 0.14 - - 3A4 
bifidobacterium longum 1 0.05 - - - 
Biperiden 149 7.17 2D6 - - 
Bisacodyl 3 0.14 - - - 
Bisoprolol 31 1.49 - - - 
Bornaprin 1 0.05 - - (x)15? 
Brimonidin 2 0.10 - - - 
Bupropion 2 0.10 2D6 - 1A2, 3A4 
Buspiron 1 0.05 - - 2D6, 3A4 
Butylscopolamin 1 0.05 - - (x)12? 
Calcitriol  2 0.10 - 3A4 - 
Calcium 2 0.10 - - - 
Candesartan 2 0.10 - - - 
captopril 2 0.10 - - 2D6 
Carbamazepin 21 1.01 - 1A2, 3A4 2D6 
Carbimazol 2 0.10 - - - 
Cefazolin 1 0.05 - - - 
Ceftriaxon 1 0.05 - - - 
Chlorprothixen 36 1.73 2D6 - 1A2,3A4 
(x)23,21 
Ciclosporin A 1 0.05 3A4 - - 
Ciprofloxacin 1 0.05 1A2, 3A4 - - 
Citalopram 33 1.59 1A2, 2D6 - 3A4 
Clindamycin 2 0.10 - - - 
Clobazam 1 0.05 - - 3A4 
Clomethiazol 1 0.05 - - 2D6, 34 
Clomipramin 2 0.10 2D6 - 1A2, 3A4 
Clonazepam 3 0.14 - - 3A4 
Clonidin 2 0.10 - - 3A4 
Clotrimazol 1 0.05 3A4 - - 
Clozapin 88 4.24 - - 1A2, 2D6, 
3A4 
Colecalciferol 2 0.10 2D6 - - 
Crataegutt 1 0.05 - - - 
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Diazepam 30 1.4 3A4 - 1A2 
Diclofenac 5 0.24 - - 1A2, 2D6, 
3A4 
Digitoxin 4 0.19 - - 3A4 
Dikaliumclorazepat 1 0.05 - - 3A4 
Donepezil 4 0.19 - - 2D6, 3A4 
Dorzolamid 2 0.10 - - 3A4 
Doxazosin 1 0.05 - - - 
Doxepin 4 0.19 - - 1A2, 2D6, 
3A4 
Duloxetin 4 0.19 2D6 - 1A2 
Efeublätter 1 0.05 - - - 
Eisen II 8 0.39 - - - 
Enalapril 9 0.43 - - 3A4 
Enoxaparin 9 0.43 - - - 
Escitalopram 1 0.05 2D6 - 3A4 
Esomeprazol 10 0.48 - - 3A4 
Estradiol 1 0.05 1A2 3A4 2D6 
Estriol 3 0.14 - - - 
Ethosuximid 1 0.05 - - 3A4 
Eucalyptusöl 1 0.05 - - - 
Fenofibrat 1 0.05 - - 3A4 
Fenoterolhydrobromid 1 0.05 - - - 
Fludrocortisonacetat 1 0.05 - - - 
Flunitrazepam 1 0.05 - - 3A4 
Fluoxetin 5 0.24 1A2, 2D6, 
3A4 
- - 
Flupentixol 12 0.58 - - 2D6 
Fluphenazin 1 0.05 1A2, 2D6 - - 
Flupredniden 1 0.05 - - - 
Fluticason 2 0.10 - 3A4 - 
Fluvoxamin 2 0.10 1A2, 2D6, 
3A4 
- - 
Formoterol 1 0.05 - - 2D6 
Furosemid 25 1.20 - - - 
Ginkgo-biloba 2 0.10 - - - 
Glibenglamid 2 0.10 - - 3A4 
Glimepirid 6 0.29 - - - 
Gramicidin 1 0.05 - - - 
Hydrchlorothiazid 13 0.63 - - - 
Ibuprofen 2 0.10 - - - 
Insulin 15 0.72 - 1A2 - 
Ipratropiumbromid 1 0.05 - - - 
Isosorbiddinitrat 10 0.48 - - 3A4 
Kalium 8 0.39 - - - 
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Kaliumiodid 2 0.10 - - - 
Lactobacillus gasseri 1 0.05 - - - 
Lactulose 11 0.53 - - - 
Lamotrigin 17 0.82 - - - 
Levetiracetam 3 0.14 - - - 
Levomepromazin 39 1.88 2D6 - 1A2 
Levonorgestrel 1 0.05 - - 3A4 
Levothyroxin 43 2.07 - - - 
Lisinopril 2 0.10 - - - 
Lithium  50 2.41 - - - 
Lorazepam 134 6.45 - - - 
Losartan 2 0.10 - - 3A4 
Macrogol  15 0.72 - - - 
Magnesium 10 0.48 - - - 
Maprotilin 1 0.05 - - 2D6 
Medroxyprogesteron 3 0.14 - 3A4 - 
Melperon 36 1.73 2D6 - - 
Metamizol 13 0.63 - 3A4 - 
Metformin 31 1.49 - - - 
Metoclopramid 1 0.05 2D6 - 1A2 
Metoprolol 25 1.20 2D6 - 3A4 
Metronidazol 1 0.05 3A4 - - 
Miconazol 1 0.05 3A4 - - 
Mirtazapin 14 0.67 1A2, 3A4 - 2D6 
molsidomin 5 0.24 - - - 
Multivitamin 1 0.05 - - - 
Mycophenolatmofetil 1 0.05 - - - 
Natriumchlorid 5 0.24 - - - 
Natriumdihydrogen-
phosphate 
1 0.05 - - - 
Natriummonohydro-
genphosphat 
1 0.05 - - - 
Natriumpicosulfat 3 0.14 - - - 
Neomycin 1 0.05 - - - 
Nitroxolin 1 0.05 - - - 
Nortriptylin 1 0.05 2D6 - 1A2, 3A4 
Olanzapin 126 6.07 1A2, 2D6, 
3A4 
- - 
Omeprazol 4 0.19 2D6, 3A4 1A2, 3A4 - 
Opipramol 2 0.10 - - 2D6 
Oxazepam 9 0.43 - - 2D6 
Oxcarbazepin 2 0.10 - 3A4 - 
Oxybutynin 1 0.05 2D6, 3A6 - - 
Oxycodon 1 0.05 2D6, 3A4 - - 
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Paliperidon 3 0.14 - - 2D6 
Pankretin 1 0.05 - - - 
Pantoprazol 94 4.53 - 1A2, 3A4 - 
Paracetamol 10 0.48 - - 1A2, 2D6, 
3A4 
Paroxetin 1 0.05 1A2, 2D6, 
3A4 
- - 
Perazin 10 0.48 - - 2D6, 3A4 
Perphenazin 1 0.05 1A2, 2D6 - 3A4 
Phenytoin 1 0.05 - 1A2, 3A4 - 
Pioglitazon 1 0.05 - 3A4 - 
Pipamperon 39 1.88 - - - 
Pirenzepin 28 1.35 - - - 
Piretanid 2 0.10 - - - 
Polymyxin B  1 0.05 - - - 
Polyvinyllkohol 1 0.05 - - - 
Prednisolon 2 0.10 3A4 3A4 - 
Pregabalin 15 0.72 - - - 
Promethazin 14 0.67 2D6, 3A4 - - 
Propiverin 1 0.05 - - - 
Propranolol 3 0.14 1A2, 2D6 - 3A4 
Prothipendyl 4 0.19 - - - 
Quetiapin 80 3.85 - - 2D6 
Ramipril 32 1.54 - - - 
Ranitidin 1 0.05 1A2, 2D6 - - 
Reboxetin 5 0.24 - - 3A4 
Repaglinid 3 0.14 - - 3A4 
Risperidon 41 1.97 2D6, 3A4 - - 
Rivastigmin 1 0.05 - - - 
Saccharomyces cerevi-
siae 
1 0.05 - - - 
Salbutamol 1 0.05 - - 3A4 
Salmeterol 2 0.10 - - 3A4 
Sertralin 2 0.10 1A2, 2D6, 
3A4 
- - 
Simeticon 3 0.14 - - - 
Simvastatin 13 0.63 2D6 - 3A4 
Solifenacin 1 0.05 - - - 
Spironolacton 1 0.05 - - - 
Sulfamethoxazol 1 0.05 - - 3A4 
Sulprid 1 0.05 - - - 
Tacrolimus 1 0.05 3A4 - - 
Tamsulosin 10 0.48 - - 2D6, 3A4 
Temazepam 23 1.11 - - 2D6, 3A4 
Terazosin 1 0.05 - - - 
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Tetryzolin 1 0.05 - - - 
Theophyllin 2 0.10 1A2 - 2D6, 3A4 
Thiamin 1 0.05 - - - 
Thioridazin 1 0.05 1A2, 2D6 - 3A4 
Tiaprid 1 0.05 - - - 
Ticlopidin 4 0.19 1A2, 2D6, 
3A4 
- - 
Tilidin 1 0.05 - - - 
Timolol 5 0.24 2D6 - - 
Tiotropiumbromid 3 0.14 - - - 
Tolperisonhydrochlorid 1 0.05 - - - 
Topiramat 4 0.19 - 3A4 - 
Torasemid 7 0.34 - - - 
Tramadol 1 0.05 - - 2D6, 3A4 
Travoprost 1 0.05 - - - 
Trazodon 2 0.10 2D6, 3A4 - - 
Triamteren 1 0.05 - - - 
Trihexylphenidylhydro-
chlorid 
2 0.10 - - - 
Trimethoprim 1 0.05 - - 3A4 
Trimipramin 7 0.34 - - 2D6, 3A4 
Trospiumchlorid 3 0.14 - - - 
Valproinsäure 116 5.58 2D6, 3A4 - - 
Venlafaxin 12 0.58 2D6, 3A4 - - 
Verapamil 3 0.14 1A2, 2D6, 
3A4 
- - 
Xipamid 1 0.05 - - - 
Zaleplon  1 0.05 - - 3A4 
Zink 1 0.05 - - - 
Ziprasidon 5 0.24 2D6, 3A4 - 1A2 
Zolpidem 4 0.19 - - 1A2, 2D6, 
3A4 
Zopiclon 22 1.06 - - 3A4 
Zotepin 2 0.10 - - 1A2, 3A4 
Zuclopenthixol 13 0.63 - - 2D6 
Total 2077 100    
Note: These co-medications were recorded in the patients’ TDM-request forms and were transferred to 
Konbest upon receipt. Substances with the percentage frequency above 4% were regarded as most fre-
quently administered co-medications, when compared to other substances. CYP 1A2, 2D6, 3A4 inhibitors, 
inducers and substrates were derived from CYP-table compiled by Ekkehard Haen and Goepfert Christine 
on 28.10.2010 and TDM-consensus, update 2011.  
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Total number of patients that received other medications alongside with haloperidol 
was 535 patients. 323 of them were male and 212 were female (see appendix 7). 
The number of administered co-medications per patient ranges from 1 to 15. One 
female patient received the highest number of co-medications (15). Most patients 
received the combination of 1 - 3 medications. 114 patients received the combination 
of 3 medications, 94 patients received 2 and 90 patients received 1 (see figure 45). 
The active substances contained in the 15 co-medications for this female patient 
were oxcarbazepine, ciprofloxacine, clindamycine, cholecalciferole, levothyroxine, 
torasemid, potassium, lorazepam, agomelatine, metamizole, Oxycodon, 
Insulinglargin, human insulin, enoxaparin, salmeterol, and fluticasonpropionate. The 
measurement of her haloperidol serum concentration gave a concentration of 1.1 
ng/ml at a haloperidol maintenance dose (oral) of 50 mg. The concentration was 
within the expected therapeutic reference range (1-10 ng/ml) but below the dose-
related reference range (30 – 50 ng/ml). The administered co-medications contain 
CYP-inhibitors as well as CYP-inducers (see table 49). The patient’s health condition 
improved under these medications. 
The 14 co-medications recorded for the male patient were amisulprid, biperidene, 
sodium picosulfate, amlodipine, clonidin, bisoprolol, ramipril, bisacodyl, magnesium, 
zopiclon, metamizol, fludpredniden, macrogol, and lorazepam. The measured 
haloperidol serum concentration of 37.3 ng/ml at a maintenance dose (oral) of 40 mg 
was above the theraupeutic reference range, but within the dose-related reference 
range (24- 40 ng/ml). The patient smoked during the therapy. There was no 
information about the health condition of the patient.  
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Figure 45. Number of co-medictions administered to each patient during haloperidol therapy. 
Note: The number of co-medication recorded for each patient was evaluated according to the name of 
the administered medications (generic name) and not according to the active substances. In some 
cases, the same co-medications were administered to more than one patient. 
 
Overview of haloperidol TDM Results with the Nine-Fold Table  
Five hundred and sixty-three Konbest data records for the therapeutic drug 
monitoring of haloperidol were evaluated. The serum samples of the patients 
submitted to TDM laboratory were measured and analysed for the concentration of 
haloperidol in serum. The obtained results were classified in too low, expected and 
too high based on the given specification for the therapeutic reference range ( 1- 10 
ng/ml) and dose-related reference range (C/D = 0.6 – 1.0). The expected DRR of 
each dose was calculated with the C/D factor haloperiol given in the TDM consensus. 
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104 patients were below the therapeutic (TRR) and dose-related reference ranges 
(DRR), 79 patients were above them while 380 patients were within the expected 
ranges (see table 50). A satisfactory overview of the state of the recorded serum 
concentrations was obtained. The result of the overview shows that the applied TDM 
was effective in the control of haloperidol serum concentration. More than 50 % of 
TDM-controlled serum concentration was within the expected therapeutic and dose-
related reference ranges. Samples with concentrations below or above the expected 
ranges were further interpreted based on the patients’ health condition, patients’ 
compliance, the administered co-medications, time and duration of drug 
administration, and the occurrence of undesired drug effects.  
For example, in cases of too low TRR where the patient is compliant, no 
improvement in his health condition and no deterioration either, no influence of co-
medication to haloperidol, and do not have any undesired drug effect, then an 
increase of medication dose and further monitoring was advised (see figure 46).  
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Figure 46. TDM-Recommendation scheme  for antipsychotic therapy from [Hiemke et al., 2011] 
and adjusted by the author. 
Note: This scheme is based on the value obtained from the measured antipsychotic serum 
concentration such as haloperidol. Steady-state concentration is reached after five elimination half-
lives (t1/2) of the drug. The t1/2 of haloperidol is 12-38 hours according to the summary of product 
characteristics Haldol
®
 2012. 
 
In cases of too high TRR with the occurrence of undesired drug effect, deterioration 
of patients’ health condition, and with co-medications that inhibit CYP 2D6, a change 
of co-medication and further monitoring was advised and if need be, the attending 
clinician was advised to change the medication, especially, if a constant dose of the 
medication has been administered and compliantly taken for more than two weeks 
(see figure 46). 
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Table 50. The nine-fold table of Konbest data collection for haloperidol-TDM. 
 
Note: The concentrations of the patients’ sample that were measured in TDM laboratory Regensburg 
were grouped in relation to the dose-related reference range (DRR) and then the number of patient for 
each group was countered. 
4.2.3.4 The Konbest Data of FLT and ZLT 
The total number of patients studied during this work was 45. Fourty-two patients’ 
samples contained FLT and 3 samples contained ZLT. The recorded co-medications, 
evaluated as active substances was 62 (see table 51).The total frequency of 
administration was 157 (100%). The most administered co-medications (active 
substances) were lorazepam (12.10%), biperidene (7.64%), bisoprolol, (5.10%), 
olanzapine (5.10%), pantoprazole (5.10%), quetiapin (4.46%). Nine co-medications 
have the same metabolic pathway with flupentixol and zuclopenthixol as substrates 
of CYP 2D6. Fifteen co-medications were CYP 2D6 inhibitors. 14 patients who 
received flupentixol got better during the therapy, the health condition of 9 patients 
deterioriated and the health condition of 11 patients did not change. The health 
status of other patients was not recorded. 
Table 51. Recorded co-medications and their active substances. 
Active Substance Frequency of 
administration 
Percentage 
frequency of 
administration 
CYP 2D6 
Inhibitor 
CYP 2D6 
Inducer 
CYP 2D6 
substrate 
 
 
 
 
Concentration in re-
lation to the dose-
related ref-erence 
range 
 
Concentration in relation to the therapeutic reference range 
 Too low As expected Too high 
Too low 104 patients   
As expected  380 patients  
Too high  
 
 79 Patients 
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Active Substance Frequency of 
administration 
Percentage 
frequency of 
administration 
CYP 2D6 
Inhibitor 
CYP 2D6 
Inducer 
CYP 2D6 
substrate 
Allopurinole 1 0.64 - - - 
Amlodipine 2 1.27 x - - 
Aripiprazole 1 0.64 - - x 
Benperidol 2 1.27 - - (x) 
Betamethason 1 0.64 - - - 
Biperidene 12 7.64 x - - 
Bisoprolol 8 5.10 - - - 
Budesonide 1 0.64 - -  
Carbamazepine 3 1.91 - - x 
Cefuroxime 1 0.64 - - - 
Chlorprothixene 2 1.27 x   
Citalopram 1 0.64 x - - 
Clomipramine 2 1.27 x   
Clozapine 4 2.55 - - x 
Cyanocobalamine 1 0.64 - - - 
Cyproterone Acetate 1 0.64 - - - 
Desmopressin 1 0.64 - - - 
Diazepam 4 2.55 - - - 
Pipamperone 2 1.27 - - - 
Drospirenone 1 0.64    
Enoxaparin 2 127 - - - 
Estraldiol 1 0.64 - - x 
Formoterol 1 0.64 - - x 
Furosemide 1 0.64 - - - 
Hydrochlorothiazide 2 1.27 - - - 
Hydroxycarbamide 1 0.64 - - - 
Lamotrigine 2 1.27 - - - 
Levofloxacin 1 0.64 - - - 
Levomepromazine 3 1.91 X - - 
Levothyroxin 4 2.55 - - - 
Lithium 1 0.64 - - - 
Lorazepam 19 12.10 - - - 
Magnesium 1 0.64 - - - 
Melperone 2 1.27 X - - 
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Active Substance Frequency of 
administration 
Percentage 
frequency of 
administration 
CYP 2D6 
Inhibitor 
CYP 2D6 
Inducer 
CYP 2D6 
substrate 
Metformine 1 0.64    
Olanzapine 8 5.10 x - - 
Oxazepam 1 0.64   x 
Pantoprazole 8 5.10 - - - 
Phenprocoumon 1 0.64 - - - 
Piperacillin 1 0.64 - - - 
Pirenzepine 1 0.64 - - - 
Potassium 1 0.64 - - - 
Prednisolon 1 0.64 - - - 
Pregabaline 1 0.64 - - - 
Prothipendyl 3 1.91 - - - 
Pyridoxine 1 0.64 - - - 
Quetiapine 7 4.46 - - x 
Ramipril 2 1.27 - - - 
Risperidon 3 1.91 x - - 
Salbutamol 1 0.64 - - - 
Salicylic Acid 1 0.64 - - - 
Simvastatine 1 0.64 X - - 
Tazobactam 1 0.64 - - - 
Thiamine 1 0.64 - - - 
Tiotropium Bromide 2 1.27 - - - 
Triamterene 1 0.64 - - - 
Trihexyphenidyl 1 0.64 - - - 
Valproic Acid 11 3.82 x - - 
 5 3.18 x - - 
Venlafxine 1 0.64 x - - 
Ziprasidon 3 1.91 x - - 
Zolpiderm 1 0.64 - - x 
Total 157 100,07    
Note: The co-medications were recorded during the TDM of flupentixol and zuclopenthixol. CYP 2D6 
inhibitors and substrates were derived from CYP-table compiled by Ekkehard Haen and Goepfert 
Christine on 28.10.2010 and TDM consensus update 2011. The percentage frequency of drug admin-
istration was evaluated based on the active substances alone. CYP 2D6 is recorded as flupentixol and 
zuclopenthixol metabolizing enzyme. X = drugs that act as inhibitor or substrate of CY 2D6. (X) = dis-
crepancy in the literatures. 
 151 
 
The patients received different number of co-medications, respectively, during the 
therapy with flupentixol and/or zuclopenthixol. The highest number of co-medications 
administered per patient was 15 and the least number was 1 (see figure 47).  
The 15 co-medications administered to the male patient were amlodipine, biperidene, 
budesonide, citalopram, formoterol, furosemid, metoprolol, quetiapine, potassium, 
ramipril, pantoprazole, pregabaline, salbutamol, tiotropium bromide, and oxazepam. 
The co-medications comprise of CYP 2D6 inhibitors as well as substrates (see table 
53). No flupentixol serum concentration was measured at a maintenance dose of 20 
mg per day. The patient smoked 10 cigarettes in a day and there was no improve-
ment in his health condition. 
 
Figure 47. Number of co-medication administered to each patient during flupentixol and/or 
zuclopenthixol therapy. 
Note: The number of co-medication recorded for each patient was evaluated according to the name of 
the administered medications (invented name) and not according to the active substances. In some 
cases, the same co-medications were administered to more than one patient. 
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4.2.3.5 ABDA Haloperidol Data Evaluation  
The price list of haloperidol medication stated in ABDA database was applied for the 
evaluation of the cost of the documented haloperidol therapy. The haloperidol 
request applied during the therapy was documented in Konbest program of the TDM 
laboratory, at the university of Regensburg between 2006 and 2011. 
The total haloperidol request of 562 gave a total cost of 184.892,58 €. The request 
and the cost reduced in 2008 and showed a significant leap between 2009 and 2010 
(see figure 48). The cost obtained by the year 2011 was reduced due to the general 
reduction of the medication cost in the German Health Care System. The least cost 
at 7.13% of the total cost was registered by the year 2006 and the highest cost at 
27.32% of the total cost was documented by 2010.  
 
Figure 48. The cost evaluation of haloperidol yearly request in euro (€). 
Note: The pillars represent the yearly request of haloperidol TDM. 
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4.2.3.6 AGATE Melperone-Benperidol Data Evaluation 
On the two index days in the years between 1995 and 2010, the AGATE identified 
9,540 (100%) frequency administration of MLP and/ or BPD for 9,483 patients 
(100%).  
8,055 (84.43%) MLP was frequently administered to 7,999 (84.35%) patients and 
1,485 (15.57%) BPD to 1,484 patients (15.65%). 82 (0.86%) patients received the 
combination of MLP and BPD. Less than one-sixth of the total patients was 
admistered only  BPD (see figure 49). 
 
Figure 49. Data comparison of single and combined administration of melperone (MLP) and 
benperidol (BPD).  
From the other co-administered medications, the most administered group of 
psychotropic medications (see table 52) were antipsychotics (20.9%) and 
anticonvulsants (18.4%).The diagnoses for the administration of melperone and/ or 
benperidol are listed in appendix 12. According to TDM consensus update, 2011, 
melperone and benperidol are under level 3 of TDM recommendation. Under level 3, 
TDM is recommended to be applied for special indications or problem solving 
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[Hiemke et al., 2011]. The observation of the data evaluation shows that the rate of 
TDM request for MLP and BPD is low. Two-hundred and ten case reports were 
recorded. Only 81 of these cases were requested for labor TDM of MLP and/or BPD. 
Table 52. Administration of combined medications to MLP and/or BPD. 
Abbreviation Medication Groups N prescriptions %Polymed 
AD  Antidepressants 17 4.0 
AEP  Anticonvulsants 78 18.4 
APM  Anti-Parkinson drugs 44 10.4 
HYP  Hypnotics 9 2.1 
NL  Antipsychotics 89 20.9 
BZD Benzodiazepine 52 12.2 
AND  Others 136 32.0 
Total 7 425 100.0 
Note: Groups of the applied polymedications (Polymed), N: total number of medication prescribed in a 
group. 
4.2.4 Influence of Smoking on HLP and FLT serum Concentration 
Polycyclic aromatic hydrocarbons in tobacco induce cytochrome P450 enzymes 
[Lucas c and Martin J, 2013] which can lead to decreased drug concentrations. The 
evaluation of the effect of smoking on serum concentrations of HLP and FLT were 
compared in smokers and non-smokers. All the study patients who smoked during 
the therapy with flupentixol also received other co-medications.  
4.2.4.1 Influence of Smoking on Haloperidol Serum Concentration 
The number of patients treated with haloperidol was 366 (100 %). 197 (64.21%) were 
smokers, and 35.79% of them were female. The mean serum concentration for 
smokers was 9 ± 10ng/ml, at a mean dose of 17 ± 15mg per day. The mean serum 
concentration for non-smokers was 10 ± 12 ng/ml, at a mean dose of 15 ± 17 mg per 
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day (see appendix 8). Dose related concentrations were different between smokers 
and non-smokers (see figure 50 and 51). In two outliers, co-medication was, melp-
erone at a dose of 100 mg for one sample which might explain the outlier value, 
since melperone is an inhibitor [Hiemke et al., 2011] and haloperidol a substrate of 
CYP2D6 [Kudos and Ishizaki, 1999]. For the other outlier, no co-medication was rec-
orded.  
 
 
Figure 50. C/D received from the measured samples of haloperidol for smokers (left panel) and 
non-smokers (right panel). 
Note:  DRR = dose-related reference range.The measured concentrations both by smokers and non-
smokers were clustered between 0 and 20 ng/ml. The slope of the graph for both patients’ groups is 
similar. DRR for samples without dose information was not applicable, as it can be observed in the 
graph. C = concentration, D = administered dose.  
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Figure 51. Comparison of C/D-low and C/D high for smokers and non-smokers during therapy 
with HLP. 
Note: Comparison with patients who smoked during the administration of HLP with that of patients 
who didn’t smoke during the therapy. Q = quartile. For C/D HLP-smokers; Q1 = 2.0 ng/ml, minimum = 
0 ng/ml, median = 8 ng/ml, mean = 11.57 ng/ml, maximum = 104 ng/ml, Q3 = 16.0 ng/ml. For C/D 
HLP- non-smokers; Q1 = 3.2ng/ml, minimum = 0 ng/ml, median = 8 ng/ml, mean = 10.75 ng/ml, max-
imum = 120.0 ng/ml, Q3 = 12.8 ng/ml. C/D-low and C/D are factors for calculation of dose-related ref-
erence ranges. 
Haloperidol Serum samples with and without Co-medication by Smokers 
 Four patients who smoked during haloperidol therapy did not receive co-
medications. Patients under sole administration of haloperidol received an average 
dose of 22 ± 19 mg and reached an average serum concentration of 5 ± 3 ng/ml. 
Their average C/D was 18 ± 16 ng/ml. Patients who received haloperidol alongside 
with other medications reached an average serum concentration of 9 ± 10ng/ml at an 
 157 
 
average dose of 17 ± 15mg. Their average C/D was 12 ± 13ng/ml. Patients who were 
treated with haloperidol monotherapy received higher dose compared with the pa-
tients who received other medications alongside with haloperidol. During monothera-
py, smokers reached a lower level of haloperidol serum concentration. Patients’ 
smokers under polytherapy, though received lower haloperidol doses, reached higher 
level of haloperidol serum concentration (see figure 52). The average serum concen-
tration reached in both cases was below the expected average dose-related refer-
ence range. 
 
Figure 52. comparison of haloperidol serum concentration in smokers with and without co-
medications. 
Note: For patients who received only HLP: Dose = 22 ± 19.4 mg, Conc = 4,63 ± 2.7 ng/ml, C/D = 17.6  
± 15.5 ng/ml. For patients who received HLP alongside with other medications: Dose = 16.56  ± 15.4 
mg, Conc  = 8.8 ± 10.0 ng/ml, C/D = 11.5 ± 13.0 ng/ml. Comed = co-medication 
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4.2.4.2 Influence of Smoking on Flupentixol Serum Concentration  
Thirty-three patients smoked under the therapy with flupentixol and ten patients did 
not smoke. The mean serum concentration found in smokers was 9.3 ± 8.2 ng/ml, at 
a mean dose of 10.0 ± 6.7 mg per day. The mean serum concentration obtained by 
non-smokers was 9.4 ± 9.3 ng/ml, at a mean dose of 11.9 ± 8.8 mg per day (see 
appendix 9). The results of the evaluation for the impact of smoking on the serum 
concentration of these patients show no significant different when compared with the 
serum concentration of the patients who did not smoke (see figure 53). The serum 
concentration of the depot administration of FLT is not linear to the corresponding 
DRR. The distribution of the obtained values both by smokers and non-smokers are 
similar. The mean DRR value for smokers is 16.2 ng/ml while that of non-smokers is 
15.1 ng/ ml (see figure 54). The number of patients’ smokers who were administered 
FLT were more when compared to that of nonsmokers. The serum concentration 
reached by smokers is lower than the concentration reached by nonsmokers. 
 
Figure 53. C/D received from the measured samples of flupentixol for smokers (left panel) and 
non-smokers (right panel). 
 159 
 
The measured concentrations both by smokers and non-smokers were clustered 
between 0 and 20 ng/ml. The slope of the graph for both patients’ groups is similar. 
The C/D obtained for samples containing depot flupentixol are not linear to the 
administered dose.  
 
Figure 54. Comparison of C/D-low and C/D high for smokers during therapy with FLT. 
Note: Comparison with patients who smoked during the administration of FLT with that of patients who 
didn’t smoke during the therapy. C/D-low and C/D high are factors for calculation of dose-related ref-
erence range. 
Q = quartile. For C/D FLT-smokers; Q1 = 12.0 ng/ml, minimum = 0 ng/ml, median = 
18 ng/ml, mean = 16.19 ng/ml, maximum = 36 ng/ml, Q3 = 21.43 ng/ml. For C/D 
FLT- non-smokers; Q1 = 12.0 ng/ml, minimum = 0 ng/ml, median = 12.44 ng/ml, 
mean = 15.09 ng/ml, maximum = 36.0 ng/ml, Q3 = 24.0ng/ml. 
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4.3 Application of TDM at the Clinic Ward  
The TDM at the clinic ward was not restricted to antipsychotic medications alone. 
Medications of different pharmacological groups reported by the attending clinicians 
and patients were treated by the pharmacist. There are different reasons observed 
for requesting the therapeutic drug monitoring of antipsychotic drugs. Clarification of 
the request is based on the result of the measured patients’ sample and the patients’ 
information on the request form, which were recorded in the konbest program. Cases 
pertaining melperone (MLP), benperidol (BPD), haloperidol (HLP), bromperidol 
(BRP), flupentixol (FLT) and zuclopenthixol (ZLT) were discussed. 
4.3.1 Konbest Case Report of the Applied Antipsychotics 
The record of the measured patients’ serum samples including their sickness and 
medication histories are covered with the help of konbest. The metabolic pathways of 
the administered medications are arranged in such a way as to give one an overview 
of any interaction between the metabolizing enzyme of the applied medication and 
other co medications. Enzyme inducers lead to a reduced serum concentration level 
of the substrate medication, resulting to a reduced efficacy of the administered 
medication. Enzyme inhibitors lead to an increased concentration of the medication 
in the serum, resulting to undesired drug effects.  
4.3.1.1 Reported Headache under Medication with Melperone  
An elderly female patient, aged 85 years, received as reserve medication, melperone 
75 mg per day as sedative, for more than one week. The patient reported of 
continues headache anytime she takes melperone. Her diagnosis was disorganised 
schizophrenia according to ICD F20.1. She received clozapine 350 mg per day for 
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the treatment of schizophrenia. Other co-medications were metformine 850 mg, three 
times per day, januvia 100 mg (active substances = metformine and sitagliptine) and 
delix plus 5 mg (active substances = ramipril and hydrochlorothiazide). Information to 
her health situation under these medications was not reported. The TDM of 
melperone gave a serum concentration of 6 ng/ml, which is below the therapeutic 
reference range of 30 – 100 ng/ml. Because of the persistent headache at low 
concentration of MLP, the patient was advised to cease the intake of melperone. 
Alternative sleeping bills from plant basis, which will not alter the patients’ 
medications, was suggested by the pharmacist. The mentioned co-medications do 
not have common metabolic pathways with melperone; they were not adjusted. 
According to the patient, the intensity of the headache reduced after the intake of 
melperone was stopped, but started again after two days even without the intake of 
melperone. Melperone was therefore ruled out as the reason for the headache with 
the help of TDM, which was also confirmed with the measured serum concentration 
below the therapeutic reference range. There was no follow-up or more information 
to this as the patient was transferred to another clinic before the next visit. 
4.3.1.2 Case Report of Hypersalivation with Benperidol and Zuclopenthixol 
Serum sample of a 66 years old female patient, diagnosed of schizophrenia, was 
sent for measurement, because of undesired drug effect- hypersalivation, which 
started after an intake of zuclopentixol and benperidol. She received 12 mg ciatyl-z 
(active substance = zuclopenthixol) and 26 mg glianimon (active substance = 
benperidol). Her other co-medications were clozapine, orfiril ret (valproic acid), 
akineton (biperiden), tavor (lorazepam), bisoprolol, and gastrozepin (pirenzepine). 
The measured serum concentration was 2 ng/ml for benperidol and 9 ng/ml for 
 162 
 
zuclopenthixol. Both measured concentrations are within the therapeutic reference 
range (1-10 ng/ml for benperidol and 4 – 50 ng/ml for zuclopenthixol) clozapine, 
valproic acid, and zuclopenthixol have a common metabolic pathways at CYP 2D6 
(see table 53). Since the patient was getting better under this condition, and the 
reported side effect is tolerable, it was advised that the medication scheme should be 
maintained, and the patient should be monitored, in case of an increase in the 
reported undesired drug effect. 
Table 53 Interaction table for cytochrom P450 relating to the concerned medication. 
substances CYP 
1A 
CYP 
2A6 
CYP 
2B6 
CYP 
2C8 
CYP 
2C9 
CYP 
2C19 
CYP 
2D6 
CYP 
2E1 
CYP 
3a4/5/6 
Ugt 
1a4 
Benperidol n.a 
Bisoprolol         X  
subst 
 
Clozapine X 
subst 
X 
subst 
   X 
subst 
X  
subst 
 X  
subst 
 
Lorazepam          X 
subst 
Pirenzepine n.a 
Valproic acid   X 
subst 
X 
 inh 
X  
inh 
X   
inh 
X  
inh 
X 
subst 
X   
inh 
 
zuclopenthixol       X 
subst 
   
Note: n.a = not available, subst = substrate, inh= inhibition, ind = induction 
4.3.1.3 Reported Case of Non- Compliance with Haloperidol  
A female patient (age unknown), has been on haldol (dose unknown) for the last five 
years. She has paranoid schizophrenia and Haldol helped her with her hallucination. 
Because of weight gain, she rejected the further intake of haldol. The measurement 
of her serum haloperidol concentration was not performed, because she has already 
stopped the intake of haldol before the report . She was switched to quetiapine at a 
dose of 600 mg per day. The TDM of her serum sample gave a serum quetiapine 
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concentration of 192 ng/ml. Her health condition remained stable and the weight gain 
was reduced. No co-medication was mentioned. 
4.3.1.4 Reported Case of Bleeding during Bromperidol Therapy 
A 48 years old male patient reported of bleeding after the intake of Impromen. He 
was administered Impromen (active substance = bromperidol) for the treatment of 
psychotic disorder at a dose of 6 mg per day. He stopped the intake of bromperidol 
on his own; two days before his admission in the hospital. As co-medication during 
the therapy with Impromen, he received risperidon. According to him, he will prefer 
not to have a similar experience. The TDM of his serum sample showed a rest 
concentration of bromperidol at 8 ng/ml. The monotherapy with risperidon dose of 0.5 
mg per day was continued and targeted to 1 mg per day. He was compliant to the 
instructions of his risperidon medication intake and to the therapy. 
4.3.1.5 Reported Hyponatremia during Therapy with Flupentixol  
A 56 years old schizophrenic male patient was recorded to have suffered a server 
side effect of hyponatremia when flupentixol was co-administered with quetiapine. 
Unfortunately the dose of flupentixol and quetiapine that lead to the named side 
effect was not reported. The flupentixol therapy was discontinued, and the patient got 
better under the continuous mono therapeutic administration of quetiapine dose at 
150 mg. The measured quetiapine serum concentration during TDM was 74 ng/ml, 
which is below the therapeutic reference range of 100 -500 ng/ml according to 
consensus. There was no clinic pharmacological report to this effect, because some 
relevant information such as the administered dose, period of the therapy before the 
onset of the reported side effect, and the co-medications were not mentioned.  
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Other reported undesired effects were tremor, tardive dyskinesia and dry mouth. 
Tremor and tardive dyskinesia reduced after the withdrawal of flupentixol, but dry 
mouth persisted. According to the information the pharmacist received on enquiry, 
the dry mouth symptomatic was locally treated by advising the patient to slip water 
regularly and/or to chew sugar-free gums or candies to stimulate the flow of saliva. 
4.3.2 TDM Processing at the Clinic Ward 
TDM was applied for some medications for the clarification of some requests at the 
clinic ward. The samples of the patients’ serum were first sent to TDM laboratory and 
measured, if need be. The clinic-pharmacological interpretation of the result was 
prepared with the given information in the request form. Discussions on compliance, 
change and/ or addition of medication, continuation of the therapy with a particular 
medication, dose increase or reduction were made based on the outcome of the 
serum concentration measurement and the health condition of the patients. 
4.3.2.1 Indications for the requested TDM 
The attending clinicians requested for TDM of their patients’ serum samples because 
of various reasons (see table 54) but for one goal, which is the optimization of the 
therapy of their individual patients. TDM requests because of drug interactions and 
dose adjustment were made at the admission of a new patient, if the attending 
clinicians see the need to reorganize the patient’s medication scheme. Compliance-
check request was made when the patient is not responding to treatment and when 
the clinical statue deteriorates instead of getting better. TDM request because of lack 
of response to therapy was also made, to find out if the applicable dose yields the 
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expected therapeutic serum concentration. The samples were accompanied with a 
completed request forms, for each sample, respectively.  
Table 54 Reasons for the request of TDM at the clinic ward. 
Compliance 
Drug interactions 
Lack of response to a therapy 
Change in the clinical status of the patients 
Dose adjustment 
 
4.3.2.2 Time Frame of the Analysis 
The entire TDM requests from the clinic ward were treated in accordance with the 
measurements standards and criteria at the TDM laboratory in Regensburg. Samples 
were grouped and measured at different days and times in a week, with the 
corresponding methods. The laboratory measurements last between 15 mins to 60 
mins depending on the substance.  
Results and interpretation of the measured serum concentrations were available 
within 1 – 2 days. Late samples were measured with another applicable and 
validated method, in order to supply the result within the given time frame. Results 
and interpretation of measured samples that arrived later, after all the measurements 
have been concluded, were available within the next five working days. 
Measurements and interpretation of the study substances melperone, benperidol, 
haloperidol, bromperidol, flupentixol and zuclopenthixol were carried out daily and 
lasted 40 mins including the clinic-pharmacological interpretation, whenever they 
were requested. Prompt alerting of the attending clinicians in cases where the 
measured drug concentration is highly above the expected dose-related reference 
range and therapeutic reference range were applied. This alert was done by making 
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a direct call to the clinic ward to the attending clinician. The requested medications 
during the study are listed in table 55. 
Table 55 Requested medications applied in TDM. 
Abilify  
Clomipramine 
clozapine 
Cymbalta 
Ergenyl 
Fluanxol 
Haldol 
Imipramine 
Lamotrigine 
Mirtazapin 
Nortrilen 
Olanzapine 
Perazine2 
Quetiapine 
Risperidon 
Seroquel  
Tavor 
Valproate 
Venlafaxine 
 
4.3.2.3 Clinic-Pharmacological Reports and Communication of Result  
Time serum samples were taken, time the last dose was taken, duration of the 
dosing regimen, indication for the therapeutic drug monitoring, co-medications were 
considered. The patients’ data and health status were as well taken into 
consideration during the clinic-pharmacological interpretation of the results. The 
interaction table for the applied medication and co-medications generated by konbest 
was included in the interpretation sheet. The unit of the measured concentration was 
given in ng/ml. The dose-related reference range and the therapeutic reference 
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range of the concerned medication were presented, so that the attending clinicians 
easily had an overview of the measured concentration in comparison with the 
expected concentration. The result and the report were communicated to the 
clinicians within 1-2 days after measurement. Prompt alerting via telephone was for 
example, applied once in this work, when a flupentixol measurement gave the 
concentration of 400 ng/ml. The serum sample was collected after the medication 
intake, so that the peak concentration instead of the steady-state concentration was 
measured. The concerned flupentixol sample was therefore nullified. 
4.3.3 Pharmacist’s Support at the Clinic Ward 
The pharmacist visited the clinic ward after the laboratory measurements. The serum 
concentration of melperone, benperidol, haloperidol, bromperidol, flupentixol and 
zuclopenthixol was reliably measured using the validated method. Some samples for 
these measurements were made available from the patients at clinic ward 1B and 
from the employees of the clinic and polyclinic for psychiatry and psychotherapy, 
University of Regensburg. The clinical pharmacological interpretations of the 
obtained values were successfully done by the pharmacist and further clarified 
through the clinic ward visitations. As mentioned already, the medications treated at 
the clinic ward were not only antipsychotics. Other medication groups which are not 
applicable in TDM were also treated. 
4.3.3.1 Clinic Ward Visitation 
The pharmacist’s clinic ward visitations, conducted with four attending clinicians, one 
pharmacist, four nurses and psychologists, two social workers, and three interns 
were successful. During field work, the number of intern students varied and one 
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attending clinician transferred to another ward. On two occasions, visiting clinicians 
were present during the discussion. Three attending clinician participants followed 
the activities of the pharmacist at the ward to the end of three years research study. 
Specific requests about drug information and their relationship with adverse drug 
reactions and the laboratory measurements were discussed only with the attending 
clinicians. Many reports and requests regarding adverse drug reactions and the 
reasons for non-compliance were obtained in the triple team discussion (patient-
clinician-pharmacist) and in the discussion with the attending clinicians. 
4.3.3.2 Therapeutic Measures at the Clinic Ward 
The groups of drugs applied during the therapy were mostly antidepressants, 
antipsychotics, mode stabilizers, anxiolytics, and sedative-hypnotics. Drugs from 
each group were either administered alone (mono-therapy) or in combination with 
another drug (co-medication) of the same group or of another group to achieve a 
better therapeutic result. Accepted standardized diagnostic criteria were used in 
accordance with the International Statistical Classification of Diseases and Related 
Health Problems (ICD). The drug administration was carried out by the attending 
clinicians applying the guidelines of the German Association for Psychiatry and 
Psychotherapy (DGPPN). 
The station offers an integrative therapeutic approach to support drug therapy during 
hospitalization. With the aid of well-documented therapeutic procedures such as 
psycho-educational groups, social skills training, cognitive training and occupational 
therapy, the patients were disposed to contribute to a successful therapy during their 
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hospitalization. These non-drug therapies were carried out under consideration of 
their medication intake and state of health. 
4.3.3.3 Clinical Requests during Clinic Ward Visitation 
There were two types of requests made during the ward visitations. Questions about 
adverse drug reactions and specific drug information were asked by the clinicians as 
well as the patients. There were cases in which requests about adverse drug 
reactions were made before beginning a drug therapy for clarification purposes. 
Information on drugs was also provided in cases where the encountered undesired 
drug effects had not been reported before. In such cases, different studies from 
reliable sources of journal were provided to help the clinicians in their daily clinical 
decisions by supplying them with the expected information on the drug. 
Recommendations to implement therapeutic drug monitoring for the determination of 
drug serum concentration were given by the pharmacist in reports concerning 
undesired drug effects, dosing, compliance problems, and a lack of effect. 
By higher serum concentrations, the dose was titrated until an optimal dose for each 
patient was achieved just as it was in the case of lower serum concentration. The 
therapeutic strategy was changed in cases where no therapeutic success was 
achieved within two to four weeks. ADR (adverse drug reaction) reports and reports 
concerning undesired drug effects given during the visit, were documented in the 
report forms (see appendix 12) of the working group for pharmacovigilance in 
psychiatry (AMÜP). 
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4.3.3.4 Groups of Clinic Therapeutic Request 
Seventy-nine requests were made during ward visitation. These requests were 
grouped into two subsets, namely requests about drug information (29 requests) and 
reports of adverse drug reactions or undesired drug effects (50 requests). Requests 
concerning information on the drug which were based on an adverse drug reaction or 
had connection to such a reaction were grouped under adverse drug reaction (see 
figure 55).  
 
Figure 55. The group of requests treated during the clinic ward visitation. 
  
Information on drug and processing period  
The processing period of the information required varied from one day to 30 days 
depending on the type of information that was sought after. Information on drug that 
required intensive research and was not urgently needed for the therapy, took more 
time to procure than types. 48.28% of the received drug information was processed 
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within one day, 34.48% was processed within 7 days, and 17.24% within 28 days 
(see figure 56). Several intensive researches regarding unexplained undesired drug 
effects were carried out with the Red-List®-Drug Directory for Germany [Rote Liste® 
Arzneimittelverzeichnis, 2012] and other recognized sources of scientific literatures.  
 
Figure 56. The average period of time applied for clinic therapeutic answers and advices. 
Certain required information was observed to appear in more than one group 
depending on what they entailed, and some did not directly involve any medication 
but rather appeared between one illness and the other. Therefore another evaluation 
was carried out based on drugs in relation to other drugs (18 requests), drugs in 
relation to illness (14 requests), and illness in relation to other illnesses (2 requests). 
See table 56 for type of drug information and their corresponding request.   
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Table 56. Number of requests concerning drugs and illnesses. 
Classification of the Received Drug 
Enquiries 
Number of Drug Information Drug Information (%) 
Drug-Drug 18 52.94 
Drug- Illness 14 41.18 
Illness- Illness 2 5.88 
Total 34 100 
The illnesses associated with the requested drug information were dissociative 
symptoms, nightmare, bipolar disorder, attention deficit hyperactivity disorder 
(ADHD), borderline personality disorder, fatigue, flash back symptoms, post 
traumatic stress disorder (PTSD), serotonin syndrome, diabetes, delirium syndrome, 
psychotic state, QTC-time increase, glaucoma, increased blood flow, and severe 
depressive episodes. The obtained information regarding drugs in relation to other 
drugs was further differentiated into 13 groups following the similarity of the required 
information and reports. Table 57 shows the related enquiry for each type of drug 
information.  
Table 57. Differentiation of requests on drug information. 
Type of drug information Enquiry 
Pharmacokinetic properties of 
drugs 
 The elimination half-life of fluphenazine retard 
 The elimination half-life of topiramate 
Combination of drugs  
 Possibility of increased seizure under the following 
co-medications: bupropion/nortriptyline and 
bupropion/citalopram 
 Influence of co-medications (methylphenidate ret / 
citalopram/ quetiapine) on the anticontraceptive 
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femigoa (ethinylestradiol/levonogestrel) 
 Combination of sertraline and warfarin and its 
effect 
 The effect of the following co-medications 
amitriptyline-clozapine-lithium-quetiapine 
Off-label use of drugs  
 General off-label use of antidepressants 
 Ineffectiveness of lorazepam at higher doses 
 Effect of methylphenidate on ADHS patients 
 Off-label application of methylphenidate and 
moclobemide 
 The risk of dosing citalopram above 40 mg 
Self medication  The contents of Morinda Citrifolia and grape; the 
relationship between grapes and morinda citrifolia 
Contents of foreign food items used 
by certain patients during the 
therapy 
 The contents of morinda citrifolia and grapes 
Differences within medication 
groups 
 Triptans, serotonine and antidepressants. 
 What differentiated Nortriptyline, fluoxetine, and 
doxepine 
Development of sickness through 
medication intake 
 Elontrile (bupropion) and glaucoma 
 Mirtazapine influence on diabetes 
 The possible development of diabetes through 
lamotrigine 
 QTC-time increase by citalopram and other SSRIs 
Triggering of an illness through a 
pre-existing illness 
 ADHD and borderline syndrome 
Explanation of sicknesses that can 
terminologically be misused 
 Differences between delirium syndrome and 
psychotic state 
Clarification of non-documented 
contraindications experienced by 
individual patients 
 Agomelatine and cardiac contraindication 
 Agomelatine and trigger effect by bipolar disorder 
 Absence of withdrawal symptoms by sudden 
discontinuation of lorazepam therapy 
Drug formulations and their 
application methods 
 Application possibilities of different risperidon 
formulations (Risperidon oral, risperidon Consta 
and xeplion) 
Comparison of European drug 
 QTC-time increase by citalopram according to FDA 
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information with other countries 
Journal researches 
 Possible application of resolor by patients with 
bipolar disorder 
 Combined application of jatrosom and lithium 
 The effect of mirtazapine on the brain 
 The use of topiramate for the treatment of PTSD 
 The treatment of flash-back symptoms with 
prazosin, by patients with PTSD 
 The use of naltrexone to treat nightmares 
 The influence of naltrexone after a long-term 
therapy by patients with dissociative symptoms 
Note: Different requests reported as regard to drug information were grouped according to similarity of 
the reports. 
Treated Medications for request concerning drug Information 
Information concerning 33 (100%) drugs and groups of drug were treated during the 
clinic ward visitation. As shown in table 58, 42.42% of the total drugs were repeatedly 
mentioned in different requests concerning drug information. 57.58% of the requests 
resulted from the therapeutic drug monitoring of patients’ drug in serum and dose 
adjustment. The most repeatedly requested drugs were citalopram (12.12%), 
bupropion (9.09%), methylphenidate (9.09%), nortriptyline (6.06%), lithium (6.06%), 
agomelatine (6.06%), flupentixol (6.06%), lorazepam (6.06%), mirtazapine (6.06%), 
quetiapine (6.06%), risperidon (6.06%), topiramate (6.06%), and phenprocoumon 
(6.06%). 
Table 58. The active substances of the reported medications. 
Drug Active substance 
Agomelatine Agomelatine 
Amitriptyline Amitriptyline 
Natural grapes Natural grapes 
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Bupropion Bupropion 
Citalopram Citalopram 
Clozapine Clozapine 
Doxepine Doxepine 
Fluanxol Flupentixol 
Femigoa Levonorgestrel + Ethinylestradiol 
Fluoxetine Fluoxetine 
Grapes Vitamines 
Jatrosom Tranylcypromine 
Lamotigine Lamotrigine 
Lithium Lithium 
Lorazepam Lorazepam 
Lyogen ret Flupehnazine 
Methylphenidate Methylphenidate 
Mirtazapine Mirtazapine 
Moclobemide Moclobemide 
Morinda citrifolia (Noni) 
Phytoestrogene + Oligosaccharides + Polysaccharides + 
Flavonide+ Iridoide + Catechin + Epicatechin + Betasitosterol + 
Alkaloide. 
Naltrexon Naltrexon 
Nortrilen Nortrilen 
Prazosin Prazosin 
Quetiapine Quetiapine 
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Resolor Prucaloprid 
Risperidon Risperidon 
Seroquel see Quetiapin 
Sertraline Sertraline 
Topiramate Topiramate 
Marcumar Phenprocoumon 
Antidepressant Drug groups 
Triptanes Drug groups  
SSRIs Drug groups 
Note: List of active substances of the drugs; the last three lines show the enquiry on groups of 
medication. 
Enquiries about Adverse Drug Reactions  
Fifty (100%) adverse drug reactions (ADRs) were reported during the clinic ward 
visitation (see figure 57). 72% of the reported ADRs are documented in the record 
sheet (see appendix 13) of Pharmacovigilance in the Psychiatry (AMÜP: Arzneimittel 
Überwachung in der Psychiatrie) at the university of Regensburg. 28% of adverse 
drug reactions are not included in the data collection sheet, because some important 
information needed to evaluate the data such as age and exact medication history of 
the patients were not reported before their discharge. All the reports concerning 
adverse drug reactions were treated immediately and the clinic therapeutic advices 
were given in less than seven days to help the clinicians in their therapeutic 
decisions. 
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Figure 57. Number of collected data records of undesired drug effects. 
The reported adverse drug reactions were grouped in psychotic reactions, neuronal 
symptoms, gastrointestinal tract reactions, skin reactions, lack of drug efficacy, 
hormonal dysfunction, clotting problems, edema, liver problems, urinary tract 
problems, cardiac problems, heart and blood circulatory system, immune system, 
drug interactions, vitamins, and water regulation of the body (see table 59).  
Table 59. List of drugs and the reported adverse drug reaction. 
Adverse Drug Reaction Related Drug 
Psychotic reactions Ciprofloxacine, Infliximab, Cortisone, Metronidazole 
Delirious symptoms Nortriptyline, Lorazepam, Carbegolin, Seroquel, Abilify 
Missing hangover effect Remergil 
Lack of drug efficacy St. Johns word 
Parkinson symptoms Fluphenazine 
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Weight gain  Seroquel, Risperidon, Abilify 
Constipation and sudden diarrhea Valdoxan, Bisoprolol, Agiocur, Vitamins B12 
Restlessness Quetiapine 
Dry mouth Risperidon, Quetiapine, Olanzapine 
Decrease in neutrophilia Valproate, Perazine 
Pressure in the heart Quetiapine, Risperidon, Lyrica 
Addiction Tilidin, Tramadol 
Encephalopathy Valproate, Perazine 
Dry skin Clomipramine 
State of confusion  Lyrica 
Urine retention Imipramine, Clomipramine 
Hyper-salivation Olanzapine 
Vocal-tics Nortrilen 
Spasms Valproic acid 
Heavy legs Gabapentin 
Itching Pregabalin 
Erectile dysfunction Fluphenazine, Mirtazapine 
Massive alopecia Venlafaxine 
Change of heart clapper Amphetamine 
Tremor Lyrica 
Vomit Seroquel 
Sexual dysfunction Cymbalta 
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Hyponatremia Fluanxol, quetiapine, seroquel 
Nightmares Pregabalin 
Reslex Quetiapine 
Suicide attempt Risperdal 
Increase of eosinophil Mirtazapine 
Akathisia Risperdal, Quetiapine 
Increased bladder pressure Cymbalta 
Fatigue Diazepam 
Steadily increase of transaminase  Seroquel, Venlafaxine 
Seizure Ergenyl 
Hypotension Bisoprolol, clozapine, venlafaxine 
Edema Jatrosom, Seroquel, Risperdal, L- thyroxine 
Haggle feeling Sertraline 
Diffuse hair loss  Valproic acid 
Platelet function and bleeding under 
medication intake 
Valproic acid 
Scabies Lamotrigine 
Nausea Venlafaxine 
QTC-time extension Zeldox, Quetiapine 
Sudden drop in blood pressure Prazosin 
Tiredness Tavor 
Vitamin B12 deficiency Topiramate 
Elevation of the Leucocytes Diazepam 
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Abnormal sleep Nortrilen 
Note: The table shows the adverse and the undesired drug reactions treated during the advice on drug 
information. For each ADR, the relevant drug is listed.  
Frequency of Medication Reports Concerning Adverse Drug  Reactions 
Forty-one (100%) different medications were involved in the reported adverse drug 
reactions. The most reported active substances were quetiapine (31.71%), risperidon 
(17.07%), valproic acid (14.63%), pregabalin (12.20%), venlafaxine (9.76%), 
Nortriptyline (7.32%), aripiprazole (4.88%), bisoprolol (4.88%), clomipramine 
(4.88%), diazepam (4.88%), duloxetine (4.88%), fluphenazine (4.88%), lorazepam 
(4.88%), mirtazapine (4.88%), olanzapine (4.88%), and piperazine (4.88%). 
4.3.3.5 Clinic Ward Questionnaires 
After the analysis of the reports received during the clinic ward visitation, a general 
evaluation regarding the impact of the pharmacist at the clinic ward activities were 
summarized in the follow-up questionnaires. 
Evaluation of the Clinicians’ Questionnaire 
There were four factors considered during the evaluation of the returned 
questionnaires (see appendix 10) namely the non-drug therapeutic forms, therapeutic 
decision undertaken through the pharmaceutical advice, the competency of the 
advisory pharmacist for the therapeutic decision of the clinicians, and general 
comments (see table 60). The therapeutic decisions were for example the decisions 
taken to reduce or increase the medication dose and/or to choose an alternative 
medication to improve individual therapy. 
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Table 60. Factors used for the clinician’s questionnaire. 
Factors Question Numbers 
The non-drug therapeutic forms 3-5 
The action taken on the occurrence of adverse drug reactions 4-10 
The competency of the advisory pharmacist for the therapeutic 
decision of the clinicians. 
11-15 
General comments - 
Note: Non-drug therapeutic forms are therapies such as ergotherapy, and psychological advices and 
practices. 
The age of the attending clinicians in ward 1B as at the time of the field work ranges 
from 34 to 64 years. 33.3% of the questioned clinicians treated both out-patient and 
inpatients, 66.7% treated only inpatients. All the attending clinicians have treated 
more than 20 patients within the period of this study. Their main diagnostic groups 
according to the ICD-10 (International Statistical Classification of Diseases) are listed 
in table 61. The secondary diagnoses were given to be F10 (mental and behavioural 
disorders due to use of alcohol), F12 (mental and behavioural disorders due to use of 
cannabinoids) and F13 (mental and behavioural disorders due to use of sedatives 
and hypnotics). 
Table 61. The diagnosis according to ICD-10. 
ICD-10 Classification Diagnoses 
F06  Organic hallusinosis 
F20.0 Paranoid schizophrenia 
F20.1 Hebephrenic schizophrenia 
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F31.1 
Bipolar affective disorder, current episode manic without 
psychotic symptoms 
F31.3 
Bipolar affective disorder, current episode mild or 
moderate depression 
F32 Depressive episode 
F33 Recurrent depressive disorder 
F33.2 
Recurrent depressive disorder, current episode severe 
without psychotic symptoms 
F40 Phobic anxiety disorder 
F41 Other anxiety disorders 
F41.1 Generalized anxiety disorder 
F43 Reaction to severe stress, and adjustment disorders 
F44 Dissociative (conversion) disorders 
F60 Specific personality disorders 
F61 Mixed and other personality disorders 
Note: ICD-10 diagnostic groups [World Health Organisation, 1993] of the treated sickness as recorded 
by the attending clinicians. 
The result obtained by the evaluation of clinician questionnaire gave information 
about the medications and group of medications applied by the attending clinicians 
for the treatment of the diagnoses mentioned in table 61. The medications included, 
among others, antidepressants, antipsychotics and mood stabilizers. Non-drug 
therapeutic forms that accompanied the drug therapy were mostly cognitive training, 
cognitive psychotherapy, psycho-educative groups, occupational therapy, and 
psychotherapy sessions with an orientation towards behavioral therapy. The 
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attending clinicians (n=4) assessed their patients with regard to drug therapy. 5% of 
their patients were assessed to be very satisfied, 70% satisfied, 15% slightly satisfied 
and 10% dissatisfied. Other answers given by the clinicians to the questions on the 
questionnaire are reported on table 62. The clinicians recommended the continuation 
of the pharmaceutical advices through drug researches and drug information, 
because they contributed to their therapeutic decisions and helped in the optimization 
of an individual therapy. 
Table 62. The evaluation of the result of the clinician questionnaire (n = 4).  
Questions 
Yes 
(%) 
No 
(%) 
Not 
Really 
(%) 
No Idea 
(%) 
Did adverse drug reactions occur? 
4 
(100) 
- - - 
Did adverse effect occur only after the 
administration of certain drugs? 
2 
(50) 
1 
(25) 
1 
(25) 
- 
Are there alternative explanations (apart from 
medication) for the occurrence of adverse drug 
reactions? 
3 
(75) 
1 
(25) 
- - 
Were the adverse drug reactions confirmed by 
documented guidance? 
3 
(75) 
1 
(25) 
1 
(25) 
- 
Did the advice of the pharmacist help in 
therapeutic decisions? 
4 
(100) 
- - - 
Are the answers and information supplied as 
regards to medication questions complied with 
your expectations? 
4 
(100) 
- - - 
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Did the supplied answers to your questions about 
adverse effect met your expectation? 
4 
(100) 
- - - 
Did the presence of a pharmacist contributed to a 
successful therapy? 
4 
(100) 
- - - 
 Good 
Not 
Good 
Bad No Idea 
How would you rate the work of the pharmacist in 
your station? 
4 
(100) 
- - - 
Note: The table contains the summary of the fifteen questions in the clinician questionnaire. The last 
question has another form of answer which does not coincide with the previous questions in the table. 
Evaluation of the Patients’ Questionnaire  
The patients’ questionnaire (see appendix 11) was carried out on a voluntary and 
anonymous base. The four sections of this questionnaire were gender, age, sickness 
progression and the involvement of patients in the treatment decisions as well as in 
the ongoing management of future treatment. Twenty-five patients were questioned. 
Any question point that was not answered was grouped under “no idea” (see table 
63). 60% of the patients that attended to the questionnaire were female and 40% of 
them were male. Their ages were between 32 and 51 years. 80% of the patients 
were inpatients and 20% of them were outpatients. The ICD-10 diagnoses of the 
patients were from F06 to F61 (mental and behavioural disorders). All the patients 
were medically advised from their attending clinicians. The therapeutic goals and 
expectations were clarified before and during the therapy. Through the collaboration 
of the clinic ward psychologists and nurses, the therapeutic goals were successfully 
strived after during the patients’ admission. 
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Table 63. The results of the patients’ questionnaire (n = 25). 
Questions 
Yes 
(%) 
No 
(%) 
Not Really 
(%) 
No Idea 
(%) 
Were you informed of the name of the consultant, nurse 
or therapist? 
20 
(80) 
- 
5 
(20) 
- 
Were you given all the privacy needed during your 
treatment? 
18 
(72) 
7 
(28) 
- - 
Were the procedures and next steps in your treatment 
explained in a way you could understand? 
20 
(80) 
4 
(16) 
- 
1 
(4) 
Did you feel involved in deciding about your treatment 
plan? 
23 
(92) 
- - 
2 
(8) 
Was the effectiveness of your medication explained to 
you? 
19 
(76) 
3 
(12) 
- 
3 
(12) 
Were you informed of the possible occurrence of 
adverse side effect of your medication? 
15 
(60) 
- 
2 
(8) 
8 
(32) 
Have you already experienced adverse side effect? 
22 
(88) 
3 
(12) 
- - 
If you were to continue your medication or treatment at 
home, were you given a clear explanation and written 
instructions of what to do? 
24 
(96) 
- - 
1 
(4) 
Did you feel you were given all the time and attention 
needed? 
20 
(80) 
- 
1 
(4) 
4 
(16) 
Note: This table contains the summary of the thirteen questions in the patient questionnaire.  
The patients’ satisfaction with the attending clinicians, the pharmacist, and the clinic 
staff regarding the explanations about their therapy and their drug-intake show a 
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good indication of treatment adherence and thus a high chance of successful 
treatment. The attending clinicians were supported in their timely therapeutic 
decisions through the help of the pharmacist in drug-related issues. They were also 
of the opinion that pharmaceutical knowledge is an inevitable help for clinicians to 
calculate dose adjustments or to analyze interactions with other drugs. All the 
answers showed that the presence of the pharmacist in the clinic ward was 
appreciated and will always be needed 
4.3.4 Survey of Literature on the Importance of a Pharmacist in the Clinic 
Ward  
Different reports were studied regarding the activities of pharmacists at different 
clinics, the ideas derived from the literature survey was successfully reviewed and 
modified for a reliable field work at the clinic ward 1B. 
Marino et al. reported in 2010 on the differences in pharmacy interventions at a 
psychiatric hospital. The 2,220 interventions made by pharmacist during their study 
were based on the documentation of medication errors, undesired effects and the 
reduction of undesired effects following pharmaceutical advices. Their results show 
the positive contribution of pharmacists on clinical therapeutic interventions for the 
optimization of individual patient therapy [Marino et al., 2010]. 
The development of a standard form for the collection of data such as drug and drug 
related problems, type of interventions, and the estimation of their significance during 
pharmacy intervention was reported by Alderman in 1997. According to his report, 
medical staffs accepted that 91.7% interventions with antidepressants top rated as 
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the cause of the intervention. The recommendation for drug therapy and patient 
monitoring brought about an optimization of treatment of outcomes [Alderman, 1997]. 
Van Wijk (2005) reported some discrepancies regarding the intervention outcomes of 
community pharmacists in the medline research carried out in 2005. Pharmaceutical 
advices, drug monitoring, and training served as effective tools for the pharmacy 
intervention in some studies and were also reported as ineffective by other studies. 
The problem was attributed to lack of well-designed and well-conducted studies on 
the effectivenss of interventions by pharmacist, which according to this report need to 
be improved [Van Wijk, 2005]. 
A systematic review of clinical pharmacist and inpatients medical care carried out by 
Kaboli et al. (2006) showed that the addition of clinical pharmacist services in the 
care of inpatients generally resulted in improved care, with no evidence of harm. 
Interacting with the health care team on patient rounds, interviewing patients, 
reconciling medications and providing patient discharge counseling and follow-up all 
resulted in improved outcomes after the revision of 36 studies consisting of 10 
evaluating pharmacists’ participation on rounds, 11 medication reconciliation studies, 
and 15 drug-specific pharmacist services [Kaboli et al., 2006]. 
During this work, the ward clinicians acknowledged the work of the pharmacist in the 
ward and acted on her suggestions for interventions regarding drug-related 
problems. Drugs reviewed by the pharmacist and follow-up discussions with 
attending clinicians and patients resulted in a reduction in suboptimal prescriptions 
among hospitalized patients in psychiatric ward 1B. This was proven from the TDMs 
carried out for different patients in that ward and out-patients as well. 
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5 Discussion 
This study aimed at developing a new analytical procedure for the accurate and 
specific determination of antipsychotics with low therapeutic concentrations and 
ranges such as melperone (MLP), benperidol (BPD), haloperidol (HLP), bromperidol 
(BRP), flupentixol (FLT) and zuclopenthixol (ZLT), in human serum. In this context, 
the application of simple, reliable, less expensive HPLC equipment and parameters 
(HPLC) and an ultra violet (UV) detector is demonstrated to be effective in providing 
high sensitivity and selectivity. The developed method provides the possibility of 
measuring these substances simultaneously and individually at low cost especially 
for routine applications at small scale TDM laboratories, where these substances 
could not be tested reliably until now.   
The HPLC/UV, a less expensive analytical equipment was employed in two 
separation methods dedicated respectively to the qualitative and quantitative serum 
determination of MLP, BPD, HLP, BRP, FLT, and ZLT. The procedures were 
designed by first testing the dissolution character of each substance in the mobile 
phase solvents, columns were tested and short sized columns with high resolution 
were preferably chosen, because this will keep the total chromatographic run time 
short.  
Several experiments were carried out to determine a pH value applicable for 
detecting the smallest concentration of all the substances, so as to ensure that all the 
substances remain stable in the solution during the simultaneous determination and 
throughout the chromatographic process. The applied UV detector has a special 
feature (diode array detector) of measuring the substances with variable 
wavelengths, so that wavelength that gave the expected peak character at small 
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concentration of each substance was chosen. Medium wavelengths between 230 nm 
and 245 nm were preferred and chosen, to reduce the risk of interference with other 
substances including serum materials, which can easily be detected at lower and 
higher wavelengths [Gunasekaran und Uthra, 2008]. With this design, this study 
succeeded to establish a method to determine lower concentrations of 
antipsychotics. This method is less expensive and easy-to-use, especially at small-
scale TDM laboratories.  
The isocratic separation method allowed a simultaneous serum determination of 
MLP, BPD, HLP, BRP, FLT, and ZLT with a time gap between MLP/BPD and 
HLP/BRP. The multistep gradient method was employed to reduce the gap between 
the peaks, thereby reducing the total run time. The same solvent that was applied for 
the isocratic separation (ACN/ MeOH/ TEMED/ H2O) was also applied for the 
gradient separation, but at different volumes and at different times. The determination 
with the gradient separation method was successful, but however the expectations 
were not met. The gap between the peaks (MLP/BPD and HLP/BRP) were not 
reduced, the total run time was longer and more volume of solvents were used for 
the measurement, when compared with isocratic separation method. The gradient 
method was therefore not continued for the validation. 
The developed HPLC/UV analytical method with isocratic separation was validated 
by following different international validation guidelines acceptable for the validation 
in human serum such as ICH validation guideline, the guidelines of GTFCH, FDA and 
the guidance for industry on biomedical method validation. The results of validation 
were all within the acceptance criteria and proved that this method is reliable for the 
serum quantification of the applied substances. The sensitivity, selectivity and the 
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precision of the validated analytical procedure enable measurements of low serum 
concentrations of the substances without additional purification steps, which proved 
less-time consuming. The method was successfully applied to the quantification of 
MLP, BPD, HLP, BRP, FLT, and ZLT in human serum.  
The method can be used in all TDM laboratories, especially small scale laboratories, 
because it is among others, precise, robust and cheap. Preliminary experiments 
suggest that it can also be applied in the serum measurements of other substance 
groups apart from antipsychotics. Only the set parameters and conditions used 
during the validation of this method should be applied for a reliable result for the 
measurement of melperone, benperidol, haloperidol, bromperidol, flupentixol and 
zuclopenthixol in human serum. No special experts are needed to operate this 
method. Users of this method in small-scaled TDM laboratories can easily operate it 
once they know the principle of HPLC/UV detector system and by following the 
validated set parameters and conditions. 
It has to be emphasized that this method is applied for the first time at TDM 
laboratory in Regensburg for the determination of the study substances. Similar 
analytical procedures have been discussed by different researchers. Seiler et al. 
(1994) and Furlant et al. (1987) succeeded respectively, with the application of 
HPLC/EC method to determine benperidol in human serum. Furlant et al. (1987) 
successfully reached a low detection limit of 0.2 ng/ml with 1 ml volume. Comparing 
to Furlant et al. (1987), this study reached a higher limit of detection at 0.7 ng/ml, but 
this limit is acceptable because it is below the expected therapeutic reference range 
of 1- 10 ng/ml, so that serum concentrations within the expected TRR will reliably be 
reached with this method. Moreover, the developed method will be applied not only 
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for the determination of benperidol but also the determination of five other 
substances simultaneously or individually in human serum. With a much lower 
detection limit of 0.1 ng/ml, Hiroshi et al. (2000) succeeded in the simultaneous 
serum determination of five butyrophenones, but with the use of an expensive 
method. The HPLC/MS, requires special experts for its application. This solution is 
not easily accessible for small-scale TDM laboratories.  
The HPLC/UV method described in this thesis is practicable to both small and large-
scale TDM laboratories. Zhou et al. (2004) in their HPLC/MS method though 
succeeded to simultaneously determine four antipsychotics. They had to alkalinize 
and extract the preparations twice before they could measure [Zhou et al. 2004]. 
These preparation steps are not required in this method, which is an advantage for a 
faster measurement and communication of the result. Both volatile and non volatile 
substances can be measured with the elaborated method of this study unlike the 
GC/MS method described by Zhu et al. (1998), where they succeeded after an 
intensive preparation of the samples, to use the obtained results for the 
pharmacokinetics of clozapine.  
Tanaka et al. (2007) used a HPLC/UV method just like in this study to successfully 
and simultaneously determine twelve phenothiazines in human serum. However, with 
the application of a pre-step method and the fourfold higher detection limit of 3.2 – 
5.5 ng/ml, their method is of less advantage in the serum determination of 
antipsychotics with low and narrow therapeutic ranges.  
Kirchherr et al. (2006) and Jain et al. (2011) both described analytical methods used 
for determination of haloperidol in human serum. Kirchherr successfully developed a 
HPLC/MS method for a simultaneous determination of forty-eight antipsychotics both 
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for butyrophenone and phenothiazine groups. The expected results were reached 
and the limit of detection for the substances showed good covering of therapeutic 
and subtherapeutic ranges [Kirchherr et al., 2006]. Though the number of substances 
that can simultaneously be measured with the developed method in this thesis is 
much lower, this method has unlike the method of Kirchherr et al. (2006) the 
advantage that it can be applied in all TDM laboratories, because of its simple and 
also reliable application. The HPLC/MS method and procedures applied by Kirchherr 
et al. (2006) are not only expensive, the samples also undergo an intensive 
preparation before they could be measured, which is not easily practicable in daily 
routine measurements in some TDM laboratories.  
Jain et al. (2011) described the successful application of HPLC/UV to determine 
haloperidol, which was effectively applied for routine estimation of haloperidol in 
psychiatric patients [Jain et al., 2011]. The disadvantage of their method is that it 
needs a pre-step extraction procedure before the measurement. Another 
disadvantage is the high limit of detection for haloperidol obtained at 1.1 ng/ml, which 
is above the set therapeutic reference range for haloperidol according to AGNP 
Consensus Guideline, Update 2011.  
The void observed by previous researches as explained above were all covered in 
the new method developed during this study. More than one substance can be 
measured individually and simultaneously. No pre-step and intensive preparations 
are needed. Both volatile and non-volatile substances are applicable. Cheap 
analytical equipment that does not require specialist for its operation can be applied. 
The disadvantage observed in this method is however, the slight higher detection 
limit obtained for flupentixol at 1.7 ng/ml, which is above the expected therapeutic 
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reference range of 1 - 10 ng/ml. Therefore, future work may be necessary here to 
obtain a lower detection limit applicable for flupentixol. 
The results of the validation corroborate the observation, described also by other 
researchers, that with HPLC/UV analytical method, substances can reliably be 
determined in human serum. The applied variable wavelength UV detector (the diode 
array detector) allows for the best wavelength to be selected for the analysis [Titier et 
al., 2003]. A good separation demands an optimal resolution of the individual 
samples, especially when the routine application is to be used to analyze a number 
of patient samples [Snyder et al., 2012].  
The isocratic separation of the substances was successfully achieved with the 
column Luna Phenyl-hexyl 150 x 3.0 mm, 3 µm for the applied butyrophenones and 
Nucleodur CN 150 x 4.6 mm, 3µm for applied phenothiazines. Both columns were 
selected for this method development because they gave satisfactory resolution in 
the mobile phase, consisting of acetonitrile/methanol/ TEMED/ water/ 
Orthophosphoric acid solvent system and they are compared with other columns less 
expensive.  
According to studies, some proteins in serum-analyte have the ability to interfere with 
or attenuate the measurement signals of the applied substances [Hiroshi et al., 
2000]. The test on interference carried out with 108 substances shows no 
interference with MLP, BPD, HLP, BRP, FLT, and ZLT. Additionally, standard 
samples were measured alongside with the unknown samples, which helped to 
control any unexpected interference. The Amount (concentration) obtained from the 
measurements of the standard solutions of melperone, benperidol, haloperidol, 
bromperidol, flupentixol, and zuclopenthixol correspond to the expected results. The 
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absorption increases with an increase in the concentration. A reduction in the 
molecular absorption unit during the long term stability test could be observed, 
though linear to the given concentrations. It can be related to redox-reactions that 
must have taken place during the preservation of the substances in the methanol 
solution. According to the reports of many journals such as Einosuke et al., (2007), 
the mentioned substances were stable for three months when preserved in -20 °C 
[Einosuke et al., 2007]. 
The developed method was successfully applied in the TDM routine measurements. 
Patients’ samples were received together with the TDM request form. Results of the 
samples requested by different hospitals were evaluated with Konbest program 
[Wirkstoffkonzentrationsbestimmung, 2012]. The information recorded in the request 
form was considered for the clinic-pharmacological reports of the TDM result of the 
concerned substance. Some discrepancies already mentioned in some journals were 
observed in the completed form, such as dosing information, duration of the therapy, 
and serum samples at steady state concentration. According to the work of Vuille et 
al., 1991 and Zernig et al., (2004), such inadequate request lead to misinterpretation 
of results and to wrong dose adjustments [Vuille et al.,1991; Zernig et al, 2004]. 
Zernig et al., 2007 also mentioned the non-conformance with steady-state conditions 
and errors on the application form as other typical errors [Zernig et al., 2007]. 
Therefore, just as Hiemke, (2008) and Conca et. al, (2011) state, the current use of 
TDM in the mental health care needs to be improved [Hiemke, 2008; Conca et. al, 
2011].  
During this study, in cases of discrepancies on the TDM request form, the attending 
clinicians were contacted for a clarification of the issue before the clinic-
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pharmacological report was written. The disadvantage is that it extended the time 
needed to communicate the result and moreover, only indicated errors were clarified. 
Errors regarding wrong information in dosing and dosage form were difficult to 
indicate, especially when the measured concentration was not significantly above or 
below the expected DRR and TRR.   
The plotted dose-concentration diagrams of the substances were carried out with few 
patients’ samples with the exemption of haloperidol and flupentixol. It is therefore 
advisable that more samples should be tested in future to confirm the results 
obtained in this study.  
Studies regarding the metabolic pathway(s) of benperidol have also not yet been 
clarified, so that the interpretation of the measured concentrations above the 
expected DRR could not be given in this study. Sun und Scott (2011) reported that 4-
aminopiperidens, example benperidol are metabolized by CYP3A4. The catalytic 
mechanism is however not yet clarified. The result of their experiments suggests that 
there are interactions between 4-aminopiperiden substrates and CYP3A4 active site 
[Sun and Scott, 2011]. It has to be mentioned that the samples above the DRR and 
TRR were co-administered with other medications which could have an impact on the 
metabolism of benperidol.  
The consensus data (DRR) comparison with the obtained concentration of the 
measured samples were carried out to evaluate the behavior of the obtained 
concentrations with the expected DRR, by sole administration and by co-
administration with other substances. The C/D values applied for the evaluation of 
DRR for flupentxiol in this study was derived from the applicable value in TDM 
laboratory Regensburg. These values differ from that of consensus. In the consensus 
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data according to AGNP guideline, Update 2011, [Hiemke et al., 2011] the given 
range of (0.78 – 0.87 ng/ml/mg) in consensus is not differentiated between the oral 
and intravenous (depot) application. Therefore two different evaluations were carried 
out in this study; firstly the comparison between the measured concentrations and 
the values obtained with DRR data from TDM laboratory, secondly the comparison of 
the measured concentration with the values obtained with the given consensus DRR 
data. The C/D calculation of consensus with regard to flupentixol should be re-
evaluated. The different behavior of the depot and oral application in serum should 
be considered, because of non-lineal relationship observed in the presented dose-
concentration diagram of flupentixol with the applied TDM-data (data from TDM 
Laboratory Regensburg).  
Jorgensen (1980) and Jann et al., (1985) reported about the observed differences in 
the pharmacokinetics of depot and oral antipsychotics. Jorgensen evaluated the 
pharmacokinetic studies of flupentixol for oral and depot application form. He 
observed that the intravenous flupentixol followed a multi-compartment model, which 
data he however did not succeed to fix to a particular compartment. Slow absorption 
was observed after oral administration while the serum concentration after 
intramuscular injection of flupentixol decanoate clearly related a depot effect. He 
mentioned the probability that the approximate half-life obtained during the study was 
not the elimination half-life but the release of drug from the oil depot [Jorgensen, 
1980]. This finding is supported by Jann et al., (1985) in their study on the kinetic 
properties, the relationship of plasma concentrations to clinical effects, and 
conversion from oral to injectable therapy. They reported the observation in the 
absorption rate constant of depot antipsychotics, which is slower than the elimination 
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rate constant and therefore the depot antipsychotics exhibit “flip-flop” kinetics 
regarding the time to steady-state and the concentration at steady state [Jann et al., 
1985]. The observation made in this study regarding the dose-concentration diagram 
of the administered flupentixol, did not however distinguish the application of 
flupentixol in intravenous and intramuscular form. As mentioned already, the correct 
administered dosage form should be recorded in the TDM request form and the C/D 
value in the AGNP Consensus Guideline for flupentixol should consider the 
differences in serum concentrations of flupentixol using different application forms.  
There are other factors that can influence the concentration of drugs in human 
serum. There are discrepancies in literature findings concerning the influence of 
smoking on antipsychotics such as the haloperidol and flupentixol and the sickness 
schizophrenia.  
Shimoda et. al, (1999), reported the impact of smoking on plasma haloperidol 
concentrations of patients who smoked ten cigarettes per day. They satisfactorily 
observed that at low maintenance doses /kg body weight, smokers showed 
significantly lower concentrations than nonsmokers. They did not observe any 
significant difference in doses more than 0.2 mg/kg body weight [Shimoda et. al., 
1999]. They however, did not pursue the impact of therapeutic monitoring of the 
haloperidol serum concentration of smokers. The data used for the evaluation during 
this study, the study of the influence of smoking on haloperidol and flupentixol serum 
concentration, did not specifically monitor the number of cigarette smoked by patients 
during therapy with haloperidol and flupentixol, because this information was not 
given for all the smokers, and also the information regarding the body weight and 
body mass index (BMI) of some patients was not recorded. This study however, 
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confirms as a major finding, that individual haloperidol and flupentixol serum 
concentrations of smokers and nonsmokers were well controlled through TDM, so as 
to minimize concentrations at toxic plasma levels and undesired drug effect. 
Therefore, no significant influence between smokers and nonsmokers as shown in 
the comparison of the DRR for smokers and non-smokers was observed for 
flupentixol. The slight difference in the high concentration of smokers is referred to 
the influence of the administered co-medication and individual variations. The two 
outlier observed in dose-concentration diagram of haloperidol by smokers were 
caused by the prescribed co-medications which have the same metabolic pathways 
like haloperidol. No co-medication was given for one of the samples with outlier 
serum concentration, and there was no evidence of drug interactions or unsual 
metabolism status of the patient. The information about the health status of the 
patient and the undesiered effect (UDE) were not given. An individual variation 
should therefore not be excluded, under the conditon that the TDM request form is 
correctly completed and that the serum sample was collecetd at steady-state as 
advised. 
Lucas and Martin, (2013), reported a significant increase of the activities of 
Cytochrome P450 (CYP) 1A2 in patients who smoked more than 20 cigarettes a day, 
compared with nonsmokers. They attribute this to the pharmacokinetic interactions of 
cigarette smoking, which induces CYP1A2. Alongside with clozapine, haloperidol is 
mentioned in their study as one of the substrates of CYP1A that can be induced 
through smoking [Lucas and Martin, 2013]. They could however not confirm how the 
number of daily smoked cigarettes and the inter-individuality of the patients affect 
CYP induction.  
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Jiang et al., (2013), researched the mechanism associated with heavy smoking by 
male schizophrenic patients and the suggested hypothesis about the alleviation of 
schizophrenic symptoms and reductions of undesired effect. They successfully 
concluded their analysis with the insight that smoking is associated with improved 
negative symptoms which could account for heavier smoking among schizophrenic 
patients [Jiang et al., 2013]. The study presented in this thesis has shown that 
through TDM and the correct data records in konbest, serum concentration of 
individual patients under the consideration of their inter-individualities can be 
controlled.  
During the therapeutic drug monitoring of haloperidol and flupentixol, an adjustment 
of the maintenance dose was repeatedly carried out by the attending clinicians to 
reach the therapeutic serum concentration for individual patients. Since smokers 
reached lower haloperidol and flupentixol serum concentration than non-smokers, 
respectively, they were prescribed higher dose by the attending clinicians, in order to 
obtain serum concentrations at their individual therapeutic level. Because of the 
desired and controlled individual dose adjustment during TDM, patients’ therapy  
were monitored effectively. The collected konbest data was enough to support the 
fact that smoking reduces the haloperidol,  but not the flupentixol serum 
concentration.  
The data evaluation on the influence of smoking on haloperidol and flupentixol 
carried out in this work is focused on the serum concentration obtained by smokers, 
irrespective of the number of cigarettes smoked, and the difference when compared 
with nonsmokers. This is to improve an effective individual therapy through dose 
adjustment and reduction of undesired drug effect. However, for better 
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understanding, control and optimization of antipsychotic therapy by schizophrenic 
patients, a compound controlled TDM study with possibly schizophrenic patients from 
different ethnicity should be carried out. It should comprise the type and the number 
of cigarettes smoked, selected antipsychotics and co-medications, measurement of 
serum concentrations before and after dose adjustments and the impact of smoking 
on the schizophrenic ailment of these patients before and after the study. The 
knowledge that will be obtained in this research will throw more light on the 
relationship between serum antipsychotic concentration, smoking, schizophrenic 
symptoms and sickness progression, among individual patients. It will also enhance 
an effective individual therapy. A compound controlled TDM study mentioned here, is 
a study in TDM context and guidelines consisting of the aformentioned factors. 
The outstanding aspect of this work is the close communication with the attending 
clinicians in terms of clarification of TDM and pharmaceutical advice at the clinic ward 
1B, not only for antipsychotics but also for other medication groups. One of the 
reasons observed during this study for the request of TDM by the attending clinicians 
is the prediction of the compliance of their patients. This coincides with the studies of 
Byerly et al., (2007) and Sajatovic et al., (2010). They state that clinicians cannot 
reliably predict their patients’ compliance due to lots of individual differences and the 
avoidance of intolerable antipsychotic undesired effects [Byerly et al.,2007; Sajatovic 
et al., 2010]. Patients’ samples that gave, for example, the concentration of 0 ng/ml in 
this study was suspected of compliance problem when the maintenance dose was 
continuously given for at least one week and especially, when the concentration of 
other co-medications gave reasonable values. In cases of oral medications, the 
attending clinicians were advised to discuss with their patients and switch to 
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intravenous application or to change the medication depending on their clinical 
decision.  
The Iimit of clinic-pharmacological interpretations lies on the absence of the clinical 
impression of the unseen individual patient. This Iimitation was handled through the 
clinic ward visits, where the measured concentrations were discussed with the 
attending clinicians and patients. The mentioned case reports were not handled 
directly at the general ward discussion, but during the triple discussion between the 
patients, the attending clinicians, and the pharmacist, during the discussion between 
the pharmacist and the patients alone and during the discussion between the 
attending clinician and the patients alone. Data of the patients were collecetd later 
from the attending clinicans. Some data could not be supplied by the attending 
clinicians, especially in cases where out-patients were involved. 
Some authors have already studied the effectiveness of the presence of a 
pharmacist at the clinic ward. Fertleman et al. (2005), reported the improvement in 
the accuracy of drug history documentation, reduction in prescribing costs, and a 
decrease in the potential risk to patients through the assistance of a pharmacist at 
the clinic ward [Fertleman et al., 2005].  
The clinic ward visits carried out during this study corresponds with the findings of 
Fertleman et al. (2005), that clinically significant drug-related problems can effectively 
be identified and solved by pharmacists. This can be achieved through therapeutic 
drug monitoring of the suspected substances and pharmaceutical advices based on 
the current state of research on the administration and guidelines of the concerned 
medication.  
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Marino et al. reported in 2010 the differences in pharmacy interventions at a 
psychiatric hospital. The 2,220 interventions made by pharmacist during their study 
were based on the documentation of medication errors, undesired effects and the 
reduction of undesired effects following pharmaceutical advices. Their results show 
the positive contribution of pharmacists on clinical therapeutic interventions for the 
optimization of individual patient therapy [Marino et al., 2010]. Their analysis is 
however not focused on the control of the serum concentrations of the suspected 
drugs through TDM, for a timely prevention and reduction of undesired effect and 
also lack of effect. Though with limited number of patients, these issues were 
effectively considered and treated in this study as shown in the case report 
examples.  
Through the evaluation of the clinic ward questionnaires, the work of the pharmacist 
at the clinic ward was assessed as positive both by the patients and the attending 
clinicians. Alderman (1997) developed a standard form for the collection of data such 
as drug and drug related problems, type of interventions, and the estimation of their 
significance during pharmacy intervention. Her study suggests an optimization of 
treatment outcomes through recommendations for drug therapy [Alderman, 1997]. 
The form created in this work is to assess how patients understand their therapy and 
the value of their drugs, and to find out how compliant they are with respect to the 
prescribed drug. The evaluation form for the attending clinicians was developed with 
a focus on the use and application of the recommendations and advice on the 
therapy of individual patient and the impact of the pharmacist activities during the 
ward visits. As confirmed by the attending clinicians and participating patients, the 
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advice of the pharmacist on different drugs during clinic admissions of the patients 
and on discharge resulted in better outcomes. 
The reported undesired drug effects obtained during clinic visits at the clinic ward 1B 
were documented in AGATE pharmacovigilance form. This is of value in further 
research of other drugs. Antipsychotic dosing guided by TDM has proven to be very 
effective and less expensive [Ostad-Haji et al., 2013]. This work has confirmed the 
application of therapeutic drug monitoring (TDM) in the realization of effective cost 
therapy from laboratory measurement of serum concentrations to the routine 
application of TDM and its clinical advantages for the health enhancement of 
individual patients. 
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6 Summary 
This study aimed at the development of a new analytical procedure for the qualitative 
and quantitative determination of antipsychotics with low therapeutic reference 
ranges such as melperone (MLP), benperidol (BPD), haloperidol (HLP), bromperidol 
(BRP), flupentixol (FLT) and zuclopenthixol (ZLT) in human serum, both individually 
as well as simultaneously. This objective was successfully achieved. The procedure 
uses on-line solid phase sample cleanup coupled to high-performance liquid 
chromatographic (HPLC) separation with ultra violet (UV) detection. The procedure is 
inexpensive and affordable for TDM routine applications at small scale TDM 
laboratories, where these substances could not be tested reliably until now. 
The development and validation of the method was carried out with the analytical 
columns Luna phenyl-hexyl 3 µm, 150 x 3.0 mm column and Nucleodur CN-RP 3 µm, 
150 x 4.6 mm column for butyrophenones and phenothiazines, respectively. The 
mobile phase was composed of 30 vol% ACN, 13 vol% MeOH, 0.4 vol% TEMED and 
56.6 vol% demineralized water. The wavelength for the detection was set at 245 nm 
and at 230 nm for butyrophenones and phenothiazines, respectively. The detection 
limits were satisfactorily obtained at 7.3 ng/ml for MLP, 0.7 ng/ml for BPD and HLP, 
1.6 ng/ml for BRP, 1.7 ng/ml for FLT and 1.7 ng/ml for ZLT.  
The developed method was successfully applied for TDM routine measurements. It 
has sufficient sensitivity to detect steady-state concentration in patients. The main 
diagnoses of the study patients were determined according to chapter five (mental 
and behavioral disorders) of the International Statistical Classification of Diseases 
and Related Health Problems. Dose-concentration diagrams of the substances and 
the boxplots were plotted to compare the obtained serum concentrations with dose-
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related reference ranges (DRR) and therapeutic reference ranges (TRR) of the re-
spective substances. The clinic-pharmacological interpretation of the measured con-
centrations relied on the information given in TDM request form, namely, the co-
medications, development of undesired drug effects, duration of the therapy, dosage 
regimen, time the sample was taken, and indication for monitoring.  
The understanding of antipsychotic TDM was improved during this study through the 
evaluation of old and new medication data. This included the Konbest data base for 
the measured antipsychotics, ABDA data for HLP cost evaluation, and AGATE data 
for the concomitant applications of MLP and BPD. Consensus C/D data were 
compared, concentrations measured in serum of patients under monotherapy and 
polytherapy. Differences between oral and depot form of flupentixol were observed. 
This study also shows that the serum concentrations of HLP and FLT for smokers 
and nonsmokers can be controlled through TDM. 
Case reports of the study substances were successfully evaluated by the pharmacist 
in the context of the clinic ward visitation. The results of the clinic ward question-
naires proved that through the application of the less expensive TDM methods in the 
clinic ward, attending clinicians were able to effectively monitor the serum drug con-
centrations of individual patients, make correct therapeutic decisions in time, and 
were therefore able to begin the therapy without unwanted delay.  
The validated isocratic HPLC separation method was the appropriate method for the 
serum determination of the study substances and through the simple developed 
HPLC procedures.   
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Appendix 1. Column Selection by Measurement with Buffer Mobile Phase 
 
 
 
Note: Parameters applied during the selection of different analytical columns with buffer mobile phase 
for the HPLC method development. 
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Appendix 2. Column Selection with TEMED Mobile Phase 
 
 
 
Note: The addition of TEMED in the mobile phase for the selection of analytical column the serum 
determination of MLP, BPD, HLP, BRP, FLT, and ZLT. 
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Appendix 3. Application of Gradients HPLC Method Development 
 
 
 
Note: Illustration of the percentage volume of solvent applied during the gradient HPLC method 
development. The mobile phase C and acetonitrile of HPLC grade were admixed with the help of 
multistep gradient method. Mobile phase C comprises of 300 ml ACN, 130 ml MeOH, 4 ml TEMED, 
and 566 ml H2O. Solvent A shows the volume and percentage portion of the constituents of mobile 
phase C at each chromatographic run, while solvent B on the table shows the volume and the 
percentage of the HPLC-grade acetonitrile added to the mobile phase C. 
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Appendix 4. Example of a Calibration Curve of Zuclopenthixol 
 
 
 
Note: The calibration curve of zuclopenthixol carried out during the TDM application of the developed 
method (n = 7). The linearity of the curve shows the precision and reliability of the method, for the 
qualitative and quantitative analysis of drugs in patients’ serum. With the curve of linearity, the 
concentration of an unknown substance can be calculated. 
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Appendix 5. The Simultaneous Test on Interference for Butyrophenones 
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 227 
 
 
 
Note: Interference test with Butyrophenones and the combined medications used during the therapy 
with butyrophenones was carried out with Luna Phenyl-hexyl column 3µm at an optimal wave length of 
245 nm. The raw substances used for the test were obtained from the TDM laboratory at the 
University of Regensburg. In brackets are the values of the drug products (met). The substances 
beyond the detection limit set for butyrophenone method were not detected (nd). 
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Appendix 6. Test on Interference for Flupentixol and Zuclopenthixol 
 
 
 229 
 
 
 230 
 
 
 
Note: The medications for the interference test were the combined medications during the therapy with 
flupentixol and/ or zuclopenthixol. The test was carried out with Nucleodur CN-RP 150 x 4.6 mm, 3µm 
at an optimal wave length of 230 nm. The raw substances used for the test were obtained from the 
TDM laboratory at the University of Regensburg. In brackets are the values of the drug products (met). 
The substances beyond the detection limit set for butyrophenone method were not detected (nd). 
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Apendix 7: Number of administered co-medication per patient 
Number of patients Number of co-medication per patient 
90 1 
94 2 
114 3 
86 4 
40 5 
30 6 
30 7 
18 8 
4 9 
18 10 
4 11 
1 12 
2 13 
3 14 
1 15 
535 120 
Note: Some haloperidol co-medications are repeatedly recorded for more than one patient. Invented 
name of the medications were calculated just as administered for each patient. 
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Appendix 8. Haloperidol Serum Concentration Data for Smokers and Nonsmokers 
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Note: DRR = dose-related reference range. The DRR is obtained by multiplying the factors C/Dlow 
and C/Dhigh with the administered dose. Conc. is the serum concentration obtained after measuring 
the patients’ haloperidol samples.  
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Appendix 9. Flupentixol Serum Concentration Data for Smokers and Nonsmokers 
 
Note: DRR = dose-related reference range, TRR = therapeutic reference range. The DRR is obtained 
by multiplying the factors C/Dlow and C/Dhigh with the administered dose. Conc. is the serum 
concentration obtained after measuring the patients’ flupentixol samples.  
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Appendix 10. Questionnaires for the Attending Clinicians 
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Note: Questionnair prepared for the attending clinicians for the evaluation of the activities of the 
Pharrmacist at the clinic ward 1b during the research study.  
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Appendix 11. Patients’ Questionnaire for the Evaluation of Pharmacist’s Activities at the Clinic 
Ward 
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Note: Questionnaire prepared for the patients for the evaluation of the activities of the Pharrmacist at 
the clinic ward 1b during the research study.  
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Appendix 12. Diagnoses for which MLP and/or BPD was Administered 
 
 
 
Note: N diagnoses= total number of diagnosis in a group. The diagnoses were grouped according to 
the grouping of the International Classification of diseases 2009 and 2010. 
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Appendix 13. AMÜP Form for the Record of ADR-Reports in the Psychiatry 
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Note: The AMÜP-form for recording the reported undesired drug effects during the clinic ward visits.  
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